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The insulin-like growth factor (IGF) pathway consists of two ligands, IGF I and IGF II, their 
two receptors, the IGF I receptor (IGF IR) and IGF MR along with several soluble insulin-like 
growth factor binding proteins (IGFBPs). The IGFBPs bind to and modify IGF activity. 
However, proteases such as pregnancy associated plasma protein A (PAPP-A) can cleave 
IGFBPs, releasing active IGF I to stimulate the IGF IR. Stimulation of the IGF IR leads to 
activation of the Akt or mitogen-activated protein kinase (MAPK) pathway that can lead to 
transformation, differentiation, proliferation and angiogenesis. Increased IGF IR expression 
has been reported in prostate cancer tissue relative to normal or benign tissue. Therefore, 
targeting the IGF pathway may prove useful in treating prostate cancer.
Tissue microarrays of prostate tumours were stained with an antibody to the IGF IR. 
IGF IR expression was significantly associated with Gleason grade with IGF IR expression 
higher in Gleason grade 3 relative to normal/benign prostatic hyperplasia (BPH) tissue and 
lower in Gleason grade 5 relative to Gleason grade 3 tissue. There was no significant 
difference in plasma IGF I levels between BPH and prostate cancer patients (Gleason score 
5 or Gleason score 7). However, there were significantly higher plasma levels of the IGFBP 
4 protease, PAPP-A, in Gleason score 5 patients relative to BPH patients.
PC-3M-luc2 cells are a human androgen independent cell line lacking the androgen 
receptor. The PC-3M-luc2 cells stably express luciferase allowing them to be imaged in  v iv o  
using bioluminescent imaging. Expression of the IGF pathway components was assessed in 
these cells to ensure the IGF pathway was active. Western blot analysis showed that the 
PC-3M-luc2 cells expressed the IGF IR which was activated by IGF I. IGFBP 3, IGFBP 4 
and PAPP-A were also expressed. PC-3M-luc2 cells were shown to proliferate in response 
to IGF (E3R) (an analogue of IGF I that cannot be bound by IGFBPs) by bromodeoxyuridine 
(BrdU) assay. However, the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)-2H-tetrazolium (MTS) assay showed PC-3M-luc2 cells proliferated in response 
to IGF I. IGF (E3R) also significantly increased vascular endothelial growth factor (VEGFies) 
expression in PC-3M-luc2 cells.
We assessed a PAPP-A resistant mouse IGFBP 4 (dBP4) as a strategy to neutralise 
the IGF I ligand. dBP4 was developed by mutation of the PAPP-A cleavage site from 119- 
KHMAKVRDIRSKMK-133 to 119-AAMAAVADASAMA-133 and cloned into pTriEx4 Neo 
plasmid with C-terminal His-tag for expression in human embryonic kidney cells. Purified 
dBP4 was resistant to PAPP-A cleavage and retained IGF I binding capacity. In  v itro , dBP4 
significantly inhibited tubule formation by endothelial cells relative to controls or IGF I treated 
cells suggesting that dBP4 possesses anti-angiogenic properties.
A Tet inducible expression system was used in  v iv o  to test the effect of dBP4 on 
tumour growth and metastasis in subcutaneous, orthotopic and experimental metastasis
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models of prostate cancer. The inducible Tet-On system allowed dBP4 expression to be 
induced by doxycycline. Following implantation of PC-3M-luc2 dBP4 cells into non-obese 
diabetic, severe combined immunodeficiency, gamma 2 receptor null (NSG) mice, tumours 
and metastasis were monitored by bioluminescent imaging and/or caliper measurements. In 
the subcutaneous tumour model, dBP4-expressing subcutaneous tumours were significantly 
smaller than controls and in the orthotopic model, bioluminescence was reduced relative to 
controls. Mice bearing dBP4-expressing subcutaneous tumours survived significantly longer 
than controls. There was no survival difference between mice bearing dBP4-expressing 
prostate tumours and controls. IGF I expression within the dBP4-expressing subcutaneous 
and prostate tumours was decreased relative to controls. Western blot analysis of tumour 
lysates showed that dBP4 inhibited IGF IR activation in both the subcutaneous and prostate 
tumours, which may be a consequence of reduced IGF I within the dBP4-expressing 
tumours. However, activated Akt was only decreased in the subcutaneous tumours relative 
to controls. As tumours require vasculature in order to supply oxygen and nutrients essential 
for tumour growth, expression of VEGF was assessed in the subcutaneous tumours. Control 
tumours expressed VEGF164/165, which was not expressed in the dBP4-expressing 
subcutaneous tumours.
dBP4 expression inhibited tumour growth in both subcutaneous and orthotopic-.. • 
prostate cancer models. As dBP4 expression inhibited endothelial cell tubule formation and 
abolished VEGF164/165 expression within PC-3M-luc2 tumours growing subcutaneously, this 
suggests that dBP4 has either anti-angiogenic or anti-proliferative properties and may 
therefore have value as a therapeutic for prostate cancer.
Chapter 1 
General Introduction
1.0 Introduction
1.1 Cancer
In 2008, 12.7 million new cancer cases and 7.6 million cancer deaths occurred worldwide. 
The number of new cancer cases ranged from 3.7 million in Eastern Asia to 1,800 in 
Micronesia/Polynesia. In men, the incidence of cancer is high in Northern America, 
Australia/New Zealand and in Northern and Western Europe because of the high rates of 
prostate cancer in these regions. The regions with the highest incidence rates in females are 
Northern America, Australia/New Zealand, Northern and Western Europe because of the 
high rates of breast cancer In these regions (GLOBOCAN2OO8 Cancer Fact Sheet, (2008)).
Between 2005 and 2007, 27,023 new cases of cancer were diagnosed in Ireland 
annually. The most common cancer excluding non-melanoma skin cancer (NMSC) was 
prostate cancer (2,462), followed by breast cancer (2,335), colorectal cancer (2,156) and 
lung cancer (1,810). Breast cancer was the most common cancer in women apart from 
NMSC and prostate cancer was the most common in men. In 2006, Ireland had the second 
highest cancer rates in Europe, with lung cancer being the major cause of cancer related 
mortality with over 1,600 deaths registered (National Cancer Registry, Cancer in Ireland 
1994 - 2007 (2009): From this data, it is clear that cancer is a major problem affecting the 
Irish population. Cancer incidence is rising yearly; this may be due to 'a ir increase "in 
screening programmes available to the public. As the life expectancy of the population 
increases, mortality rates from prostate cancer are also expected to rise.
1.2 Development of cancer
Carcinogenesis is the term used to describe cancer growth or development. Irrespective of 
the cause of cancer, initiation of the disease involves transformation of healthy cells. This 
causes a change in the cells’ genetic material, priming the cells to become cancerous. This 
change can occur spontaneously as a consequence of inherited mutations or by exposure to 
carcinogens. Tumours develop when a mutation occurs in key genes that are important in 
control of cell growth (Whang e t a l., 1998). Key genes involved in cancer formation are 
termed oncogenes and tumour suppressor genes (Pesche e t a l., 1998). C -m y c  is one such 
oncogene that regulates cell proliferation and is overexpressed in prostate cancer (Ellwood- 
Yen e t a l., 2003). Tumour suppressor phosphatase and tensin homolog (P T E N )  is 
commonly mutated or lost in prostate cancer, leading to overactivation of the Akt pathway 
(Me Menamin e t a/., 1999). Once the initial transformation event has occurred, other co­
factors such as growth factors and chemicals promote the growth of the cancerous cells 
(Liotta and Kohn, 2001).
Tumours can be broadly classed as either benign or malignant. Benign tumours grow 
slowly, are not aggressive, do not invade surrounding tissues and do not metastasise.
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In contrast, malignant tumours grow rapidly, are aggressive, invade surrounding tissues and 
cause metastasis. Once the tumour cells invade local tissue they can access and circulate 
in, the lymphatic or circulation system and cause metastasis in distant organs (Fidler e t a l., 
2007).
1.3 Prostate Cancer
Prostate cancer is the second most common cancer in men following skin cancer. One in 12 
men will be diagnosed with prostate cancer in their lifetime. In 2009, 2,758 men were 
diagnosed with the disease in Ireland and over 500 deaths occur annually. The number of 
cases of prostate cancer is rising annually (3 %) due to an increase in the life expectancy of 
the population. One of the largest changes between 1994 and 2009 was in the 55 - 64 year 
age group, with the number of cases increasing from 134 cases in 1994 to 859 in 2009 (15 
% increase annually). However, the largest relative increase was seen in younger men less 
than 55 years old (19 % annually). The number of men receiving prostate specific antigen 
(PSA) tests increased 5 fold from 1994 - 2004 and this may explain the increase in prostate 
cancer rates in young men (National Cancer Registry, Cancer trend No.3. Recent trends in 
prostate cancer (2010)).
1.3.1 Risk factors for prostate cancer
Risk factors increase an individual’s likelihood of developing a certain disease. In the case 
of prostate cancer, the main risk factors are age, family history, race and diet.
1.3.1.1 Age
Age is the strongest risk factor for prostate cancer. Prostate cancer is less common in men 
under the age of 40, but the risk of developing the disease increases in men over 50 years 
of age. The link with age may be due to an increase in oxidative stress seen with ageing. 
Ageing is associated with many metabolic disorders (Furukawa e t a l., 2004) and various 
cancers (Szatrowski and Nathan, 1991). An increase in oxidative stress may explain the 
increased incidence of prostate cancer with advancing age. Studies show an altered pro- 
oxidant:anti-oxidant status in prostatic tissue, with decreased anti-oxidant enzymes 
observed in prostatic intraepithelial neoplasia (PIN) and prostate cancer (Bostwick e t a l., 
2000). In  v itro , LNCaP cells, an androgen dependent human prostate cancer cell line, 
treated with a synthetic androgen (R1881) showed an increase in oxygen consumption and 
catalase activity relative to untreated controls (60% and 40%, respectively). R1881 
treatment resulted in a decrease in intracellular glutathione concentrations and an increase 
in Y-glutamyl transpeptidase activity in LNCaP cells relative to untreated controls suggesting
3
that androgen receptor signalling may alter the pro-oxidant:anti-oxidant balance of prostatic 
cells (Ripple e t  a/., 1997).
1.3.1.2 Family History
Family history is associated with an increased risk of prostate cancer. One study has shown 
that men with first degree relatives (father or brother) with prostate cancer had double the 
risk of developing prostate cancer and of early onset disease (Ahn e t  a/.} 2008). Men with a 
positive family history were four times more likely to have advanced stage disease when 
diagnosed (Ahn e t  a i ,  2008). Evidence also suggests that men are at a 70 % higher risk of 
developing prostate cancer if there is a family history of breast and/or ovarian cancer, 
indicating a possible genetic involvement (Cerhan e t  a i , 1999). As family history is a strong 
risk factor for prostate cancer, individuals with a family history of the disease should be 
screened early on to prevent diagnosis at an advanced stage.
1.3.1.3 Race/Ethnicity
African-American men have a higher risk of prostate cancer development relative to non 
African-Americans (Thompson e t a i ,  2006). African-American men also have a higher risk of 
high-grade disease (odds ratio: 2.61). Asian countries such as Japan have, the lowest 
incidence and risk of prostate cancer. The difference in prostate cancer risk between the two 
countries may be attributed to diet as well as genetic background, with higher consumption 
of red meat in the USA compared with fish in Japan. Lack of access to healthcare and 
health insurance was another factor involved in the higher rates of prostate cancer in 
African-American men (Jones e t a f., 2008).
1.3.1.4 Diet
The involvement of a high fat diet in prostate cancer risk is conflicting, with pre-clinical 
models showing that energy intake may be more important than dietary fat (Mukherjee e t a !., 
1999). However, a correlation was established between increased body weight and 
increased risk of prostate cancer (Andersson e t  a i ,  1997). Obesity has a strong link with 
prostate cancer risk; in particular men with a body mass index (BMI) greater than 30 are at a 
higher risk of high grade prostate cancer (Gong e t aL , 2006). This illustrates the importance 
of physical activity and weight control in prostate cancer development.
Vitamin E (a-tocopherol) is an anti-oxidant. Long-term supplementation with Vitamin 
E reduced prostate cancer incidence and mortality in smokers (Heinonen e t  a i ,  1998). In 
lung cancer, female A/J mice were injected with urethane to initiate tumour development, 
Vitamin E inhibited cell proliferation in the promotion phase of lung tumourigenesis via 
blockade of the ERK pathway (Yano e t a i ,  2000). A derivative of Vitamin E called Vitamin E
succinate (VES) inhibited the growth of androgen dependent LNCaP prostate cancer cells in  
v itro  by suppressing androgen receptor function and expression of PSA (Zhang e t a/., 
2002b).
Low levels of Vitamin D are hypothesised to be associated with increased cancer 
incidence and mortality in men (Giovannucci e t a/., 2006). Gene polymorphisms in the 
Vitamin D receptor (VDR) are thought to be associated with prostate cancer risk (Habuchi e t  
a l., 2000). Men with a particular polymorphism (B s m \) in the VDR were protected against 
prostate cancer and benign prostatic hyperplasia (BPH) in a Japanese cohort (Habuchi e t  
a l., 2000). However, further studies are needed to verify the correlation with age and other 
racial groups. Prostate cancer cells express the VDR (Skowronski e t a l., 1993) and in  v itro , 
1,25 dihydroxy vitamin D3l a metabolite of Vitamin D, inhibited the growth of androgen 
dependent LNCaP prostate cancer cells (Blutt e t a l., 1997). By decreasing calorie intake and 
increasing Vitamin D and E intake prostate cancer risk may be decreased substantially 
(Dunn e t a l., 1997, John e t a l., 2004, Heinonen e t a l., 1998). However, changing dietary 
habits does not completely rule out development of prostate cancer as other risk factors 
previously mentioned also play a role.
1.3.2 Treatment of prostate cancer *
Stage, grade, age, size o f  tumour, PSA levels and general health of the patient are all taken 
into account when deciding on treatment options. The most commonly available treatment 
options include active surveillance, surgery, external beam radiotherapy, brachytherapy, 
hormone therapy and chemotherapy.
1.3.2.1 Active Surveillance
In early stage prostate cancer, the tumour is usually slow growing. Some specialists may 
wait to see if the cancer is growing before deciding on a treatment. Advanced age may also 
be a clinical indicator for active surveillance. Active surveillance is also recommended if the 
cancer is small and localised to one area within the prostate and not causing any symptoms. 
Active surveillance involves regular check ups to monitor PSA levels with rectal examination 
and prostate biopsy carried out if needed. If PSA levels increase dramatically and symptoms 
begin to occur, other treatment options are then considered (Irish Cancer Society (2010)).
1.3.2.2 Surgery
In 2007, 27 % of prostate cancer patients in Ireland had a radical prostatectomy (National 
Cancer Registry, Cancer trend No.3. Recent trends in prostate cancer (2010)). A radical 
prostatectomy involves removal of the.whole prostate. This can occur only if the tumour is 
localised within the prostate. This procedure can be carried out by open surgery or “key­
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hole” surgery. The main side effects associated with radical prostatectomy are incontinence 
and impotence (Irish Cancer Society (2010)).
1.3.2.3 Radiation Therapy
The number of prostate cancer patients receiving radiotherapy has increased from 19 % in 
1996 to 41 % in 2007 (National Cancer Registry, Cancer trend No.3. Recent trends in 
prostate cancer (2010)). Radiation therapy damages the DNA within a ceil when it is dividing 
and as cancerous cells divide more rapidly than healthy cells, damage to healthy cells is 
reduced. This therapy is useful in the treatment of early stage prostate cancer and it is used 
if the cancer cannot be completely removed or a recurrence occurs. There are two types of 
radiation therapy available, external beam radiotherapy and brachytherapy.
1.3.2.3.1 External Beam Radiotherapy
External beam radiotherapy uses high energy X-rays to destroy cancer cells and cause as 
little harm to normal cells as possible. Side effects of this therapy include impotence, 
incontinence, tiredness, skin irritation, diarrhoea, upset stomach and burning urination 
(Prostate Cancer Treatment Guide, (2010)).
1.3.2.3.2 Brachytherapy
Brachytherapy is radiation therapy given within the body. Small radioactive pellets are 
placed into the tumour. Radiation is emitted slowly over time, but this therapy is only useful if 
the tumour is confined within the prostate. Commonly used radioactive isotopes are iodine- 
125 and palladium-103. Side effects include impotence, incontinence and blood in the urine 
(Prostate Cancer Treatment Guide, (2010)).
1.3.2.4 Chemotherapy
Chemotherapy is used in advanced prostate cancer with bone metastasis (Prostate 
Treatment Guide, (2010)). It is ineffective, against dormant métastasés that are not 
proliferating. Chemotherapy is given intravenously and the most commonly used drugs are 
paclitaxel (Morris, 2006) and docetaxel (Petrylak, 2006). Similar to radiation therapy these 
chemotherapeutics specifically target dividing cells in the body. As chemotherapy is not 
directed at any particular organ, chemotherapeutics kill normal proliferating cells, as well as 
cancer cells. Normal cells affected include those of hair follicles, gastro-intestinal (Gl) tract 
and bone marrow resulting in the side effects associated with chemotherapy - nausea, 
vomiting, hair loss, immunosuppression and infertility (Prostate Treatment Guide, (2010)).
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1.3.2.5 Hormone Therapy
The male hormone testosterone promotes the growth of androgen receptor positive prostate 
cancer, hence blocking its activity inhibits androgen dependent tumour growth (Ross e t a l . , 
1998). Hormone therapy can be given before surgery with the aim of shrinking primary 
tumours to allow surgical excision or as an adjuvant alongside another therapy (Aus e t a/., 
2002, Bolla e t a l., 2002) and also in metastatic prostate cancer (Messing e t a l., 1999). An 
orchidectomy can be carried out, which removes the testes thus removing the source of 
androgen production. Other hormone therapies include anti-androgens (flutamide) and 
luteinising hormone releasing hormone agonists (Tolis e t a l., 1982). The percentage of 
prostate cancer patients receiving hormone therapy has decreased from 46 % in 2000 to 35 
% in 2007. (National Cancer Registry, Cancer trend No.3. Recent trends in prostate cancer 
(2010)). Hormone therapies can be taken in tablet form as an outpatient, which avoids 
hospital visits and improves the patient’s quality of life. This may explain the apparent 
decrease in patient’s receiving hormone therapy, as all cases are not recorded by the 
National Cancer Registry (National Cancer Registry, Cancer trend No.3. Recent trends in 
prostate cancer (2010)). However, inhibition of testosterone production can lead to 
unwanted side effects: hot flashes, memory loss, erectile dysfunction and osteoporosis. 
Blocking testosterone production does not eradicate the tumour, but prevents disease, 
progression. Within 1 8 - 2 4  months of hormone therapy, the cancer may become resistant 
(Rau e t a l., 2005) particularly in advanced disease. This is known as hormone refractory or 
androgen independent (Al) disease.
1.4 Androgen independent prostate cancer
Androgens are involved in normal prostate growth as well as prostate cancer cell growth 
and proliferation. Androgens mediate their effects via the androgen receptor (AR) to 
promote growth and survival (Xu e t a l., 2006). Testosterone is the main circulating androgen 
that is primarily secreted by the testes. Testosterone enters the cell and is converted to 
dihydrotestosterone (DHT) by the enzyme 5a-reductase. DHT is a more active hormone 
with a higher affinity for the AR than testosterone (KD=4.4 nM vs. 10.9 nM, respectively) 
(Deslypere e t a l., 1992, Kumar e t a l., .1999). The AR is a member of the steroid-thyroid- 
retinoid receptor superfamily. It contains an activating domain, a ligand-binding domain and 
a DNA-binding domain. In the resting state, the AR is bound to heat shock proteins that 
prevent DNA binding. Upon binding of DHT, a conformational change in the AR leads to 
dissociation from the heat shock proteins and receptor phosphorylation occurs (Nazareth 
and Weigel, 1996). The ligand induced conformational change allows the AR to form 
homodimers that bind to androgen response elements (ARE) in promoter regions of target 
genes. Once the AR is bound to the DNA co-activators, co-regulatory proteins or co­
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repressors are recruited. During androgen independent progression, prostate cancer ceils 
develop numerous cellular pathways to survive in an androgen depleted environment. The 
main mechanisms are hypersensitive pathway, a promiscuous pathway, an outlaw pathway 
and a bypass pathway (Pienta and Bradley, 2006).
1.4.1 Hypersensitive Pathway
One mechanism by which prostate cancer cells circumvent androgen blockade is by 
developing the ability to respond to low levels of androgen. AR amplification has been 
observed in Al prostate cancer, with a 6 fold higher expression of AR in Al prostate cancer 
patients relative to androgen dependent patients (Linja e t a/., 2001). It has also been shown 
that prostate cancer cells (CWR22, LNCaP, LuCap23, LuCap35, LuCap41, LAPC-4 and 
LAPC-9) grown subcutaneously in castrated nude mice (androgen-depleted) required 80 % 
lower concentrations of androgen relative to the same cells growing in non-castrated nude 
mice (androgen sensitive) (Chen e t a l 2004). Alternatively, increasing AR expression 
allows for enhanced ligand binding even in an androgen-depleted environment.
A second mechanism is increased sensitivity of the AR to androgens. Gregory e t a l  
(2001) used androgen dependent LNCaP cells and cell lines derived from recurrent prostate
‘"■s.
cancer tumours to show that in the absence of androgen.the AR was more stable .in ,the 
recurrent , tumours relative to the LNCaP cells and this stability was associated with 
hypersensitivity to DHT. The concentration of DHT needed to stimulate growth in the 
recurrent tumour cell lines was 4 orders of magnitude lower than that needed for the 
androgen dependent LNCaP cells (Gregory e t a l., 2001).
The third hypersensitive mechanism proposed is increased local production of 
androgens by prostate cancer cells. This most likely occurs by increased rate of conversion 
of testosterone to DHT by 5a-reductase. Several studies support this mechanism. One 
study showed that ethnic groups with higher levels of 5a-reductase activity had a higher rate 
of prostate cancer (Makridakis e t a l., 1997). Also, genes involved in steroid biosynthesis 
have been found to be overexpressed in recurrent prostate tumours (Holzbeierlein e t a l.,
2004).
1.4.2 Promiscuous Pathway
The AR is specifically activated by testosterone and DHT, but mutations in the AR broaden 
its specificity. The majority of the AR mutations are present in the ligand-binding domains 
(Me Phaul e t a l., 1992). These mutations allow non-androgenic steroid molecules, usually in 
circulation within the body and anti-androgens to activate the AR (Miyamoto et al., 1998,
Zhao et al., 2000). Mutations in the AR are more frequent in metastatic Al prostate cancer 
(Taplin e t a l., 1995) and mutations in the AR are involved in the progression of prostate
4i.
i
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cancer to androgen independence (Tilley e t a/., 1996). An anti-androgen syndrome has 
been associated with a mutated AR. Flutamide, a commonly used anti-androgen can 
activate the mutated AR (Miyamoto e t  a/., 1998). Metastatic prostate cancer patients 
(n=107) given flutamide showed a progression in disease, however upon withdrawal of 
flutamide, PSA levels decreased by 50-80 % (Small and Srinivas, 1995). Androgen ablation 
may lead to clonal selection of prostate cancer cells harbouring the AR mutations thus 
conferring a growth advantage. Alterations in proteins that act together with the AR, such as 
co-activators or co-repressors, which, act as intermediaries between the AR and 
transcriptional machinery, have been observed in Al disease. An increase in co-activator 
levels such as* cell division cycle 25b has been shown in higher Gleason score tumours 
relative to lower Gleason score tumours (Comuzzi e t a l., 2003, Ngan e t a l., 2003).
1.4.3 Outlaw Pathway
The outlaw pathway involves activation of the AR independent of androgens. Growth and 
proliferation of tumour cells is no longer under androgen control. Growth factors including 
insulin-like growth factor I (IGF I) and epidermal growth factor (EGF) directly phosphorylate 
and activate the AR (Culig e t a l., 1994). Androgen dependent genes can be activated by de­
regulated signal transduction pathways. The HER2/Neu receptor is a member of thergj3F 
receptor family and overexpression of this receptor in androgen dependent LAPC-4 prostate 
cancer cells converted them to Al cells. HER2/Neu expression led to activation of androgen 
receptor dependent genes in the absence of ligand (Craft e t a l., 1999). PTEN, a tumour 
suppressor, which negatively regulates Akt activity (Stambolic e t a l., 1998) is often lost or 
mutated in advanced prostate cancer (Li e t a l., 1997, Me Menamin e t a l., 1999). Akt has 
been implicated in tumourigenesis due to its anti-apoptotic activity. In Zhou e t a l, (2000b) 
Akt phosphorylated and inactivated the pro-apoptotic proteins Bcl-2 associated death 
promoter (BAD) and procaspase-9 in hybrid motor neuron 1 cells. Therefore, by blocking Akt 
activity, PTEN allows cells to undergo apoptosis. Therefore, loss of PTEN results in 
resistance to apoptosis (Stambolic e t  a l (1998)). Prostate cancer cells that have lost PTEN 
function have increased Akt activity (Graff e t a i., 2000). Graff e t a ! (2000) established 
androgen independent cell lines (LNAI) from xenografts of LNCaP cells grown 
subcutaneously in castrated male nude mice. In that study, increased Akt activity was 
observed in the Al LNAI cells relative to the parental androgen dependent LNCaP cells. 
High levels of phospho Akt in prostate cancer is a strong predictor of biochemical recurrence 
(Ayala e t a l., 2004). Akt may also be an alternative pathway by which HER2/Neu activates 
the AR signalling as the HER2/Neu receptor activates Akt (Zhou et al., 2000).
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1.4.4 Bypass Pathway
This mechanism does not require the AR and its signalling cascade allowing Al prostate 
cancer cells to proliferate independently of ligand mediated AR activation. The most studied 
bypass pathway involves modulation of apoptosis. In androgen dependent cells the AR 
stimulates cell proliferation and survival, therefore depletion of androgens leads to death of 
the androgen dependent cells. However, in Al cells, anti-apoptotic molecules are frequently 
up-regulated. Bcl-2 levels are higher in Al prostate carcinomas relative to androgen 
dependent prostate carcinomas, suggesting that Bcl-2 is involved in the progression from 
androgen dependent to Al disease (Me Donnell e t  a l., 1992). Overexpression of Bcl-2 
protects androgen dependent LNCaP prostate cancer cells from apoptosis in  v itro  and in a 
subcutaneous nude mouse model. LNCaP/bcl-2 tumours grew in castrated mice compared 
with parental LNCaP cells, which did not form tumours in castrated mice (Raffo e t  a/., 
1995). However, overexpression of Bcl-2 is not essential for the development of Al prostate 
cancer (Furuya e t a l., 1996) suggesting a role for other bypass mechanisms or substitution 
by one of the other pathways mentioned.
1.5 Metastasis
Metastasis occurs, when cancer spreads from where.it first arose (primary tumour) to^other 
organs in the body. Métastasés that arise from the primary tumour prior to removal can lie 
dormant before they are detected, making them difficult to treat. Metastasis occurs more 
often in advanced cancers where cells become more invasive and aggressive. The 
formation of métastasés is a highly selective process consisting of many interrelated steps. 
In order for cancer cells to metastasise they must first disseminate from the primary tumour. 
Some tumour cells detach from neighbouring cells and then invade the extracellular matrix, 
which requires motility, migration of the tumour cells and breakdown of the extracellular 
matrix (Hasan e t a l., 1998, Hazan e t a l., 2000, Webber e t a t., 1995). Tumour cells can then 
penetrate blood vessels and the lymphatic system thus entering the circulation. While 
circulating in the blood, tumour cells must evade immune cells and the mechanical stress of 
blood flow. Tumour cells that survive will leave the blood circulation and develop a 
secondary tumour at another site. This complex process involves factors and events such as 
invasion, migration, angiogenesis, interaction between tumour cells and the 
microenvironment (Fidler e t a l., 2007). Microenvironment is important in establishment of 
metastasis, which was first shown by Stephen Paget (1889) - The ‘seed and soil 
hypothesis’. He proposed that the tumour cell (seed) has a specific affinity for a particular 
organ (soil) and the métastasés would only grow if they were compatible (Paget, 1889).
The role of microenvironment in cancer involves the host tissue participating in the 
progression of the disease, such as secreting certain growth factors which can enhance
10
• | M
migration, proliferation and survival of tumour cells (Liotta and Kohn, 2001). Interaction with 
the host’s microenvironment results,, in phenotypic differences between cells from the 
primary tumour and cells from the metastasis. Cells that form the metastasis have 
encountered many different stimuli, which can make them more aggressive than the primary 
tumour cells.
One factor which contributes to metastasis is hypoxia, which develops as the tumour 
grows. Hypoxia up-regulates a transcription factor called hypoxia inducible factor (HIF 1a), 
which then activates vascular endothelial growth factor (VEGF) and other hypoxia regulated 
genes. Under normoxia HIF 1a is degraded by an enzyme called VHL (Von Hippel Lindau), 
but in many cancers this enzyme is mutated resulting in de-regulated expression of HIF 1a 
(Gnarra e t  a/., 1994). It has been reported that in breast cancer cells, (DU-4475, MCF-7, T- 
47D, Hs578T, MDA-MB-468, MDA-MB-361, MDA-MB-231,) normal VHL decreased CXCR4 
receptor expression (chemokine receptor). Binding of this receptor to its ligand (CXC4), 
allows migrating cells to navigate to specific organs where there are also high levels of the 
ligand (Muller e t a/., 2001).
1.5.1 Bone metastasis
Bone is the most common metastatic s ite  rc f prostate c a n c e r ;  with SO. % of-patients yvith 
advanced prostate cancer having skeletal metastasis (Bubendorf e t a/., 2000). Skeletal 
metastases result in complications that affect the patients quality of life such as bone pain, 
impaired mobility and spinal cord compression. Certain factors account for the frequency of 
bone metastasis in prostate cancer. The blood supply to the prostate may facilitate' 
dissemination of tumour cells to certain bone types. A venous plexus surrounds the prostate 
and this connects to the venous drainage in the spine. This collection of veins may 
potentially be one of the reasons why lumbrosacral metastases are common in advanced 
prostate cancer (Batson, 1940). However, anatomical explanation does not account for 
other areas of bone involved in bone metastasis. As previously mentioned the ‘seed and soil 
hypothesis’ may provide more information about the formation of bone metastases. Tumour 
cells express adhesion molecules that allow them to bind to bone marrow stromal cells. In 
particular avp3 integrin is highly expressed in androgen independent PC-3 cells and it may 
play a role in the attachment of tumour cells to bone cells (Zheng e t  a/., 1999). Bone itself is 
a rich source of growth factors including IGF I, transforming growth factor p (TGF p), 
fibroblast growth factor (FGF) and platelet-derived growth fa c to r  (PDGF) (Hauschka e t a i. t 
1986), all of which can stimulate growth of prostate cancer cells. In prostate cancer, 
osteoblastic lesions are commonly seen (Hall e t  a/., 2005). Osteoblasts are bone-forming 
cells. Osteoblastic bone metastases result in an imbalance between bone resorption and 
bone formation, the latter being favoured. Prostate cancer cells secrete numerous factors
that stimulate osteoblasts, such as IGFs, VEGF, endothelin-1 (ET-1 ), urokinase 
plasminogen activator (uPA) and PSA (Achbarou e t  a/., 1994, Granchi e t  a l., 2001, Kawada 
e t  a l., 2006, Wang and Klein, 2007, Webber e t a l., 1995). Plasma levels of IGFBP 3 are 
lower in prostate cancer patients with bone metastases relative to controls and IGFBP 3 
levels were an independent predictor of biochemical progression (Shariat e t a l., 2002).
VEGF promotes bone formation by directly activating osteoblasts and facilitating 
angiogenesis (Ackerstaff e t a l., 2004). Evidence suggests ET-1, a potent vasoconstrictor, is 
a central mediator of osteoblastic metastasis (Yin e t  a l., 2003). Serum levels of ET-1 are 
increased in prostate cancer patients with osteoblastic lesions relative to controls or organ 
confined prostate cancer patients (Nelson e t a l., 1995). ET-1 mediates its effects via the ETA 
receptor. Atrasentan, an ETA receptor antagonist was used in a clinical trial in Al metastatic 
prostate cancer. Atrasentan delayed PSA progression, attenuated acid phosphatase and 
reduced skeletal morbidity (Carducci e t a l 2003). Proteases such as uPA and PSA are 
also implicated in osteoblastic bone metastasis. uPA is produced by prostate cancer cells 
and overproduction of uPA in Mat LyLu rat prostate carcinoma cells following intracardiac 
injection (Copenhagen rats) led to increased skeletal metastases relative to controls 
(Achbarou e t a l., 1994). uPA can also cleave IGFBP 3 resulting in an increase in free IGF I 
(Bang and Fielder, 1997). PSA is a kallikrein serine proteinase secreted by. prostate canc^r*^
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cells. Like uPA, PSA can also cleave IGFBPs (IGFBP 3, 4 and 5) (Rehault e t a l., 2001) 
enhancing the effects of IGF I. While osteolytic lesions are more commonly seen in 
metastatic breast cancer patients (Park e t a l., 2007), metastatic prostate cancer patients can 
also develop osteolytic lesions. Osteolytic bone metastases involve destruction and 
resorption of bone with the involvement of osteoclasts. Elevated serum levels of bone 
resorption markers such as alkaline phosphatase are seen in prostate cancer patients and 
can be used as marker for the presence of bone metastasis (Jung e t  a l., 2004).
In prostate cancer and many other cancers, the major clinical challenge is metastasis 
as the primary tumour can normally be effectively treated by surgery, chemotherapy, 
radiotherapy or a combination of these therapies. Treatment options for metastatic disease 
are limited and commonly involve radiation therapy, chemotherapy and bisphosphonates.
Treatment of PC-3, DU 145 and LNCaP cells with pamidronate or zoledronate significantly 
reduced the growth of all three cell lines In  v itro  (Lee e t a/., 2001). Long-term treatment with 
zoledronic acid reduced the incidence of skeletal related events (pathologic fracture, spinal 
cord compression, radiation therapy or surgery to bone) in Al metastatic prostate cancer 
patients compared with placebo controls (Saad e t a l., 2004). Bisphosphonates block bone 
resorption when administered to breast cancer patients at a high risk of bone metastasis, 
Administration of the bisphosphonate, clodronate, decreased the incidence of bone 
metastasis along with the death rate in high risk breast cancer patients (Powles e t a l.,
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2002). As metastases are heterogeneous from organ to organ and tissue specific, it makes 
it difficult to develop a therapy that will target all metastases. Therapies targeting growth 
factors and proteases present either on the tumour cells or in the microenvironment may be 
of benefit in inhibiting the formation of metastases.
1.6 Insulin-like growth factor (IGF) pathway
The IGF pathway is important in cell growth, proliferation and differentiation (Coolican e t a l.,
1997). The two ligands, IGF I and IGF II, are single chain polypeptides and have 62 % 
homology in their amino acid sequences; their structure also resembles that of proinsulin 
(Rinderknecht and Humbel, 1978). The main production sites for both ligands are the liver 
and bone marrow. IGF I is a potent mitogen for a number of cells and it exerts its mitogenic 
activity by increasing DNA synthesis (Dufourny e t a l., 1997). IGF I also inhibits apoptosis by 
stimulating the expression of Bel proteins which block the apoptosis pathway (Parrizas and 
Leroith, 1997). IGF II is thought to play a less important role in postnatal growth than IGF I. 
IGF II is crucial during embryonic and foetal growth (Chen e t a l., 2010). IGF I levels change 
with age as levels increase from birth to puberty and then decrease with age. However, IGF
II levels remain stable after puberty. The actions of both IGF I and IGF II are mediated 
through the insulin-like growth.factor I receptor (IGF IR); IGF. II can.also- interactwith the IGF
II R. IGF I has a 15-fold higher binding affinity for the IGF IR than |GF H (Germain-Lee e t a l., 
1992). The IGF IR and IGF MR are glycoproteins expressed on the cell surface. Moreover, 
these receptors differ structurally and functionally. The IGF IR is a receptor tyrosine kinase 
consisting of two identical a  subunits and two identical ¡3 subunits. The a subunits are 
located extracellularly forming the ligand-binding domain and the p subunits are located 
intracellularly forming the tyrosine kinase domain. The IGF IR shares 60 % homology with 
the insulin receptor (IR) (Ullrich et a l., 1986). Hybrid receptors also form composed of one a 
subunit and one p subunit of the IGF IR and one a subunit and one p subunit of the IR, its 
binding affinity for IGF I higher than that for insulin. Therefore, hybrid receptors are thought 
to function predominantly as an IGF I receptor (Johansson and Arnqvist, 2006).
The IGF HR is monomeric, has no tyrosine kinase activity and binds only IGF II 
(Morgan et al., 1987, Oates et al., 1998). Binding of IGF II to IGF MR leads to degradation of 
IGF II, therefore the IGF MR acts an antagonist to IGF II reducing its biological activity 
(Oates e t a l., 1998). Ligand binding to the IGF IR leads to a conformational change resulting 
in autophosphorylation of tyrosine residues located on the p subunit, allowing docking of 
adaptor proteins, insulin receptor substrate 1 (IRS 1) and Src homology (SH)-2 containing 
protein (She) (Tartare-Deckert e t a l., 1995). The IGF IR activates two signal transduction 
pathways, the RAS mitogen-activated protein kinase (MAPK) and the phosphatidylinositol 3 
kinase (PI3K)/Akt pathway (Valentinis e t a l., 1999). Activation of the MAPK and PI3K/Akt
13
pathway results in activation of anti-apoptotic pathways, cell proliferation and differentiation 
(Gao e t a t., 2000, Ge e t  a/., 2007, Parrizas e t  a/., 1997b). Figure 1.1 summarises the IGF 
pathway components.
1.6.1 Insulin-like growth factor binding proteins (IGFBPs)
Several insulin-like growth factor binding proteins (IGFBPs) regulate IGF bioavailability and 
activity. IGFBPs share some structural homology, which is highly conserved. A conserved 
amino terminal (N-terminal) domain contains disulfide bonds and the conserved carboxy 
terminal (G-terminal) is cysteine rich. IGF binding occurs at the N terminal, but the C 
terminal is also necessary for IGF binding (Qin e t a l., 1998). The central domain is not 
conserved and contains sites for post translational modification and proteolytic cleavage 
(Conover e t a l., 1995a). The major role of IGFBPs is to transport IGFs, protect IGFs from 
degradation and regulate their interaction with the IGF IR. IGFBPs have a higher affinity for 
IGFs than the IGF IR. Therefore, IGFBP binding to IGFs can inhibit activation of IGF IR 
(Gockerman e t a l., 1995).
The majority of IGF I in circulation is bound to IGFBP 3 in a complex with an acid 
labile subunit (ALS), which.acts as a reservoir for IGF I and increases the half life of IGF I 
within the body (Payet e t  a l., 2004), IGFBPs have IGF dependent and independent effpqts,. ... 
which inhibit or enhance the actions of IGFs. IGFBP 1, JGFBP. 2 and IGFBP 5 have been 
shown to have IGF independent roles effecting cell migration, apoptosis and cell growth 
(Chesik e t a i ,  2010, Frommer e t  a i., 2006, Tripathi e t  a l., 2009). IGFBP 3 also exerts IGF 
independent effects. One study discovered an IGFBP 3 death receptor which binds IGFBP 3 
and induced apoptosis in breast (MDA-231) and prostate cancer (M12) cells implanted 
subcutaneously in female athymic mice (Ingermann e t a l., 2010). Unlike the other IGFBPs, 
IGFBP 4 and IGFBP 6 do not enhance IGF activity. IGFBP 4 exclusively inhibits IGFs. It 
exists in two forms, non-glycosylated (24 kDa) and N-glycosylated (28 kDa). IGFBP 4 binds 
IGF I and IGF II with equal affinity (Kiefer e t a l., 1992). Local administration of IGFBP 4 in 
mouse bone inhibits bone formation (Miyakoshi e t a l., 1999). Overexpression of IGFBP 4 in 
smooth muscle cells of transgenic mice using a smooth muscle a-actin-IGFBP 4 fusion gene 
induced smooth muscle hypoplasia (Wang e t a l., 1998). This indicates that IGFBP 4 inhibits 
IGF I actions. IGFBP 4 proteolysis is important in regulating IGF I bioavailability. PSA 
cleaves IGFBP 3, IGFBP 4 and IGFBP 5 (Rehault e t  a l., 2001) releasing active IGF I. The 
metalloproteinase, pregnancy-associated plasma protein A (PAPP-A), is the main protease 
involved in IGFBP 4 cleavage (Boldt and Conover, 2007). PAPP-A cleaves IGFBP 4 into two 
fragments of 14 kDa and 18 kDa with reduced affinity for IGF I (Conover e t aL, 1995a). 
Regulation of IGFBP proteolysis remains poorly understood. It has been shown that IGFs 
modulate IGFBP degradation, suggesting IGFs work in an autocrine manner to regulate
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their own action (Angelloz-Nicoud and Binoux, 1995). Due to the importance of the IGF 
pathway in cell growth and differentiation, deregulation of this pathway leads to aberrant 
growth of cells, which is seen in cancer. The involvement of the IGF pathway in numerous 
cancers including prostate cancer has been well established (Browne et a/., 2011, Chan et 
a/., 2002).
1.6.2 IGF pathway and prostate cancer
IGF I and IGF II mitogenic effects have been shown in vitro in a wide variety of cell lines 
including prostate and breast cancer cell lines (Connolly and Rose, 1994, Stewart et a/., 
1990). In vivo experiments in transgenic mice show that overexpression of IGF I under the 
control of the bovine keratin 5 promoter or IGF II under control of mouse mammary tumour 
virus promoter increased the likelihood of spontaneous tumour development in certain 
tissues such .as mammary ducts and lungs (De Ostrovich et a/., 2008, Moorehead et a/.,
2003). The IGF IR is involved in transformation and maintenance of a transformed 
phenotype (Kaleko et a/., 1990). Constitutively active IGF IR expression in normal mammary 
epithelial cells caused transformation of cells and epithelial to meschenchymal transition 
(EMT) in vitro (Kim et a/., 2007).
The IGF !R plays an important role-in numerous cancers; IGF IR is oyerexpressedjn,, 
certain cancers (breast, prostate, sarcoma) and is associated with more aggressive tumours 
(Xie et a/., 1999). As well as IGF IR involvement in primary tumours, the IGF IR has been 
implicated in metastasis. Neuroblastoma metastasises to bone. Neuroblastoma cell lines 
constitutively expressing high levels of IGF IR (highly aggressive, IMR32) or transfected with 
IGF IR (SHEP/IGFR) adhered tightly to bone stromal cells following intratibial injection into 
female SCID mice relative to non-aggressive cells (SHEP) expressing low levels of IGF IR 
(Van Golen et a/., 2006). Furthermore, inhibition of the IGF IR inhibits metastasis. MDA-MB- 
435 breast cancer cells transfected with a dominant negative form of the IGF IR showed 
decreased metastasis formation following implantation into the mammary fat pad of female 
nude mice relative to vector controls (Dunn et a/., 1998). Specifically, in prostate cancer, 
the IGF IR is overexpressed in primary tumours and remains expressed in metastatic 
disease (Hellawell et a/., 2002). Numerous studies have shown that elevated IGF I levels 
increase the risk of prostate cancer development. An association between serum IGF I 
levels and prostate cancer risk was seen in a cohort study (n=210 newly diagnosed prostate 
cancer patients). A strong association between elevated IGF I levels and prostate cancer 
risk was observed in men younger than 70 years of age (odds ratio: 2.93) (Wolk et al.t
1998). In 1998, results of a prospective case control study of IGF I and IGFBP 3 was 
reported. Blood samples were taken in 1982 from 14,916 male physicians, frozen and
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Figure 1.1 IGF signalling pathway. IGF I/ll are bound by IGFBPs in circulation; upon 
proteolysis of IGFBPs both ligands are free to bind the IGF IR. Ligand binding to IGF IR 
results in autophosphorylation of tyrosine residues in the p subunit. Docking molecules 
IRS-1 and She interact with phosphorylated tyrosines in the p subunit and activate the 
PI3K and MAPK pathways, respectively. Akt phosphorylation inhibits apoptosis and 
activates mammalian target of rapamycm (mTOR) leading to cell proliferation, growth and 
protein synthesis. PTEN negatively regulates Akt thus inhibiting its actions. Activation of 
Ras ultimately leads to phosphorylation of ERK, which stimulates cell proliferation. 
Binding of IGF II to the IGF MR leads to degradation of IGF II via lysozyme mediated 
pathway.
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archived. 10 years later in 1992, 520 individuals in this cohort were diagnosed with prostate 
cancer. Plasma IGF I and IGFBP 3 levels were measured in the 1982 samples. Men with 
high IGF I levels and low IGFBP 3 levels had increased risk for advanced-stage prostate 
cancer compared with men with low levels of both. The association was stronger in older 
men (Chan et al, 2002). Another cohort study (n=52) using blood samples from caises with 
histologically confirmed prostate cancer in Sweden showed an age-adjusted odds ratio for 
development of prostate cancer of 1.56. It was shown that the association between IGF I 
levels and prostate cancer risk was higher in the younger age group (Mantzoros et a/.,
1997). Overall, these studies show an increased risk of developing prostate cancer with 
elevated IGF I levels.
As previously mentioned, IGFBPs regulate IGF I bioavailability. IGFBP 2 is increased 
in malignant prostate tissue and IGFBP 3 is decreased, relative to normal epithelium 
(Tennant et a/., 1996b). PSA is elevated in prostate cancer and cleaves IGFBP 3 (Rehault et 
a/., 2001). IGFBP 3 inhibits IGF I interaction with IGF IR, therefore cleavage of IGFBP 3 by 
PSA reverses this inhibition. IGFBP 2, IGFBP 3 and IGFBP 5 expression changes with 
Gleason score. High levels of IGFBP 2, IGFBP 5 and low levels of IGFBP 3 are observed in 
high Gleason score tumours relative to low Gleason score or benign tissue (Figueroa et a/.,
1998). Increased IGFBP 2 may play an important-role in ^positive growth regulationjry 
prostate cancer. As well as elevated IGFBP 2 and decreased IGFBP 3 in prostate cancer 
tissue, serum IGFBP 2 is increased in prostate cancer relative to controls and is highly 
correlated with a rise in PSA (r =0.619) (Cohen et a/., 1993). Serum IGFBP 3 levels are 
decreased in prostate cancer relative to controls (Kanety et a l 1993). As PSA levels rise 
this allows for liberation of more IGF I suggesting that IGF I plays an active role in prostate 
cancer progression. IGFBP 5 may enhance IGF I interaction with IGF IR as IGFBP 5 binds 
the extracellular matrix (Jones et a/., 1993).
Signal transduction pathways downstream of the (GF IR also become de-regulated in 
cancer making the IGF pathway a target for inhibition in cancers overexpressing the IGF IR. 
PTEN, a tumour suppressor, is frequently lost or mutated in prostate cancer (Li et al., 1997). 
Loss of PTEN correlates with high Gleason score and advanced stage prostate cancer 
(Me Menamin et al., 1999). PTEN negatively regulates Akt, therefore loss of PTEN leads to 
increased activity of Akt (Graff et a/., 2000). Phospho Akt is a strong predictor of 
biochemical recurrence (Ayala et a/., 2004) and is higher in high Gleason score (8-10) 
prostate cancer relative to PIN or lower Gleason scores (Malik et a/., 2002).
1.6.3 Targeting the IGF signalling pathway
Due to the involvement of the IGF signalling pathway in cancer development and 
progression, numerous strategies have been developed to target this pathway, which
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include reducing IGF I production, neutralising IGFs, anti-sense strategies, monoclonal 
antibodies (mAbs) against the IGF IR and IGF IR tyrosine kinase inhibitors.
1.6.3.1 Therapies targeting the IGF I ligand
As IGF I levels are associated with increased risk of prostate and breast cancer 
(Schernhammer et al., 2005, Stattin et al., 2000), reducing circulating IGF I levels could 
reduce the incidence of cancer. Growth hormone-releasing-hormone (GHRH) antagonists 
have been developed. Growth hormone (GH) regulates synthesis and secretion of IGF I 
within the liver (Mathews et a/., 1986). Therefore, GHRH antagonists inhibit GH release thus 
inhibiting IGF I synthesis and secretion. The peptide JV-1-38 is a GHRH antagonist that 
inhibited growth of NCI-M838 non-small cell lung cancer cells in vitro and in athymic mice 
(Szereday et al., 2003). JV-1-38 also exerted anti-tumour activity in prostate cancer models. 
Nude mice bearing subcutaneous tumours of LNCaP (androgen dependent), MDA-PCa-2b 
(androgen dependent) or DU145 (androgen independent) cells were treated with JV-1-38. 
Androgen sensitive models showed JV-1-38 potentiated anti-tumour effect following 
androgen deprivation by castration only relative to castrated controls. JV-1-38 alone 
inhibited the growth of androgen independent tumours (Letsch et a/., 2003). Pegvisomant, 
pegylated GH, is a GH receptor antagonist that was developed and approved f^or treatment 
of acromegaly where GH excess is seen. Pegvisomant had anti-tumour activity in 15 primary 
cultures of human meningiomas tumours implanted subcutaneously in nude mice (Me 
Cutcheon et al., 2001).
An additional strategy targeting the IGF pathway is to neutralise IGF I/IGF II 
therefore inhibiting binding to the IGF IR. The inhibitory effects of IGFBPs on IGFs and the 
IGF-independent effects of IGFBPs have been investigated as possible therapeutics in 
cancer. In prostate cancer, epidemiological studies have demonstrated that high plasma 
levels of IGF I and low levels of IGFBP 3 are associated with an increased risk of prostate 
cancer development (Winter et a/., 2001). IGFBP 3 is the most studied of the binding 
proteins as the majority of IGF I (70 %) in circulation is bound to IGFBP 3 as a complex with 
ALS (Baxter et a l 1989). Recombinant IGFBP 3 (rhIGFBP 3) inhibits the growth of HER2- 
overexpressing breast tumours and potentiates Herceptin™ (Roche) activity in vitro and in 
vivo. MCF-7/HER 2-18 (HER 2 transfected cells) xenografts (female athymic mice) were 
treated with Herceptin™, rhIGFBP 3 or both for 3 weeks. Herceptin™ treatment did inhibit 
tumour growth. However, when Herceptin™ and rhIGFBP 3 were given in combination, a 
statistically significant reduction in tumour volume (76-106 %) was noted relative to controls 
(Jerome et aL, 2006). M12 (malignant prostate cancer cell line) cells transfected with IGFBP
3 implanted subcutaneously into male nude athymic mice resulted in smaller tumours 
relative to controls. (Devi et a/., 2002). Lung cancer (M-3LL) cells were used in vivo (female
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nude, mice) to test the effect of rhIGFBP 3 alone or with carboplatin (Bristol-Myers Squibb). 
In the lung cancer model, rhIGFBP 3 had a greater growth-inhibitory effect than carboplatin. 
The combination of rhIGFBP 3 and carboplatin did not result in an enhancement of the anti­
proliferative effects of either agent alone (Alami et a/., 2008). IGFBP 3 binds specific 
proteins on the cell surface such as the IGFBP-3R, which mediate inhibition of cell 
proliferation (Ingermann et a/., 2010, Oh et a/., 1993a). A mutant IGFBP 3 unable to bind 
IGF I and IGF II stimulated apoptosis in androgen independent PC-3 prostate cancer cells in 
vitro (Hong et ai., 2002). Ingermann et a\ (2010) identified a novel cell death receptor 
mediating IGFBP 3 induced apoptosis. This study discovered that the IGFBP-3R binds 
specifically to IGFBP 3. In breast and prostate cancer tissue, IGFBP 3 and IGFBP-3R levels 
were significantly reduced relative to benign breast or prostate tissue, respectively. In 
subcutaneous models of breast (MDA-231 cells) and prostate (M12 cells) cancer, 
intratumour injection of IGFBP-3R resulted in a 40% reduction in tumour mass with little 
toxicity to the mice relative to controls (Ingermann et a/., 2010). IGFBP 3 has been used in 
combination with other drugs. The retinoid X receptor-a (RXR) has been identified as a 
nuclear binding partner to IGFBP 3 which is involved in IGFBP 3 induced apoptosis (Liu et 
a/., 2005). A RXR ligand, VTP194204 (Vitae Pharmaceuticals) and rhIGFBP 3 in 
combination were shown to have a synergistic effect on prostate cancer sGihapGptosisv/? 
vitro and in vivo in a LAPC-4 (androgen dependent) subcutaneous tumour models In vivo, 
treatment with both VTP194204 and rhIGFBP 3 inhibited tumour growth and reduced serum 
PSA levels relative to either treatment alone (Liu et ai., 2005). Prostates of IGFBP 3 
knockout mice (IGFBP 3 KO) failed to undergo apoptosis or develop prostate tumours. 
Following castration, lung metastases developed in 55 % of IGFBP 3 KO mice relative to 
controls. The IGFBP 3 KO was crossed with a c-Myc driven prostate cancer model, which 
develops slow growing, non-metastatic tumours. Cell lines derived from the Myc:IGFBP 3 
KO tumours were more aggressive in terms of proliferation, invasion and colony formation 
relative to Myc tumour cell lines in vitro (Mehta et ai., 2011). However, human ectocervical 
cells, immortalised by retroviral transduction with the human papillomavirus type 16 E6/E7 
secreted high levels of IGFBP 3 and exerted an increased sensitivity to IGF I, including 
increased cell proliferation (Baege et ai., 2004).
IGFBP 2 is the second most abundant IGFBP in circulation and it is often elevated in 
prostate cancer and involved in cancer progression (Busund et a/., 2005, Degraff et al., 
2009). Therapeutic strategies have been developed to block IGFBP 2 activity. In androgen 
dependent LAPC-4 prostate cancer cells, IGFBP 2 stimulated growth, but had a growth 
inhibitory effect on normal prostatic epithelial cells (Moore et a/., 2003). MDA-MB-231BP-2 
(oestrogen receptor negative) breast cancer cells constitutively overexpressing IGFBP 2 
grew quicker and were more resistant to paclitaxel in vitro and in vivo relative to the parental
cells (So et al., 2008). By using an antisense oligonucleotide to IGFBP 2 (OGX-225) the 
aggressive phenotype of MDA-MB-231 BP-2 cells was decreased in vitro and in vivo (So et 
ai, 2008). A Phase I clinical trial has been established in order to test the side effects of 
using a DNA plasmid based vaccine encoding amino acids 1-163 of IGFBP 2 in advanced 
ovarian cancer (www.clinicaltrials.gov, (2011)).
IGFBP 1 is the least studied of the IGFBPs and little is known about its role as a 
possible therapy in cancer. IGFBP 1 has been reported to inhibit motility of the bone-seeking 
metastatic breast cancer cell line, MDA-231BO in vitro by inhibiting the interaction of the 
integrin with the IGF IR (Zhang and Yee, 2002).
IGFBP 5 overexpression can accelerate progression to androgen independence in a 
human prostate LNCaP tumour model. After castration tumour growth and serum PSA levels 
increased faster in mice bearing IGFBP 5-transfected LNCaP tumours relative to controls 
(Miyake et ai., 2000). However, in human breast cancer cells (MDA-MB-231 and Hs578T), 
IGFBP 5 inhibits growth in vitro and in vivo in nude mice (Butt et al., 2003). IGFBP 5 can act 
as an inhibitor to tumour growth by inhibiting angiogenesis. Overexpression of IGFBP 5 in 
HUVECs (human umbilical vein endothelial cells) treated with VEGF led to inhibition of tube 
formation and cell proliferation. In vivo, following injection of rhIGFBP 5, SKOV3 ovarian
cancer -cells Implanted subcutaneously in nude mice showed a 70 % reduction ;?n typiour
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volume relative to controls (Rho et a/., 2008). Due to conflicting data, IGFBP 5 needs to be 
investigated further before being considered as a cancer therapeutic.
IGFBP 6 has a high affinity for IGF II (Chandrashekaran et ai, 2007). IGFBP 6 
inhibits PC-3 (androgen independent) and LNCaP (androgen dependent) prostate cancer 
cell proliferation following treatment with diethylstilbestrol (DES), a synthetic oestrogen used 
as an androgen antagonist in the treatment of advanced human prostate cancer (Koike et 
al., 2005). Upon treatment of PC-3 cells with DES, an increase in IGFBP 6 was noted. 
rhIGFBP 6 alone inhibited cell proliferation suggesting that IGFBP 6 may be involved in the 
effect of DES in androgen independent human prostate cancer (Koike et al., 2005). IGFBP 6 
induced programmed cell death in non-small cell lung cancer (NSCLC) cells transduced with 
IGFBP 6 in vitro. Intratumoural injection of an adenovirus expressing IGFBP 6 under the 
control of a cytomegalovirus (CMV) promoter (Ad5CMV-BP6) in NSCLC subcutaneous 
tumours established in nude mice reduced the size of NSCLC xenografts by 45% relative to 
controls (Sueoka et al., 2000). In a neuroblastoma model, IGFBP 6 inhibits cell proliferation 
in SK-N-SH cells in vitro and subcutaneous tumour development in nude mice in vivo, 
further supporting IGFBP 6 as a candidate for cancer therapy (Seurin et al., 2002). As 
IGFBP 6 binds IGF II with higher affinity compared with IGF I, IGFBP 6 may be useful in 
cancers where IGF II is primarily involved.
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The body naturally produces IGFBPs, therefore they may not stimulate an immune 
response, making them tolerable to patients. IGFBPs can also have IGF dependent and 
independent effects; under certain conditions the IGFBPs can enhance IGF activity thus 
leading to an increase in proliferation and tumour growth (Baege et a/., 2004, Miyake et al.,
2000). All of the IGFBPs are regulated by proteases. Such proteases include PAPP-A and 
PSA, which cleave IGFBP 3 and 4 (Rehault et a/., 2001, Boldt and Conover, 2007). Recently 
it has been shown that overexpression of PAPP-A in ovarian cancer cells (SKOV3) led to 
accelerated anchorage-independent growth in soft agar relative to a SKOV3 cells 
expressing a mutant PAPP-A with reduced proteolytic activity. In vivo, accelerated growth of 
PAPP-A-overexpressing SKOV3 cells was seen relative to mutant PAPP-A or controls (Boldt 
and Conover, 2011). Therefore, IGFBPs may not have a long half-life in circulation due to 
cleavage by such proteases. IGFBP 4 is inhibitory to IGFs without any known IGF 
independent actions. Therefore, a protease resistant IGFBP 4 would be useful to overcome 
proteolytic cleavage of IGFBPs.
A protease resistant form of IGFBP 4 was used in a porcine model of neointimal 
hyperplasia. Upon infusion of the protease resistant IGFBP 4 into the arteries of 
hypercholesterolemic pigs, a significant decrease in lesion formation was observed in the
protease: resistant IGFBP 4 treatment group relative to cojitrGls.or pigs treated with wildtype ,
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IGFBP 4. A decrease of 53.3 + 6.1% in lesion development within blood vessels was seen in 
hypercholesterolemic pigs treated with protease resistant IGFBP 4 compared with controls 
or wildtype IGFBP 4. The decrease in neointimal expansion was due to decreased cell 
proliferation (Nichols et a/., 2007). Overexpression of wildtype IGFBP 4 delayed the onset of 
subcutaneous prostate tumour formation in athymic nude mice in vivo using M12 prostate 
cancer cells transfected with IGFBP 4. In vitro, overexpressed IGFBP 4 increased apoptosis 
and decreased cell proliferation in the M12 transfected cells relative to controls, while in vivo 
M12 cells transfected with IGFBP 4 grew significantly slower than controls (Damon et al.t 
1998). In a subcutaneous nude mouse model of colon cancer, peritumoural injection of a 
mammalian vector (pcDNA3) containing wildtype IGFBP 4 cDNA increased apoptosis and 
decreased mitosis of HT-29 colon cancer cells (Durai et a/., 2007). In. the Harmey group, a 
protease resistant IGFBP 4 was previously developed. In vivo, following injection of 4T1.2 
cells transfected with the protease resistant rat IGFBP 4 (dBP4) grew significantly slower 
than controls or cells expressing wildtype IGFBP 4. Inhibition of tumour growth by dBP4 was 
accompanied by increased endothelial cell apoptosis and mice bearing dBP4-expressing 
tumours took longer to reach a mean tumour diameter (MTD) of 17 mm relative to controls 
or wildtype IGFBP 4 tumours (Ryan et al.t 2009). Therefore, dBP4 may be a strong 
candidate as a cancer therapeutic.
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A second strategy to neutralise IGFs ¡s a soluble receptor. Dunn et al (1998) created 
a soluble mutant IGF IR, which functioned as a decoy receptor. It was shown to inhibit cell 
motility and adhesion in vitro in MDA-MB-435 breast cancer cells transfected with the 
dominant negative form of the IGF JR. When MDA-MB-435 cells expressing the dominant 
negative form of the IGF IR were injected into the mammary fat pad of female nude mice, 
metastasis to the lungs, liver, lymph nodes and lymph vessels was significantly decreased 
compared with vector controls (Dunn et a/., 1998).
Antibodies to IGF I and IGF II have also been described. KM1468, a rat monoclonal 
antibody neutralised IGF I and IGF II and inhibited development of bone metastases in 
MDA-PCa-2b prostate cancer cells injected into subcutaneously implanted human bone 
fragments (Goya et al., 2004).
1.6.3.2 Anti-sense oligonucleotides and RNAi to inhibit IGF IR expression
Overexpressing the IGF IR leads to transformation of cells which is important in cancer cell 
development (Kaleko et al., 1990). Therefore, decreased expression of the IGF IR may 
inhibit IGF IR transforming ability along witlvits cell proliferative and anti-apoptotic effects. 
Antisense and ribonucleic acid (RNA) interference are two methods, to decrease IGF IR 
expression. Antisense RNA involves the introduction .of antisense RNA . moleci.ijes^cir. 
oligonucleotides into the cell. Binding of the RNA molecules or oligonucleotides to a 
complementary sequence in the target mRNA inhibits translation of' mRNA or causes 
degradation by RNase H (Walder and Waider, 1988). Intratumour injection of antisense 
oligonucleotides to IGF IR inhibits the growth of C4HD mammary adenocarcinomas in vivo 
(Salatino et al., 2004). Treatment of the breast cancer cell line MDA-MB-435 with antisense 
IGF IR showed a decrease in cell proliferation in vitro and when cells were injected 
subcutaneously into SCID mice an increase in survival was reported relative to controls 
(Chernicky C.L. et al., 2000). An antisense oligonucleotide to the IGF IR was tested in a 
clinical trial for malignant astrocytomas. Ex vivo, IGF IR oligonucleotide treatment of 
autologous glioma cells induced apoptosis. In vivo, a host response was seen without 
unusual side effects (Andrews et a/., 2001). The efficacy of systemic administration of 
antisense oligonucleotides is restricted by limited cellular uptake and non-specific toxicity 
due to poor target sequence specificity.
RNA interference (RNAi) is a second method to decrease IGF IR expression. RNAi is 
a process by which long double stranded RNAs are cleaved into short nucleotide fragments. 
The cleavage products, short interfering RNAs (siRNAs) are incorporated into a RNA 
inducing silencing complex where the siRNA acts as a guide to target the cleavage of 
complementary mRNA (Fire et al., 1998). siRNAs have been used to decrease IGF IR levels 
and signalling in cancer. In vitro, silencing of the IGF IR in LNCaP, PC-3 and DU145
prostate cancer cells enhanced their sensitivity to DNA damaging agents (mitoxantrone, 
etoposide, nitrogen mustard and ionizing radiation) (Rochester et al., 2004). However, the 
delivery of these agents has similar problems as that of the antisense oligonucleotides.
1.6.3.3 Monoclonal antibodies to inhibit IGF I and the IGF IR
Therapies targeted at inhibiting IGF IR activation are furthest along in terms of clinical 
development. The two main IGF IR inhibiting strategies are monoclonal antibodies (mAb) 
and small molecule tyrosine kinase inhibitors.
Neutralising antibodies to block receptor-ligand interactions leads to receptor 
internalisation and degradation (Burtrum et al., 2003). Down-regulation of the IGF IR is the 
most important mechanism of action of these drugs. The first available mAb blocking the 
IGF IR was alR3, a mouse monoclonal IgGi antibody. alR3 inhibited growth of MCF-7 
breast cancer cells in vitro, but did not inhibit in vivo growth (Arteaga et a/., 1989). However, 
alR3 inhibited subcutaneous growth of other types of cancers including MDA-MB-231 breast 
cancer cells (Arteaga et a/.t 1989) and rhabdomyosarcoma (Kalebic et al., 1994). However, 
alR3 can act as an IGF I agonist stimulating phosphorylation of the IGF IR (Kato et al., 
1993). Therefore, this antibody was not developed clinically, but it led to development of fully 
humanised mAbs. r 1 ' - - <
CP-751,871 (Figltumumab, Pfizer), a fully human lgG2 antibody with high affinity for 
the human IGF IR, has the largest clinical test to date compared with other IGF IR mAbs. 
CP-751,871 induced down-regulation of the IGF IR protein in NIH 3T3/IGF-IR (IGF IR 
overexpressed), MCF-7 breast cancer cells and RPMI 8226 multiple myeloma cells in vitro 
and showed significant anti-tumour activity in athymic mice bearing subcutaneous 
NIH3T3/IGF-1R tumours relative to controls (Cohen et al., 2005). A phase I pharmacokinetic 
and pharmacodynamic study in patients with multiple myeloma showed no dose limiting 
toxicities when CP-751,871 was administered (Lacy et al., 2008). Administration led to a 
decrease in serum IGF I at high doses, thus suggesting systemic IGF IR inhibition. Phase I 
dose escalation studies were also conducted in patients with refractory solid tumours. Some 
of the most common adverse effects were hyperglycaemia, anorexia, nausea, diarrhoea and 
fatigue. At a dose of 20 mg/kg, 10 out of 15 patients experienced disease stabilisation (Lacy 
et al., 2008). Treatment with CP-751,871 increased serum insulin and GH levels and caused 
a modest increase in blood glucose, suggesting target inhibition (Haluska et al., 2007). In a 
phase II study, CP-751,871 combined with paclitaxel and carboplatin was shown to be safe 
and effective in patients with treatment-naive, locally advanced, or metastatic lung cancer 
(Karp et al., 2009).
IMC-A12 (Cixutumumab, ImClone Systems) is a fully human IgGi antibody. IMC-A12 
inhibited subcutaneous growth of androgen dependent (LuCaP 35) and androgen
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independent (LuCaP 35V) prostate cancer cell lines and induced apoptosis and growth 
cycle arrest (Wu et a/., 2005). In MCF-7 breast cancer cells, 1MC-A12 administration led to 
inhibition of both MAPK and Akt signalling and demonstrated strong anti-tumour activity in 
subcutaneous tumour models (Burtrum et a/., 2003). IMC-A12 works effectively alone and in 
combination with the epidermal growth factor receptor (EGFR) blocking antibody cetuximab 
(C225, Merck) in head and neck cancer cell lines (183A and TU159) and tumour xenografts 
(Barnes et a/., 2007). IMC-A12 has been tested in phase I trials in adults and children with 
advanced solid tumours. Toxicities included hyperglycaemia, anaemia, psoriasis and 
infusion related reaction (Higano et a/., 2007).
AMG-479 (Amgen) is a fully human IgGi antibody with high affinity for the human 
IGF IR and no cross reactivity with the insulin receptor. AMG-479 reduced cell viability in the 
pancreatic cell lines BxPC-3 and MIAPaCa2. Its mechanism of action was different in the 
two cell lines, being pro-apoptotic in BxPC-3 and anti-mitogenic in MIAPaCa2 cells. AMG- 
479 inhibited subcutaneous tumour growth of BxPC-3 and MIAPaCa2 pancreatic carcinoma 
xenografts relative to controls (Beltran et a/., 2009). AMG-479 in combination with 
cetuximab in cetuximab-refractory head and neck squamous cell carcinoma showed a 
decrease in phosphorylated IGF IR (Chung et a/., 2010). Phase I trials performed with 
patients with solid tumours and non-Hodgkin's lymphoma; revealed no severe toxicity gf tfeis-. 
antibody (Tolcher et a/., 2009). Clinical trials are now underway to determine the anti tumour 
activity of AMG-479 in numerous cancers such as breast, colorectal, lung and pancreatic 
cancer (www.clinicaltrials.gov (2011)).
R1507 (Roche), a recombinant human IgGi monoclonal IGF IR antibody, was first 
tested in NSCLC cell lines, showing that high levels of total IGF IR and not phosphorylated 
IGF IR are associated with relative sensitivity to the R1507 when administered as a single 
agent. However, its effect was enhanced when used in combination with the EGFR.small 
molecule inhibitor Erlotinib (Roche) in R1507-sensitive NSCLC cells in vitro (Gong et a/., 
2009). R1507 was tested in 6 osteosarcoma cell lines (OS1, OS2, OS9, OS 17, OS31 and 
OS33) implanted subcutaneously in SCID mice. R1507 was administered either as a single 
agent or in combination with the mTOR inhibitor, rapamycin. R1507 alone delayed tumour 
. growth in four of six osteosarcoma xenografts and rapamycin alone enhanced Akt 
phosphorylation in all the tumours. Phosphorylation of Akt was inhibited when rapamycin 
was administered in combination with R1507 (Kolb et a/., 2010). The safety and 
pharmacokinetics of R1507 was evaluated in patients in a phase I trial with solid tumours 
and lymphomas. Hyperglycaemia and lymphopenia were common side effects and a 
significant reduction in IGF IR expression on peripheral blood mononuclear cells was 
observed (Rodon et ai., 2007). A phase II trial was undertaken in patients with recurrent or 
refractory sarcomas (Patel et ai., 2009) and while initial activity was observed subsequent
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findings following a portfolio review led to termination of the clinical development of this 
agent.
SCH-717454 (Robatumumab, Schering-Plough), a fully humanised monoclonal 
antibody previously known as 19D12, was tested in vitro and in vivo under the Paediatric 
Preclinical Testing Program, in vitro tests of this antibody on 23 cell lines including 
neuroblastoma, osteosarcoma, Ewing’s sarcoma, kidney/rhabdoid and gliomas showed little 
effect on cell growth, whereas in vivo it possessed broad anti-tumour activity in 43 xenograft 
models, the strongest effects seen in neuroblastoma, osteosarcoma and Ewing's sarcoma 
models (Kolb et al., 2008). SCH-717454 was further evaluated in rhabdomyosarcoma, 
neuroblastoma and osteosarcoma tumour xenografts. It was effective as a single agent with 
enhanced activity in combination with cisplatin or cyclophosphamide. In vivo results showed 
tumour growth inhibition by SCH-717454 was due to a reduction in cell proliferation and 
angiogenesis (Wang et al., 2010). When SCH-717454 was initially tested in healthy 
volunteers, no adverse side effects were seen 8 weeks post dosing (Seraj et al., 2007). 
SCH-717454 is currently being evaluated in a Phase II trial in patients with relapsed or 
recurrent colorectal cancer and in patients with relapsing sarcomas (Ewing’s sarcoma) 
(www.clinicaltrials.gov, (2011)).
Monoclonalantihody EM164 (Immunogen) inhibited proliferation of several hum^- 
cancer cel! lines in vitro, including breast, lung, colon, cervical, ovarian, pancreatic, 
melanoma, prostate, neuroblastoma, rhabdomyosarcoma and osteosarcoma lines. Tumour 
regression was also seen in established BxPC-3 human pancreatic subcutaneous tumours 
treated with EM 164 relative to untreated controls with increased anti-tumour efficacy in 
combination with the cytotoxic agent, gemcitabine (Eli Lilly and Co.) (Maloney et al., 2003). 
Treatment of MCF-7 breast cancer cells with AVE-1642, the humanized version of EM164 
conjugated with quantum dots led to down-regulation of IGF IR levels and reduction of cell 
proliferation in vitro (Zhang et al., 2009). Intravenous (IV) injection of AVE-1642 conjugates 
(with quantum dots or small-molecule fluorophores) to mice bearing subcutaneous tumours 
of human-IGF IR expressing mouse embryo fibroblasts or MCF-7 breast cancer cells, 
specifically targeted the tumour xenograft following in vivo fluorescent imaging and were 
therefore suitable to detect the expression and down-regulatlon of IGF1R in vivo (Zhang et 
a l 2009). AVE-1642 has also demonstrated activity in chemoresistance towards 5- 
Fluorouracil (5-FU) and oxaliplatin (Sanofi-Aventis) for chemoresistant metastatic colorectal 
cancer (HT-29 cells) in vitro (Dallas et al., 2009). A dose escalation study using AVE-1642 
was conducted in multiple myeloma patients and was well tolerated (Moreau eta!., 2007).
MK-0646, a humanised \gGA monoclonal antibody (Pierre Fabre), inhibited 
subcutaneous tumour growth in nude mice bearing either human breast cancer cells (MCF1 
7) or NSCLC cells (A549). Further inhibition of A549 tumour growth was observed in mice
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treated with the anti-IGF IR antibody combined with vinorelbine (Pierre-Fabre) or an anti- 
EGFR antibody, C225 (Goetsch et a/., 2005). MK-0646 also exhibited potent inhibition of 
subcutaneous tumour growth in MDA-MB-231 breast cancer mouse models (Pandini et a/., 
2007). MK-0646 is currently in phase II clinical trial in combination with irinotecan (Pfizer) 
and/or cetuximab in colorectal cancer (Watkins et a/., 2009)
Recently Biogen have developed a range of monoclonal and bispecific antibodies 
against the IGF IR. Combination of two inhibitory IGF IR antibodies with distinct epitopes for 
the receptor (BIIB4 and BIIB5) were more effective in osteosarcoma (SJSA-1 cells) and 
hepatocellular carcinoma (HepG2 cells) subcutaneous tumour models compared with the 
use of the monospecific antibodies (Dong et a/., 2010).
1.6.3.4 Tyrosine kinase inhibitors to block IGF IR activation
A second group of inhibitors targeting IGF IR activation are small molecule tyrosine kinase 
inhibitors (TKIs). TKIs inhibit tyrosine kinase activity by binding the adenine triphosphate 
(ATP) binding site or substrate binding site in the kinase domain of the IGF IR. TKIs have a 
higher affinity for IGF IR than the IR, thus minimising cross-reactivity with the IR. One 
advantage of TKIs over mAbs is the ease of oral administration. A number of TKIs are 
currently in clinical development . - „ ;
Some of the earliest TKIs were tyrphostins such as„AG1024 (Merck), a synthetic 
protein kinase inhibitor which was not specific to the IGF IR as it cross-reacted with the IR 
(Parrizas et al.f 1997a). This led to the production of NVP-AEW541 (Novartis), a novel 
tyrosine kinase inhibitor to the IGF IR. NVP-AEW541 is 27-fold more selective for IGF IR 
than the IR (Garcia-Echeverria et a/., 2004). NVP-AEW541 has anti-proliferative effects in 
vitro and in vivo in neuroblastoma (HTLA-230 or SK-NBE2c cells), in vitro, NVP-AEW541 
also increased apoptosis relative to controls, while in vivo 100 mg/kg/day significantly 
inhibited the growth of subcutaneous neuroblastoma tumours in nude mice relative to 
controls without any major toxic effects (Tanno et al., 2006). In an SKBR3/Tr (breast cancer 
cells resistant to trastuzumab (Roche)) model of acquired trastuzumab resistance, NVP- 
AEW541 inhibited growth of the resistant cells, to a comparable level to that of the 
trastuzumab sensitive parental cells when given in combination with trastuzumab. 
Therefore, NVP-AEW541 improved the response to trastuzumab in HER2-positive breast 
cancer cells (Browne et a/., 2011). Numerous studies have examined toxicity of NVP- 
AEW541 due to high homology between the tyrosine kinase domains of IGF IR and IR 
(Ullrich et a/., 1986). In a mouse model of Ewing’s sarcoma, no increase in serum glucose 
was seen. In contrast, there was a significant decrease in serum glucose due to increased 
glucose uptake at a cellular level. However, this was only evident in cells expressing IGF IR 
and IR and was not observed when only IR was present (Manara et a/., 2007). NVP-
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AEW541 given at a dose of 50mg/kg twice daily in an orthotopic pancreatic cancer (BxPC-3 
cells) model led to an increase in blood glucose levels and a 16% decrease in mouse body 
weight (Moser ef a/., 2008), suggesting that the IR could be affected by NVP-AEW541 
(Garcia-Echeverria et al., 2004). This inhibition may be due to dosing regime and the dose 
given. NVP-AEW541 was only tested pre-clinically and was not tested in clinical trials.
INSM-18 (Insmed), also known as nordihydroguaiaretic acid (NDGA), is a small 
molecule inhibitor of the IGF IR, which also targets the HER 2 receptor. MCF-7 breast 
cancer cells treated with low doses of INSM-18 showed inhibition of IGF IR phosphorylation 
and inhibition of phosphorylated Akt. In mouse mammary carcinoma MCNeuA cells 
(overexpress the HER2/neu receptor) derived from a spontaneous tumour in a female neu 
transgenic mouse, INSM-18 inhibited ligand independent phosphorylation of HER2/neu and 
IGF l-induced growth. INSM-18 treatment also decreased the activity of the IGF IR and the 
HER2/neu receptor in vivo in MCNeuA subcutaneous tumours (Youngren ef a/., 2005). 
INSM-18 has demonstrated anti-proliferative activity in LNCaP prostate cancer cells in vitro 
(Ryan et al., 2006). Two single dose phase I trials conducted in healthy volunteers showed 
INSM-18 was well tolerated. A dose escalation phase I/ll trial has been completed in 15 
patients with relapsed prostate cancer where INSM-18 was well tolerated up to the 
maximum dose (Ryan ef ai., 2008),- ....  r - -
OSI:906 (OSI Pharmaceuticals) is a potent small molecule inhibitor.of the IGF IR. In 
a pre-clinical mouse model of lung cancer (NCI-H292 cells), 18FDG-PET was used to 
monitor the effect of OSI-906 on subcutaneous tumour growth. A decrease in glucose 
uptake within the tumour was observed following OSI-906 administration. The decrease in 
glucose uptake coincided with a decrease in phosphorylated IGF IR and reduced PI3K and 
MAPK activity, showing tumour arrest ¡n lung tumours relative to controls (Me Kinley et ai., 
2011). Phase I trials of continuous and intermittent administration of OSI-906 in patients with 
advanced solid tumours have only reported mild hyperglycaemia (Lindsay et al., 2009).
XL228 (Exelixis) is a small molecule TKI targeting the IGF IR, FGFR 1-3 and SRC 
family kinases. Phase I studies tested XL228 in patients with solid tumours and 
hematological malignancies. Side effects included hyperglycaemia, nausea, fatigue, 
anorexia and flushing (Smith et al., 2008).
The IGF system is emerging as a promising new target in cancer treatment. Early 
clinical testing has shown that IGF IR inhibition is well tolerated, with hyperglycaemia as the 
main side effect. Single agent activity of these agents is well documented and combination 
studies with other conventional therapies such as chemotherapy, hormone therapy and 
radiotherapy are currently being explored. Identification of biomarkers may help select 
patient populations that will benefit from IGF pathway directed therapies. However, newer
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therapies are needed which avoid the hyperglycaemic effects seen with many existing IGF 
IR-targeted agents.
1.7 Animal models of prostate cancer
The selection of suitable animal models in which to assess novel therapies is important pre- 
clinically. It is crucial that an appropriate model is chosen to establish the potential of such 
therapies. Elucidation of the molecular mechanisms underlying prostate cancer initiation and 
progression has been facilitated by laboratory and clinical models of the disease. Due to the 
heterogeneity of prostate cancer between and within patients, numerous complementary 
model systems have emerged including dog, rat, transgenic mice and xenografts. Aside 
from man, dog is the only animal known to spontaneously develop high grade PIN and 
prostate adenocarcinomas (Waters et a/., 1998).
Canine disease shares numerous similarities with human disease, including 
morphologic and phenotypic heterogeneity, metastatic propensity and development of 
androgen independence and late age of onset. These similarities make canines an attractive 
model, but this model has limitations due to low incidence of spontaneous disease and the 
cost of maintaining dog colonies.
Several rat strains develop prostate adenocarcinomas after a long latency period. 
Prostate cancer can also be induced in rats by stimulation with androgens, pestrogens or 
treatment with chemical carcinogens (Cavalieri et a/., 2002), but prostate tumours formed in 
this way display variations in reproducibility and reliability. The most beneficial resource 
developed from spontaneous and induced rat tumours is a set of metastatic and non­
metastatic cell lines developed from the Dunning R3327 rat (Isaacs et al., 1986). These 
sublines have been utilised in studies on androgen responsiveness and metastatic 
progression (Bussemakers et a/., 1992, Quarmby et a/., 1990).
Transgenic mice have been used in modelling numerous cancer types. In prostate 
cancer, these models have not fared well as they are not representative of the human 
disease. The murine prostate does not spontaneously develop neoplasia and the anatomy 
of the murine prostate differs greatly from that of the human prostate. The murine prostate 
consists of three lobes, dorsolateral, ventral and anterior, which are positioned around the 
urethra. The human prostate is alobular, but can be divided into three zones- central, 
peripheral and transitional and it envelops the upper part of the urethra.
Despite these differences, prostate cancer has been engineered in mouse strains 
using prostate specific promoters to express oncogenes. Generation of transgenic mice 
overexpressing numerous oncogenes, growth factors and kinases have been developed. 
The most commonly used transforming agent is the gene for SV40 T antigens. SV40 
oncoproteins inactivate the tumour suppressor p53 which is involved in tumour suppression
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(Mietz et al., 1992). This pathway is also mutated in human prostate cancer (Bookstein et 
al., 1993). The SV40 antigens and several other oncoproteins have been utilised in the 
murine prostate along with a variety of promoters.
The rat minimal probasin promoter belongs to a family of ligand carrier proteins 
localised to epithelial cell nuclei and ducts of dorsolateral and ventral prostate (Greenberg et 
al., 1994). The minimal probasin promoter is subject to steroid hormone regulation and 
developmental regulation (Greenberg et a/., 1994). The minimal probasin promoter was 
used to develop the transgenic adenocarcinoma mouse prostate (TRAMP) model of 
prostate cancer. The TRAMP model contains the minimal probasin promoter that drives 
expression of the SV40 large T antigen. TRAMP mice develop high grade PIN or prostate 
cancer 12 weeks after birth and develop metastases after 30 weeks with the majority of 
metastases forming in the lung and lymph nodes (Gingrich et al., 1997, Greenberg et al., 
1995). The TRAMP model has been used to analyse changes in the course of androgen 
deprivation following castration (Gingrich et a i, 1997), to assess aberrant growth factor 
signalling in prostate cancer (Kaplan et a/., 1999) and to test chemotherapeutics (Gupta et 
al., 2004).
The promoter of rat C3 (1) is an androgen regulated promoter that promotes 
expression of a-ventral lobe protein using SV40. large T antigen gene. These, mice develop 
low grade PIN to high grade PIN to invasive carcinoma, but their use is limited due to 
multiple tissue sites of tumour onset (Maroulakou et al., 1994). However, this model has 
been valuable in the study of progression from low grade PIN to invasive carcinoma, thus 
supporting PIN as a precursor to carcinoma. Transgenic mice overexpressing IGF I under 
the control of the keratin 5 promoter in basal cells in various tissues develop PIN and 
carcinoma by nine months of age (Digiovanni et a/., 2000). However, the existing transgenic 
models have limitations. The SV40 based models do not allow analysis of the initiating 
events as SV40 viral oncoprotein does not cause prostate cancer in humans. In addition, the 
majority of transgenic models do not reliably metastasise to bone, a common feature in 
prostate cancer.
In human xenograft models of prostate cancer, xenografts are created by 
implantation of human tissue or cells into immunodeficient rodents such as nude, SCID 
(severe combined immunodeficiency) or NOD (non-obese diabetic) SCID mice. Xenografts 
allow investigation of human prostate cancer and facilitate determination of the influence of 
microenvironment on growth and behaviour of tumour cells. Xenograft models are 
commonly used to test therapeutic agents for clinical trials serving as a link between 
laboratory and clinic. Subcutaneous implantation of human cancer tissue or cells has 
traditionally been utilised to test potential therapeutics. This model is easy to use, is 
technically straightforward and creates a great amount of data, but it is not relevant to
f
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clinical cancer. One of the obvious drawbacks is that subcutaneous tumours do not 
reproduce the microenvironment of the prostate and rarely metastasise.
To overcome these issues orthotopic models using implantation of tissue or cells into 
the corresponding anatomical site have been established. Metastasis formation is more 
efficient and mimics that of human metastasis when cells or tissue are implanted 
orthotopically. In one model, PC-3 cells were transduced with green fluorescent protein 
(GFP) and implanted subcutaneously in order to select high expressing GFP-fluorescent 
tumours. Subcutaneous tumour fragments expressing high levels of GFP were then 
implanted into the prostate of nude mice. Subsequent metastasis formation was seen in 
bone (Yang et a/., 1999). By implanting tissue or cells orthotopically, targeting factors 
involved in invasion can be carried out in a more clinically relevant site and testing novel 
therapeutics may better reflect activity in patients. Kuo et al (1993) used an in vivo SCID 
beige model of NSCLC and showed that cisplatin had significant effects against lung 
tumours growing orthotopically, but had no effect against the same tumours growing 
subcutaneously (Kuo et al., 1993). One disadvantage of orthotopic implantation is that for 
certain anatomical sites, including prostate, implantation requires surgical skills and is more 
time consuming than subcutaneous implantation of cells or tissue. Caliper measurement 
cannot be carried out; therefore determining endpoints for effects, of therapy, can be difficult 
There have been many significant .developments in orthotopic implantation techniques to 
study cancer and metastasis.
Many animal tumours do not give rise to spontaneous bone metastasis despite 
orthotopic implantation. Therefore, experimental bone metastasis models are used. 
Intracardiac injection of cell lines into the left ventricle of immunodeficient mice gives rise to 
bone metastasis in vivo (Chu et al., 2008). Advancements in small animal imaging now 
allows for non-invasive imaging of animals bearing orthotopic tumours and metastasis.
1.7.1 Non-invasive imaging of animal models of cancer
A variety of non-invasive imaging techniques have been optimised for small animal imaging, 
including magnetic resonance imaging (MRI), computed tomography (CT), positron emission 
tomography (PET), single photon emission tomography (SPECT), fluorescent imaging and 
bioluminescent imaging (BLI). Non-invasive imaging allows monitoring of changes in blood 
perfusion or volume within the tumour and metastatic lesion, tracking tumour specific 
markers and monitoring effects of novel therapeutics (Genove et al., 2005, Lewin et al., 
1999, Me Kinley. et al., 2011). MRI and CT rely on energy-tissue interactions whereas PET 
and BLI rely on injection of molecular probes to visualise tumours.
MRI works on the principle that unpaired nuclear spins (hydrogen bonds in water) 
align themselves in a magnetic field. A radio frequency is used to alter the alignment of
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spins and the return to baseline is the change in electromagnetic flux. The rotating magnetic 
field is detected by a scanner and an ¡mage is constructed of the scanned body. High 
resolution is commonly used for screening transgenic mice for tumours as it can visualise 
tumour size, location and metastatic burden. MRI analysis can also be useful to quantify 
vascular volume and capillary flow of deep tumours (Lewin et al., 1999, Neeman et al.,
2001). MRI has reportedly been used to detect endothelial cell proteins such as E-selectin 
by using a superparamagnetic contrast agent obtained by grafting a synthetic mimetic of 
sialyl Lewisx, a natural ligand of E-selectin expressed on leukocytes, on the dextran coating 
of ultrasmall particles of iron oxide (Boutry et a/., 2006). Another study used an adenovirus 
to deliver an MRI reporter gene, which encoded metalloproteins from the ferritin family. 
When cells sequestered iron a superparamagnetic compound was formed, allowing cells to 
construct the MRI contrast agent in situ (Genove et al., 2005).
CT (X-ray CT) imaging measures x-rays as they pass through tissue. Due to 
differences in absorption between bone, fat, water and air, high contrast images of 
anatomical structures are obtained. Compared with MRI, CT has poor soft tissue contrast 
and does not distinguish between tumours and surrounding tissue. To overcome this, an 
iodinated contrast agent is injected, which delineates organs and tissues, as different tissue 
types will absorb the contrast agent at different rates. High resolution-CT is flu e n tly  used 
in mice to detect lung tumours (De Clerck et al., 2004). MRI is usually preferred over CT for 
tumour screening, but CT is useful in certain circumstances such as bone metastasis 
(Mahner et al~ 2008) as CT imaging is faster than MRI and gives a better image of bone.
PET imaging is a technique used to detect decaying nuclides such as 11C, 18F and 
124l. Once administered the decaying nuclides emit positrons that collide with free electrons 
converting matter to energy in the form of y rays, y rays are detected by numerous 
detectors surrounding the subject. The radionuclides are typically conjugated to small 
molecules that can bind to receptors or other cellular targets. For example, 18F 
fluorodeoxyglucose is used to detect tumours due to increased glucose uptake and 
metabolism and has been used extensively in testing novel therapeutics such as the IGF IR 
TKI, OSI-906. Administration of OSI-906 in a subcutaneous model of lung cancer (NCI-H292 
cells) led to a decrease in glucose uptake following treatment (Me Kinley et al., 2011) 
demonstrating that PET imaging may be useful in determining response to drug therapies. 
18F labelled thymidine has also been used to measure proliferation in NSCLC tumours (Yap 
et al., 2006). However, PET imaging is a costly approach to monitoring mouse models of 
cancer and in addition to a PET scanner, a cyclotron and radiochemistry facility is required 
for daily use of this technology.
SPECT imaging is used.in experimental oncology as it detects gamma radionuclides 
to track individual molecules or cells. Gamma emitting nuclides are inexpensive and readily
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available. Molecules or cells are labelled with y-ray emitting nuclides such as 123l and 125l 
then administered to animals and labelled molecules or cells can then be monitored by 
sodium iodide gamma cameras. SPECT has been used to image programmed cell death 
induced by anti-Fas antibody injection in BALB/c mice and cyclophosphamide treatment of 
transplanted 38C13 murine B cell lymphomas (Blankenberg et a/., 1998). Wild type RG2 
glioma or W256 mammary carcinoma cells were injected into one flank of rats and RG2TK+ 
glioma or W256TK+ mammary carcinoma cells that had been transduced in vitro with the 
Herpes simplex virus 1-tyrosine kinase gene were injected into the opposite flank. Herpes 
simplex virus 1-tyrosine kinase expression was visualised using 131 Mabelled 2'-fluoro-2'- 
deoxy-1-ft-d-arabinofuranosyl-5-iodo-uracil. High levels of radioactivity (>1% dose) were 
localized to areas of Herpes simplex virus 1-tyrosine kinase gene expression. In contrast, 
significantly lower levels of radioactivity (<0.01 %) were observed in the surrounding non­
transduced tumour tissue or contralateral wild type tumours (Tjuvajev et a/., 1996). SPECT 
has also been used to follow radiolabelled HER2-specific antibodies. Two anti-HER2/neu 
mAbs (TA1 and 520C9) were radioiodinated. Internalization and cellular processing of the 
labelled mAbs were assessed in SKOV3 9002-18 ovarian cancer cells in vitro (Zalutsky et 
a/., 1999). Another study synthesised and evaluated the in vivo biodistribution of 2 
radiolsbelled urea derivatives with high affinity for prostate specific membrane antigen 
(PSMA), an integral membrane glycoprotein. SCID mice harbouring MCF-7 (breast, PSMA- 
negative), PC-3 (prostate, PSMA-negative) or LNCaP (prostate, PSMA-positive) 
subcutaneous tumours showed that imaging PSMA-positive prostate cancer was achieved 
using low molecular weight agents (Foss et ai., 2005).
Fluorescent imaging is an inexpensive tool to visualise cells in mice. Light of one 
wavelength illuminates the specimen; a shift in wavelength (emission) is detected by charge 
couple device (CCD) camera. To minimise autofluorescence imaging in the near infrared is 
recommended, this also maximises tissue penetration. Fluorochromes can be conjugated to 
antibodies for specific targets as well using tumour cells transfected with fluorescent protein 
(Folli et ai., 1994, Yang et ai., 1999).
BLI is used to detect photons emitted from cells genetically engineered to express 
luciferase. BLI is a sensitive and quantitative method allowing molecular and cellular events 
involved in tumourigenesis to be monitored. BLI can rapidly reveal therapeutic efficacy in 
pre-clinical studies of novel therapeutics. The most commonly used bioluminescent reporter 
gene has been luciferase from the North American firefly (Photinus pyraiis, luc). Luciferase 
catalyses the conversion of the substrate d-luciferin to oxyluciferin in an ATP-dependent 
manner, leading to emission of photons which are detected by a CCD camera or 
luminometer in vitro. BLI of cancerous tissue requires the luciferase-encoding gene be 
transferred to cells or tissues. Cells stably expressing luciferase are then injected into
i  'nI
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animals and imaged externally. Some of the earliest experiments testing BLI were mouse 
xenograft models of human cancers implanted into immunodeficient mice. One such study 
involved monitoring tumour growth in SCID mice, which had been injected subcutaneously, 
intravenously or intraperitoneally with HeLa cells transfected with luciferase reporter gene. 
As few as 1 x 103 cells were detected following i.p. injection and the bioluminescent signal 
correlated with the number of cells inoculated (Edinger et a/., 1999). BLI is an extremely 
useful imaging tool as mammalian tissues do not have significant intrinsic bioluminescence. 
Therefore, bioluminescence is restricted to cells expressing the luciferase reporter gene. 
Moreover, d-luciferin is not toxic to mammalian cells (Sweeney et a/., 1999). BLI is one of 
the most sensitive technologies available for detection of cancer in small animals. In a gene 
delivery experiment, a recombjnant adeno-associated virus transduction system was used 
to deliver the luciferase gene under the control of the elongation factor 1 a promoter to mice 
in utero. Long-term expression of luciferase was seen in the liver and peritoneum. Limiting 
dilution PCR performed 8 months after birth showed that signal intensity generated from 1 
Luc+ liver cell in 106 Luc'cells was enough to be detected externally (Lipshutz et a/., 2001).
Advances in BLI have led to the development of transgenic mouse models 
expressing luciferase. One such transgenic mouse was generated to strongly express 
luciferase (PSA-luc) in the epithelium of all 4 lobes-of-the murine prostate gland.under 
control of the human PSA promoter. Following establishment of mice expressing both PSA- 
luc and the SV40-antigen T large antigen, spontaneous tumour growth was monitored. As 
light emission should be proportional to the cellularity of the luciferase-expressing tissue, a 
relative increase in bioluminescence was indicative of spontaneous tumour development. Ex 
vivo analysis confirmed the presence of large bioluminescent prostate tumours (Lyons et a/., 
2006). BLI is fast and relatively inexpensive compared with MRI and PET. Even though BLI 
is a useful technique in small animal studies it does not transfer to the clinic as BLI can only 
image tumours expressing a fluorescent or luminescent reporter gene.
Understanding of human cancer biology has been greatly enhanced by the study of 
mouse models. Current technologies available for monitoring tumour growth in vivo have 
also contributed greatly to understanding tumour biology and in testing new therapies. All 
molecular imaging technologies have advantages and disadvantages. The use of 
multifunctional reporter genes that link two or more imaging modalities will be of great 
benefit in monitoring cancer. Fusion genes for bioluminescent and fluorescent imaging are 
currently available (Day et a/., 1998). The ability to non-invasively image small animals will 
greatly enhance early detection of tumours and facilitate evaluation of new therapies.
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1.8 Overall aim:
In prostate cancer, the major clinical challenge is the development of androgen independent 
disease and metastasis. The primary tumour can normally be effectively treated by surgery, 
chemotherapy, radiotherapy or a combination. However, therapies previously used against 
the primary tumour may not effect the growth of androgen independent disease and 
metastases. Therefore, new therapies are required to treat advanced prostate cancer. 
Therapies targeting the interaction of the host tissue and tumour such as growth factors that 
promote cell proliferation, migration and angiogenesis may be of value in the treatment of 
prostate cancer.
The IGF pathway plays a role in cell growth, proliferation and angiogenesis, all of 
which are important in tumour growth. Due to the involvement of the IGF pathway in 
prostate cancer, targeting this pathway may prove beneficial in treating prostate cancer.
1.8.1 Specific Aims:
1. To assess membrane and cytoplasmic IGF IR expression in prostate cancer tissue 
microarrays and its association with Gleason grade.
2. To measure plasma IGF I and PAPP-A levels in prostate cancer patients relative to
BPH patients. ------ - r , m .
3. To investigate the expression and activation of the IGF signalling pathway (IGF IR, 
IGFBPs, PAPP-A, Akt and ERK) in a human androgen independent prostate cancer cell 
line, PC-3M-luc2.
4. To purify protease resistant IGFBP 4 (dBP4) from dBP4 transfected HEK 293 cells 
and to evaluate the effect of dBP4 and TKIs on cell proliferation in vitro using PC-3M-luc2 
cells.
5. To assess the effect of dBP4 on tubule formation (angiogenesis) by human 
endothelial cells in vitro.
6. To examine the effect of inducible vector-expressed dBP4 on prostate cancer growth 
and metastasis by BLI in subcutaneous, orthotopic (prostate) and experimental metastasis 
models. In addition, the effect of dBP4 on blood glucose, IGF I levels and activation of the 
IGF pathway (IGF IR, Akt, ERK and VEGF) was assessed in these models.
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2.1 Reagents
All reagents were purchased from Sigma-Aldrich chemical company (MO, USA) unless 
otherwise stated. All reagents were stored as recommended by the supplier. Reagents in 
powder-form were prepared in distilled water, unless otherwise stated. Solid reagents were 
weighed using an electronic balance (XS205 Dual Range, Mettler Toledo, OH, USA) and 
disposable weigh boats. The pH of all solutions was measured using an AP5 pH meter 
(Denver Instruments Company, CO, USA) calibrated with standards at pH 4.0, pH 7.0 and 
pH 10.0. Volumes of 0.5 pi - 1000 pi were delivered using calibrated pipettes (Gilson S.A, 
France). Volumes from 1 - 20 ml were measured using disposable plastic pipettes. Volumes 
in excess of 20 ml were measured using graduated cylinder.
2.2 Cell Culture
All tissue culture was carried out using aseptic technique in a Heraeus Class II A laminar 
airflow hood. The hood was wiped down with 70 % (v/v) ethanol (EtOH) before and after use 
and cleaned on a regular basis with 70 % (v/v) EtOH and MicroSol (Anachem Ltd, UK).
2.2.1 Cell lines
The human androgen independent orostate cancer cell line PC-3M-luc2 (PO-3M cells 
transfected with luciferase) was purchased from Caliper Life Sciences (MA, USA) and was 
maintained in Modified Eagle Medium ( MEM, Sigma-Aldrich, MO, USA) supplemented with 
10 % (v/v) FCS (fetal calf serum, Biosera, East Sussex, UK). The human embryonic kidney 
cells (HEK 293) and HEK 293T (contains SV40 Large T antigen) cells were obtained from 
the American Type Culture Collection (ATCC Md, USA) and maintained in high glucose (4.5 
g/L ) Dulbecco’s Modified Eagle Medium (DMEM, Biosera, East Sussex, UK) supplemented 
with 10 % (v/v) FCS. Cell lines were grown in 75 cm2 flasks (Sarstedt, Nubrecht Germany) 
with filter caps and were incubated at 37°C in a humidified atmosphere of 5 % C02 and 95 
% air (NuAire™ IR Autoflow C02 incubator, MN, USA).
2.2.2 Subculture of PC-3M-luc 2 cells, HEK 293 and HEK 293T cells
All cell lines were checked daily using an inverted microscope (Nikon Eclipse TS100, Micron 
Optical, Wexford, Ireland). Once cells reached 70-80 % confluency, they were subcultured. 
Flasks were removed from the incubator into the laminar airflow hood wiped down with 70 % 
(v/v) ethanol (EtOH). Cell culture medium, phosphate buffered saline (PBS (0.137 M) with 
calcium and magnesium, Biosera, East Sussex, UK) and 1x trypsin-ethyldiamine tetraacetic 
acid (EDTA) (0.05 % (w/v) trypsin, 0.02 % (w/v) EDTA, Biosera, East Sussex, UK) were 
heated to 37°C in a water bath.
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Cell culture medium was removed and the monolayer was washed with 10 ml of pre-warmed 
PBS. Trypsin-EDTA (2 ml) was then added to the monolayer of cells. The cap was replaced 
onto the flask and cells were Incubated at 37°C until cells detached from the base of the 
flask. The flask was placed into the laminar airflow hood and 10 ml of pre-warmed medium 
(containing 10 % (v/v) FCS) was added to each flask. Cells (12 ml) were seeded in fresh 
flasks at a ratio of 1:6 (2 ml cells per flask) and fresh medium added to a final volume of 13 
ml. Cells were maintained as described in 2.2.1.
2.2.3 Preparation of frozen cell stocks
Frozen stocks were prepared from cells at 70 - 80 % confluency in 75 cm2 flasks. Cells were 
harvested as described above (2.2.2). Cells were pelleted (ALC PK 121 Centrifuge, DJB 
Labcare, UK) at 1100 x g for 3 min. In the laminar airflow hood the supernatant was 
removed and cells were resuspended in 1.5 ml PBS, layered on top of 1 ml FCS and 
centrifuged at 1100 x g for 10 min. Supernatant containing cell debris was removed and cell 
pellet was in itself, made up to 1 ml with FCS and transferred to a 2 ml cryovial (Greiner Bio- 
One, Frickenhausen, Germany). An equal volume of cryoprotectant (90 % (v/v) FCS, 10 % 
v/v DMSO (dimethyl sulfoxide)) was added dropwise to the cell suspension with gentle 
mixing between drops. The cryovial was sealed and then placed at -80°C in 
container (Nalgene Labware, NY, USA) for 24 h and then transferred to a liquid nitrogen 
tank (Cryomed CRM-2800, Forma Scientific, OH, USA) for long-term storage.
2.2.4 Revival of frozen cells
A vial of frozen cells was removed from liquid nitrogen and thawed rapidly at 37°C. The 
thawed vial was taken in the laminar airflow hood and wiped down with 70 % EtOH. Pre- 
warmed culture medium (12 ml) was added to two 75 cm2 flasks and 1 ml of cells was added 
to each flask. The cells were allowed to recover and adhere overnight at 37°C. The following 
day medium was replaced with fresh pre-warmed medium and flasks were maintained as 
per section 2.2.1 and 2.2.2
2.2.5 Cell counting assay
The Trypan-Blue dye (Gibco-BRL, Paisley, UK) exclusion test is based on the ability of 
viable cells to actively exclude the dye due to an intact membrane whereas dead cells are 
unable to exclude the dye and appear blue under a microscope. Following trypsinisation of 
cells, 20 pi of cell suspension was added to an equal volume of Trypan Blue dye and mixed 
by pipetting. After 2 min, 10 pi was added to a haemocytometer (Brightline model, Sigma- 
Aldrich, MO, USA) and cells were counted under 20 x magnification.
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Cells within the outer 4 x 4  boxes were counted and the mean was used to calculate the cell 
density.
Cell density was calculated using the following formula:
N/4 x 2 x 104 = cells / ml 
N = mean cell number per field counted,
4 = number of fields counted,
2 = dilution factor and 
104 = haemocytometer constant
2.2.6 Single cell cloning by serial dilution
A serial dilution method was used to obtain HEK 293 dBP4 clones expressing high levels of 
protease resistant IGFBP 4 (dBP4). The PAPP-A cleavage site of wildtype IGFBP 4 was 
previously mutated by site directed mutagenesis from 119-KHMAKVRDIRSKMK-133 to 119- 
AAMAAVADASAMA-133. To all wells in the 96 well plate except A1 100 pi of medium was 
added. To well A1 2 x 103 HEK 293 dBP4 cells (200 pi) were added. Using a single channel 
pipettor 100 pi from the first well was transferred into B1 and mixed gently. The 1:1 serial 
dilutions were continued down the column, discarding 100 pi from H1. An additional 100 pi
of medium was added to each well in column 1. Using the~pipet£orr 10G p! fron'H.ihe,.we!!s*ln
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the first column was transferred to those in the second column (A2 - H2) with gentle mixing. 
These 1:1 serial dilutions were carried out across each column making sure to discard 100 
pi from the last column (A12 - H12), the final volume was of all wells was 200 pi. Figure 2.1 
shows a schematic of the dilutions. Cells were incubated at 37°C in a humidified C02 
incubator. After 4 -5  days, clones were identified and on day 7-10 clones were scored by 
marking wells that contained a single colony. Single colonies were subcultured into 24 well 
plate. dBP4 expression by clones was assessed by Western blot (Section 4.2.2)
2.2.7 Mycoplasma Testing
2.2.7.1 MycoAlert Assay
Mycoplasma testing was carried out monthly using a commercial MycoAlert® (Lonza, Basel, 
SWI) mycoplasma detection assay. This test exploits the reaction of mycoplasma enzymes 
with MycoAlert® Substrate catalysing the conversion of adenosine diphosphate (ADP) to 
adenosine triphosphate (ATP). Increased levels of ATP due to the presence of Mycoplasma 
can be detected using luciferase bioluminescence, emission read at 565 nm.
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Figure 2.1: Schematic for serial dilutions. 2 x 103 HEK 293 dBP4 
cells were added to A1 and diluted 1:1 down column 1, then 1:1 
across each column as shown.
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The ratio of ATP before and after addition of MycoAlert is indicative of presence or absence 
of Mycoplasma. Cell culture supernatant (2 ml) was added to a 15 ml tube and cell debris 
was pelleted by centrifugation at 1100 x g for 5 min. Cleared supernatant (100 (jl) was 
transferred to a white walled 96 well plate. All solutions were allowed to equilibrate to room 
temperature. The Luminometer (Victor X Multilabel Plate reader, Perkin-Elmer, Oy, Finland) 
was programmed to take a 1s integrated reading. MycoAlert® Reagent (100 |jl) was added to 
each sample and incubated at room temperature for 5 min. A565 was measured, in the 
Luminometer (Reading A). MycoAlert® Substrate (100 |jl) was then added to each sample 
and incubated at room temperature for 10 min. A565 was measured in the Luminometer 
(Reading B). The ratio of Reading B: Reading A was calculated. A ratio of < 1 indicated 
absence of Mycoplasma. If the ratio was > 1 this indicated samples were Mycoplasma 
positive. For samples giving a borderline ratio (0.9-1.1) a mycoplasma PCR (polymerase 
chain reaction) was carried out. Mycoplasma positive cells were discarded.
2.2.7.2 Mycoplasma PCR
Samples with a borderline ratio in the-MyeoA!ert®-test and cells grown in antibiotic^ .^er'e 
tested using the PCR Mycoplasma Test Kit II (Promocell,, Heidelberg, Germany). PCR 
method allowed identification of low levels of Mycoplasma infection. Cell culture supernatant 
(1 ml) was added to a 15 ml tube and cell debris pelleted at 1100 x g for 5 min. The cleared 
supernatant was transferred into a 1.5 ml Eppendorf tube (Eppendorf International, 
Hamburg, Germany) and Mycoplasma pelleted (Eppendorf 5417R, Eppendorf International, 
Hamburg, Germany) at 14, 000 x g for 10 min. Supernatant was discarded and the pellet 
was resuspended in 50 pi of Buffer Solution and heated at 95°C for 3 min. In a separate 
tube 35 pi distilled water, 10 pi Reaction Buffer (containing primers, dNTPs, Taq 
Polymerase) and 5 pi of denatured sample or 1 pi positive control were added. A negative 
control containing only buffer was also set up. All samples were placed in a PCR 
thermocycler (PTC-100, Pegasus Scientific Inc., MD, USA) and subjected to 1 cycle at 94° 
for 30 s followed by 35 cycles of 94°C for 30 s, 60°C for 120 s and 72°C for 60 s followed by 
1 cycle of 94°C for 30 s, 60°C for 120 s and 72°C for 5 min. Samples (20 pi) were analysed 
on a 2 % (w/v) agarose gel with Ethidium bromide (EtBr 0.5 pg/ml). Amplification of 
Mycoplasma resulted in a 270 bp PCR product.
2.3 Tissue Microarray (TMA) Construction
Archival, formalin fixed paraffin embedded (FFPE) prostate tumour samples from patients on 
file within Beaumont Hospital, Dublin were selected by Tony O’Grady. Ethics approval was
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awarded as part of the Prostate Cancer Research Consortium. All FFPE blocks were 
sectioned, haematoxylin and eosin (H & E) stained and graded by a pathologist (Prof. Elaine 
Kay) to confirm stage and grade of .the tumours. The relevant tumour areas were marked 
and used for TMA construction. TMAs were constructed from tissue blocks using the 
Beecher Instruments R Tissue Microarrayer (Beecher Instruments Inc, Wl, USA). Three 1 
mm cores of varying Gleason grades and three 1 mm cores of benign prostatic hyperplasia 
(BPH) were selected from each case of prostate carcinoma.
2.3.1 Immunohistochemical staining of TMAs
2.3.1.1 IGF IRß staining of TMAs
4 pm sections from all TMAs were prepared for immunohistochemistry. Sections were 
immunostained with IGF IRß rabbit polyclonal antibody (Cell Signalling Technology, MA,
USA) at 1:100 dilution on Bond Max Automated Immunohistochemistry system (Leica 
Microsystems GmbH, Wetzlar, Germany). TMAs were deparaffinised and pre-treated with 
the Epitope Retrieval Solution 2 (EDTA-buffer pH8.8) at 98°C for 20 min. After washing 
steps (Bond wash buffer (Leica Microsystems GmbH, Germany)), peroxidase blocking was 
carried out for 10 min using the Bond Polymer Refine Detection Kit DC9800 (Leica 
Microsystems GmbH, Germany). Tissues were^again washed and thenHnoubated with . w
IGF IRß (diluted in Bond antibody diluent, Leica Microsystems GmbH, Germany) for 30 min. 
Subsequently, tissues were incubated with anti-rabbit secondary conjugated with dextran 
polymer for 10 min and developed with DAB (Diaminobenzidine)-Chromogen for 10 min. All 
sections were counterstained with haematoxylin. For negative controls, primary antibody 
solution was omitted. Breast cancer tissue was used as a positive control. Each tissue 
microarray was scored based on staining strength in either the membrane or cytoplasm (0 
negative, +1 weak, +2 moderate, +3 strong).
2.3.1.2 Haematoxylin and Eosin staining of TMAs
Briefly, cut sections were subjected to on-board dewaxing (Dewax solution - Vision 
BioSystems™). Slides were stained in Haematoxylin for 2 min, rinsed in water followed by 
addition to acid alcohol for 2 s (0.1 % (v/v) HCL in 50 % (v/v) EtOH). Slides were rinsed in 
water for 15 min, stained with Eosin for 1 min, rinsed in 3 changes of water. Slides were 
dehydrated in 95 % (v/v) EtOH for 1 min followed by 100 % (v/v) EtOH for 1 min, rinsed in 
xylene twice for 5 min then coverslipped.
2.4 CD31* staining of human endothelial cells
Dr. Constanze Schadow carried out analysis of tubule formation in response to dBP4 
treatment. An Angiokit was purchased from TCS Cell works (Buckingham, UK). The kit,
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contained growing human endothelial cell cultures at the earliest stages of tubule formation 
in a 24 well plate format. This allowed for analysis of tubule formation (angiogenesis). 
Tubules were stained for CD31+ an endothelial cell adhesion molecule. Medium was 
aspirated from each well and washed with 500 pi of wash buffer (PBS). Cold fixative (500 pi, 
70 % (v/v) EtOH) was added to each well and incubated at room temperature for 30 min. 
The fixative was decanted and wells were washed 3 times with 500 pi of blocking buffer 
(PBS/1 % (w/v) BSA). The final wash was carefully decanted. The primary antibody (mouse 
anti-CD31+) was diluted 1:400 in blocking buffer. 500 pl/well of primary antibody was 
incubated for 1 h at 37°C. The plate was washed 3 times with 500 pl/well blocking buffer. 
Secondary antibody (goat anti-mouse IgG alkaline phosphatase conjugate) was diluted 
1:500 in blocking buffer. 500 pl/well of the secondary antibody was added and incubated for
1 h at 37°C. The plate was washed 3 times with 500 pl/well dH20. Two 5-bromo-4-chloro-3'- 
indolyphosphate/nitro-blue tetrazolium (BCIP/NBT) tablets were dissolved in 20 ml dH20 and 
filtered through a 0.2 pm filter. 500 pl/well of substrate was added and incubated at room 
temperature until tubules developed a dark purple colour (3-10 min). The plate was washed
3 times with 500 pl/well dH20. The final wash was discarded and the wells were air dried. 
Tubule formation was assessed with TCS Cell Works Angiosys Imaging Analysis software 
(Buckingham, UK), ^
2.5 RNA and DNA analysis
2.5.1 Isolation of RNA
As RNA is susceptible to degradation by RNases which are ubiquitous in the laboratory, all 
materials for RNA isolation were autoclaved at 121°C for 20 min. The bench and pipettes to 
be used were wiped down with RNAse Zap (Applied Biosystems, TX, USA). Trizol® (1ml, 
Invitrogen, CA, USA) was added to a 75 cm2 flask, cells were incubated on a shaker table 
for 5 min. After cells were fully lysed, the Trizol® was transferred to a 2 ml Eppendorf tube. 
For every ml of Trizol® 270 pi chloroform was added, the tube was mixed vigorously for 15 s, 
then incubated at room temperature for 5 min. Phases were separated by centrifugation at 
12,000 x g for 15 min. The aqueous (top) layer was placed into a fresh tube. RNA was 
precipitated by adding 670 pi isopropanoi, mixed and incubated at room temperature for 10 
min. RNA was pelleted by centrifugation at 12,000 x g for 10 min at room temperature. 
Supernatants were carefully decanted and pellets washed with 1 ml 75 % (v/v) EtOH (in 
DEPC (diethylpyrocarbonate) treated water. RNA was pelleted by centrifugation at 12,000 x 
g for 10 min at 4°C. Supernatant was decanted, the pellet was air dried for 5 min and then 
resuspended in 50 pi TE Buffer (10mM Tris-HCI (pH 7.4), 1mM EDTA Buffer (pH 8.0)). 
Samples were kept on ice from this stage.
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2.5.2 RNA/DNA quantification
A nanodrop (ND-1000 UV-Vis Spectrophotometer, NandDrop Technologies, DE, USA) was 
used to quantify RNA/DNA. 1 pi of distilled water was used as a blank, followed by 1 pi TE 
buffer. Once the nanodrop was at zero, 1 pi of RNA/DNA sample was added with software 
(ND-1000) set to RNA 40 / DNA 50. A ratio of 1.8 - 2.0 indicates pure RNA/DNA, below 1.8 
may indicate the presence of protein and above 2 may indicate the presence of organic 
solvents. Using the Beer-Lambert law it is possible to relate the amount of light absorbed to 
the concentration of the absorbing molecule. At a wavelength of 260 nm, the extinction 
coefficient for.double-stranded DNA is 50 (pg/ml)'1 cm"1; for single-stranded DNA and RNA it 
is 38 (pg/ml)_1 cm"1.
Concentration of double stranded DNA = absorbance at 260 nm x 50 x dilution 
Concentration of single-stranded DNA and RNA = absorbance at 260 nm x 38 x dilution
2.5.3 cDNA synthesis
cDNA was produced from total RNA. 1 pg total RNA was digested with 1U DNase I 
(Invitrogen, CA, USA) in a total volume of 10 pi at room temperature for 15 min (to degrade 
any contaminating DNA present in the RNA sample): DNase I was inactivated ^by "the 
addition of 1 pi 25 mM'EDTA (Invitrogen, CA, USA) and heating to 70°C for 10 min. cDNA 
was synthesised from total RNA using the Superscript H First-Strand Synthesis System for 
reverse transcriptase PCR (RT-PCR, Invitrogen, CA, USA). To the DNase treated RNA, 4 pi
5 x First Strand Buffer, 2 pi 0.1 M DTT, 1 pi random primers and 200 U Superscript II 
reverse transcriptase (RT) (M-MLV) was added. cDNA synthesis was carried out at 42°C for 
50 min and RT inactivated at 70°C for 15 min, then stored at -20°C.
2.5.4 Primer Design
Primers were designed based on published mRNA sequence data and Genbank data. 
Where possible each primer was designed with 50 % G - C content to maximise primer 
annealing to template without an excessively high annealing temperature. This allows stable 
binding of primer to cDNA as G - C base pairs contain three hydrogen bonds, whereas A - T 
only contains two. Sequence complimentarity between primer pairs was avoided so as to 
prevent the formation of primer dimers. Primer Blast was used to design primers 
(http://www.ncbi.nlm.nih.qov/tools/primer-blast/). Selected primer sequences were compared 
to published sequences (Genbank) using BLAST (http://www.ncbi.nih.gov/BLAST) to ensure 
there was no cross reactivity with sequences other than the desired mRNA. Primers were 
synthesised by Eurofins MWG Operon (Ebersburg, Germany) and LGC Genomics (Berlin, 
Germany).
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PAPP-A specific primers:
Forward primer: 5’ AGGTGGCATTGTCTTGAACC 3’
Reverse primer: 5’ AAGCCACAGGTGTCAI I ICC 3’
(3-actin specific primers
Forward primer: 5’ TGTGATGGTGGGAATGGGTGAG 3’
Reverse primer: 5’ TTTGATGTCACGCACGATTTCC 3’ 
p-actin primers were purchased from Stratagene (CA, USA).
Primer sequences for cloning protease resistant IGFBP 4 (dBP4) into tetracycline inducible 
lentiviral vector (pLVX Tight Puro) •
Forward primer: 5’ GGGGATCCAAAGGAGATATACCATGGTGCCCT 3’
The underlined sequence is the BamH\ restriction enzyme site, the sequence in bold is the 
start codon. The italicised sequence is dBP4 sequence. The sequence AAAGGAG is the 
ribosomal binding site and TACCATGG is the Kozak sequence.
Reverse primer: 5’ GGGAATTCTTAGTGATGGTGATGGTGATGGTG 3’
The underlined sequence is the EcoRI restriction enzyme site, the sequence in bold is the 
stop codon and the normal text is the sequence for the His-tag (6 x histidine codons) which 
allows identification of the recombinant dBP4 protein by Western blotting.
2.5.5 Polymerase chain reaction (PCR)
cDNA or plasmid DNA was used as a template for PCR. A master mix was aliquoted to each 
reaction tube before template was added. Each reaction contained 5 jjl 10 x PCR Buffer,
2 |jl 25 mM MgCI2, 1 pi 10 mM dNTPs, 0.5 pi Taq DNA Polymerase (5U/pl, Fermeritas, 
Germany), 1.5 pi cDNA and 38 pi dH20. No template was added to negative controls, cDNA 
from HEK 293 cells was used as a positive control for PAPP-A PCR and pTriEx4 Neo dBP4 
(Appendix 1) plasmid was used as positive control for colony PCR.
Amplification of PAPP-A:
cDNA generated from RNA isolated from PC-3M-luc2 and HEK293 cells was amplified using 
PAPP-A primers. cDNA was denatured at 94°C for 5 min, followed by 35 cycles of 94°C for 
45 s, 58°C for 45 s (primer annealing), 72 °C for 45 s (primer extension) followed by 72°C 
for 10 min.
Amplification of p-actin:
cDNA generated from RNA isolated from PC-3M-luc2 and HEK293 cells was amplified using 
P-actin primers. cDNA was denatured at 94°C for 5 min, primers annealed at 60°C for 5 min, 
primer extension at 72°C for 90s followed by 35 cycles of 94°C for 45s, then 60°C for 45s 
and 72°Cfor 90s.
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Amplification of dBP4 for cloning into tetracycline inducible lentiviral vector (pLVX Tight 
Puro)
dBP4 was amplified from 1 ng of pTriEx4 Neo dBP4 for subcloning into pLVX Tight Puro 
lentiviral vector. Using the forward and reverse primers PCR was carried out, 94°C for 90 s, 
50°C for 30 s, 72°C for 2 min, 30 cycles of 95°C for 45 s, 55°C for 30 s, 72°C for 2 min and 
72°C for 10 min.
Amplification of IGFBPs and IGFs by Multiplex PCR
cDNA generated from RNA isolated from PC-3M-luc2 cells was amplified using a Mulitplex 
PCR human IGF and IGFBPs Kit (Maxim Biotech, CA, USA) as per the manufacturer’s 
instructions which were 2 cycles of 96°C for 60 s followed by 63°C for 4 min and 35 cycles 
at 94°C for 60 s, 63°C for 2 min and 70°C for 10 min.
PCR products from PAPP-A, p-actin and Multiplex PCR were fractionated on a 2 % (w/v) 1 
x TAE (40 mM Tris, 20 mM acetic acid, 1 mM EDTA) agarose gel containing 0.5 |jg/ml EtBr 
(Sigma-Aldrich, MO, USA). Products from dBP4 PCR were fractionated on a 0.8 % (w/v) 
TAE low melting point agarose gel containing 0.5 pg/ml ethidium bromide.
2.5.6 DNA Electrophoresis
DNA was fractionated on a non-denaturing 0.8 2 % (w/v) agarose ge! in 1 x TAE. Where 
DNA was to be recovered, low melting point (LMP) agarose (Invitrogen, CA, USA) was 
used. Agarose (0.4 - 1 g) was added to 50 ml 1 x TAE and dissolved in the microwave then 
to this 5 pi of ethidium bromide (10 mg/ml) was added to the molten agarose. The agarose 
was mixed and poured into a gel tray with well forming comb in place and allowed to set at 
4°C. The comb was then removed, 1 kb DNA molecular weight marker (5 pi, Fermentas, 
Germany) was loaded alongside samples. All samples were mixed with appropriate amount 
of 6 x loading buffer (0.25 % (w/v) bromophenol blue, 0.25 % (w/v) xylene cyanol FF in 30 % 
(v/v) glycerol (Sigma-Aldrich, MO, USA), distilled water) before loading into wells. 
Electrophoresis was carried out at 100 V for 1 h or until the dye front was 2/3 way down gel 
depending on size of fragments. DNA was visualised using a UV transilluminator (TFX-20M 
UV illuminator, Vilber Lourmat, Marne-la-Vallee, France). Gels were photographed using 
Genesnap (Syngene, MD, USA).
2.6 Molecular cloning
Molecular cloning, A Laboratory Manual (Sambrook & Russell, 2001) was used as a guide 
for cloning methods. Sections 2.5.4-2.5.6 have already described the methods used to 
amplify dBP4 insert. Following DNA electrophoresis, the dBP4 PCR product was recovered 
from the agarose gel.
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2.6.1 DNA recovery from agarose
The desired DNA bands were visualised using a UV transilluminator (TFX-20M UV 
illuminator) and excised from LMP agarose with a clean sterile scalpel. The agarose slice 
was transferred into a pre-weighed 1.5 mi tube. The tube was weighed again after addition 
of the gel slice. GeneJet Gel Extraction Kit (Fermentas, Germany) was used to extract the 
DNA from the gel. A 1:1 (weight: volume) volume of binding buffer was added to the gel 
slice (100 mg: 100 pi binding buffer). The slice was liquefied at 60°C for 10 min and added 
to a GeneJet purification column. The column was centrifuged at 14,000 x g for 1 min and 
flow through was discarded. Wash buffer (700 pi) was added to the column, then centrifuged 
at 14, 000 x g for 1 min, flow through discarded and the empty column was centrifuged for a 
further 1 min. The GeneJet column was placed into a clean 1.5 ml Eppendorf tube, 50 pi 
elution buffer was added to the centre of the column and DNA was eluted at 14, 000 x g for
1 min. DNA quantification was carried out as described in section 2.5.2.
2.6.2 DNA digestion with restriction enzymes
All fast digest restriction enzymes were purchased from Fermentas (Fermentas, Germany). 
Double digests were carried out together in Fast Digest reaction buffer (Fermentas, 
Germany). Each reaction contained 5 pi 10 x FaslDigest: Rea'ction Buffer; 0.5/pg D^A,.i . 
10 U EcoRI, 15 U BamH\, 1 pi alkaline phosphatase and sterile distilled water to a final 
volume of 50 pi. Restriction enzymes were added after all other reaction components were 
mixed well and then DNA was digested at 37°C for 40 min. Digested DNA was fractionated 
by electrophoresis through LMP agarose gel (2.5.6) and purified as described (2.6.1). 
Purified DNA was precipitated (2.6.3) and quantified (2.5.2).
2.6.3 Ethanol precipitation of DNA.
DNA was precipitated at -20°C for 30 min by addition of 0.1 volumes of 3 M sodium acetate 
(pH 5.2) and 2.5 volumes of 100 % (v/v) EtOH based on the combined volume of DNA and 
sodium acetate: DNA was pelleted at 14,000 x g for 20 min. Supernatant was decanted and 
the DNA pellet was washed with 70 % (v/v) EtOH, air dried for 5 min and resuspended in TE 
buffer.
2.6.4 DNA ligation
DNA was ligated at a molar ratio of 10:1 and 20:1 insert (5 ng/ml) to vector DNA (5 ng/ml). 
Vector and insert were mixed with 10 x ligation buffer (Fermentas, Germany) and 5 U T4 
DNA ligase (5U/pl, Fermentas, Germany) in a final volume of 20 pi. Controls for self ligation 
contained vector DNA only or a ligation control containing no T4 DNA ligase. Reactions 
were incubated for 4 hours at room temperature then placed on ice.
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2.6.5 Bacterial transformation
2.6.5.1 Media/Solutions
Ampicillin
100 mg ampicillin (Sigma-Aldrich, MO, USA) was added to 10 ml distilled water, filter 
sterilised through a 22 pm syringe filter and stored in aliquots at -20°C. Once thawed 
aliquots were discarded.
LB (Luria Bertani) Broth
LB Broth mix (25 g, Merck, Nottingham, UK) was dissolved in 1 L distilled water and 
autoclaved. LB broth contains 10 g/L Bacto-tryptone, 5 g/L yeast extract and 10 g/L NaCI, 
pH 7.5.
LB agar
LB agar mix (35 g, Merck, Nottingham, UK) was dissolved in 1 L distilled water and 
autoclaved. LB agar contains the same components as the LB broth, but with 15 g/L of agar.
Antibiotic containing LB broth
Before use, ampicillin stock solution (100 mg/ml) was added to LB ..broth to affinal 
concentration of 100 pg/ml (LBAmp100).
Antibiotic containing LB agar
LB agar prepared earlier was dissolved in the microwave, allowed to cool to 50°C and 
ampicillin (100 pg/ml) added. LBAmp100 agar plates were prepared by pouring 30 ml agar 
into sterile petri dishes under aseptic conditions, allowed to set and stored at 4°C.
SOC medium
SOC medium was purchased from Invitrogen (Invitrogen, CA, USA) and stored at room 
temperature. SOC medium contains 2 g/L tryptone, 0.5 g/L yeast extract , 0.05 g/L NaCI, 
250 mM KCI, 1 M glucose and 2 M MgCI2.
2.6.5.2 Transformation of bacterial cells
One Shot® TOP10 competent E.coii (Invitrogen, CA, USA) were used as the host cells for 
plasmids and stored at -80°C until use. Cells were thawed on wet ice and 50 jjI aliquoted 
into pre-chilled 1.5 ml tubes. DNA ligations (2 pi) were added to E.coii, incubated on ice for 
30 min, then heat pulsed at 42°C for 30 s before cooling on ice for 2 min. SOC medium (250 
pi) was added to each tube and incubated at 37°C for 1 h with shaking at 225 rpm. Cells 
(100 pi) were then spread on LBAmp100 agar and incubated inverted overnight at 37°C.
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2.6.6 Colony PCR
Bacterial colonies were screened for the presence of insert (dBP4) by colony PCR. 
Individual colonies (28) were spotted onto a gridded LBAmp100 agar plate with a sterile 
pipette tip and the remainder of the colony added to 5 pi (5 % v/v) Triton X-100 (Merck, 
Nottingham, UK) and lysed at 95°C for 5 min, then used as template for PCR (2.4.5).
2.6.7 Plasmid purification from bacterial cultures
Single bacterial colonies selected from LBAmp100 agar were inoculated into LBAmp100 broth 
(10 ml in 50 ml polypropylene tube) and grown overnight at 37°C with shaking. For small 
scale purification (10 ml) Qiaprep Spin Miniprep Kit (Qiagen, MD, USA) was used. For large 
scale purification (100 ml culture) Qiagen Endofree Maxi Prep system (Qiagen, MD, USA) 
was used. The maxi prep kit was also used when preparing DNA for transfection to remove 
bacterial endotoxins, which interfere with transfection efficiency. Purification protocols were 
as per manufacturer’s instructions.
2.6.8 Sequencing of cloned inserts
All sequencing was carried out by LGC Genomics (Berlin, Germany) single read 
sequencing. Primers were designedio span the vector insert junctions (Section JA 4 ),r  
Sequence data was compared to published sequences (Genbank) using BLAST 
(http://www.ncbi.nlm.nih.gov/BLASTV If deviations from expected sequences were identified 
samples were re-sequenced.
2.7 Mammalian cell transfection and transduction
2.7.1 Transfection of HEK 293 T cells with pLVX pTet-On Advanced and pLVX Tight 
Puro dBP4
All work was carried out in a class II facility. HEK 293 T cells were used as packaging cells 
to produce virus particles for transduction of PC-3M-luc2. Figure 2.2 shows a flow diagram 
of the steps involved in generating cells expressing dBP4 under the control of a Tet 
inducible promoter. HEK 293 T cells were transfected with pLVX pTet-On Advanced (3 pg, 
Appendix 2) or pLVX Tight Puro dBP4 plasmids (3 pg, Appendix 3), psPAX2 plasmid (3 pg, 
viral packaging, Appendix 4) and pmD2.g plasmid (2.5 pg, envelope, Appendix 5) using 
Genejuice (Merck, Nottingham, UK) in 600 pi Optimem (Gibco-BRL, Paisley, UK). 
Transfection reaction was mixed and incubated at room temperature for 10 min, then added 
to 70 % confluent HEK 293 T cells in 25 cm2 flasks and incubated at 37°C overnight. The 
following day the medium was replaced with fresh pre-warmed medium and incubated 
overnight to increase viral titers.
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2.7.2 Transduction of PC-3M-luc2 with pLVX pTet-On Advanced and pLVX Tight 
Puro dBP4
Medium containing virus particles from the HEK 293 T cells was filtered through a 0.45 |jm 
syringe filter to remove any cellular debris then added to 70 % confluent PC-3M-luc2 cells in 
a 25 cm3 flask and incubated at 37°C overnight. The following day, medium was replaced 
with pre-warmed fresh medium, cells were allowed to recover for 3 days. PC-3M-luc2 cells 
were first transduced with pLVX pTet-On Advanced plasmid and clones selected by 
incubating in 400 pg/ml G418 (geneticin, Gibco-BRL, Paisley, UK) for 4 weeks. Once stable 
clones were established the pTet-On PC-3M-luc2 cells were then transduced with the pLVX 
Tight Puro dBP4 plasmid and clones were selected by incubating cells in 2 |jg/ml puromycin 
(Sigma-Aldrich, MO, USA) for 7 days. dBP4 expression by selected clones was induced by
0.1 jjM Doxycycline to culture medium for 3 days and followed by Western blot analysis of 
conditioned medium.
2.8 Luciferase assay
A 200 x luciferin stock solution (30 mg/ml) was prepared in sterile water. A 1 x stock (150 
fjg/ml) was prepared in fresh cell culture medium. The 1 x stock was added to cells for 2 min
at 37 °C. Cells were then imaged using the IVIS Spectrum, . .
2.9 Protein analysis
2.9.1 Collection and storage of cell lysates and conditioned medium
Cell lysates were prepared from 6 well plates. Medium was discarded and cells were 
washed with PBS (3 ml/well). RIPA Buffer (200 pl/well, 25 mM Tris HCl pH 7.6, 150 mM 
NaCI, 1% v/v NP-40, 1% w/v sodium deoxycholate, 0.1% w/v SDS buffer, Sigma, MO, USA) 
containing 2 pi of 100 x protease inhibitor cocktail (4-(2-aminoethyl) benzenesulfonyl fluoride 
(AEBSF), pepstatin-A, E-64, bestatin, leupeptin and aprotinin, Merck, Nottingham, UK) and
2 pi 100 x phosphatase inhibitor cocktail (sodium orthovanadate, sodium molybdate, sodium 
tartrate and imidazole, Sigma, MO, USA) was added. Cells were scraped into 0.5 ml tubes, 
lysed by pipetting, and incubated on ice for 30 min and debris was pelleted at 14,000 x g for 
10 min. Lysates were stored at -80°C until use and thawed on ice.
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Figure 2.2: Flow diagram of generation of PC-3M-luc2 with tetracycline (Tet) inducible 
vector expressing dBP4. The diagram shows the steps taken to create the Tet inducible 
PC-3M-luc2 cells. HEK293 T cells were transfected with the pTet-On Advanced vector 
along with psPAX2 (viral packaging) and pmD2.g (viral envelope) to produce virus particles. 
PC-3M-luc2 cells were transduced with the virus particles containing the pTet-On Advanced 
vector and selected in geneticin (400 pg/ml) for 4 weeks to produce stable clones. HEK 293 
T cells were used to package the pLVX Tight Puro dBP4 vector as before. pTet-On PC-3M- 
Iuc2 cells were transduced with virus particles containing pLVX Tight Puro dBP4 and stable 
clones selected in puromycin (2 pg/ml) for 7 days. Doxycycline was added to cells to test for 
induction of dBP4. Doxycycline interacts with reverse transcriptional transactivator (rtTA) 
and binds to the tetracycline response element (TRE mod) switching on dBP4 by use of the 
CMV (cytomegalovirus) promoter.
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Serum-free culture medium (conditioned medium) was collected from 75 cm2 flasks (10 ml) 
after 48 h. Conditioned medium was concentrated using 3 kDa Centricon YM-3 filters 
(Millipore, MA, USA) according to manufacturer’s instructions. Once a volume of 0.5 ml or 
less was obtained 5 |jl of 100 x protease inhibitor cocktail and 100 x phosphatase inhibitor 
cocktail was added and conditioned medium was stored at -80°C until use and thawed on 
ice.
2.9.2 Protein quantification using Bio-Rad DC protein assay
Bio-Rad DC (detergent compatible) protein assay was purchased from Bio-Rad (Bio-Rad, 
CA, USA). The assay is based on the reaction of protein with an alkaline copper tartrate 
solution (Reagent A) and Folin reagent. There are two steps that lead to colour 
development, the reaction between protein and copper in an alkaline medium and the 
subsequent reduction of Folin reagent by the copper-treated protein. Colour development is 
primarily due to the amino acids tyrosine and tryptophan. Proteins effect a reduction of the 
Folin reagent by loss of 1, 2, or 3 oxygen atoms, producing one or more of several possible 
reduced species with a characteristic blue colour. The maximum absorbance (Amax) is 750 
nm. Using a standard curve of known protein concentrations (0.125 - 2 mg/ml, bovine serum
albumin.(BS A)/diluted’ in RIPA:buffer or serum free medium) the protein concentration oft
unknown samples can be determined through comparisons of optical densities of known, 
protein concentrations. Sample or standard (5 |jl) were added to a 96 well plate in duplicate. 
Working reagent, 20 [jl Reagent S (detergent) (25 |jl/well) in 1 ml Reagent A (alkaline 
copper tartrate solution) was added followed by 100 |jl/well Folin solution (Reagent B). 
Plates were incubated for 15 min at room temperature. Optical density of samples and 
standards at 750 nm was determined using the Victor X Multilabel Plate reader (Perkin- 
Elmer, Oy, Finland). A linear standard curve was generated from the standards and the 
equation of the line was used to calculate the protein concentration of the unknown samples 
(See Appendix 7).
2.9.3 Immunoprécipitations
Sepharose G beads were washed twice with 1 x TBS (25 mM Tris, 150 mM NaCI, Sigma, 
MO,USA) at 664 x g for 30 s. Antibodies to be used (Appendix 8) were coupled to 
Sepharose G beads on a rotating platform overnight at 4°C. Cell lysates were prepared as 
per section 2.7.1 and 2.7.2. Sepharose G beads were pelleted at 664 x g for 30 s and 
supernatant was discarded. Cell lysate (250 pg) was added to the antibody coupled 
Sepharose G beads on a rotating platform for 2 h at 4°C. Beads were pelleted at 664 a g for 
30 s, supernatant removed and beads washed 3 times with RIP A buffer. Dry beads were 
then stored at -20°C until use and thawed on ice when needed.
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2.9.4 Protein purification
2.9.4.1 Nickel agarose purification of recombinant dBP4
HEK 293 cells were transfected with a construct containing dBP4 tagged with 6 histidine 
residues (6 x His-tag) at the C-terminal end. As dBP4 is secreted, conditioned medium was 
collected from the HEK 293 cells and concentrated 20 fold.
Qiagen Superflow Ni-NTA agarose (Qiagen, MD, USA) bead slurry (3 ml) was loaded onto 
Bio-Rad disposable chromatography columns and compacted to 1.5 ml by washing with 
distilled water (30 ml) and equilibrated with 1 x Binding Buffer (15 ml, 300 mM NaCI, 50 mM 
sodium phosphate, 10 mM imidazole). Conditioned medium (500 ml) was loaded on column 
and allowed to flow through. Beads were washed with 1 x binding buffer (45 ml), followed by 
1 x wash buffer (10 ml, 300 mM NaCI, 50 mM sodium phosphate, 20 mM imidazole). Finally, 
His-tagged dBP4 was eluted from the column using 1 x elution buffer (10 ml, 300 mM NaCI, 
50 mM sodium phosphate, 250 mM imidazole). Samples were taken at each step to check 
for loss of dBP4 during the purification. Eluate was concentrated to a final volume of 500 pi 
using Centricons YM-3, purified by FPLC (fast protein liquid chromatography).
2.9.4.2 Fast protein liquid chromatography (FPLC)
FoJIowing. purification of dBP4 with nickel agarose beads, FPLC was used.to further,nurify. 
the dBP4. A Superdex 200 column (GE Healthcare, Bucks, UK) was attached to the FPLC, 
to purify protein by size exclusion. Based on the size of dBP4 (28 kDa) it was estimated 
using the user manual, that after 12 ml of running buffer (10 mM HEPES, 150 mM NaCI and 
1 mM CaCI2, pH 7.5, Sigma, MO, USA) dBP4 should elute from the column. FPLC was 
cleaned with 50 ml sterile water followed by 50 ml 20 % (v/v) EtOH. Protein samples were 
loaded into the FPLC using a syringe and fractions (500 pi) collected in 1.5 ml tubes. All 
samples were analysed by Western blot to check for dBP4.
2.9.5 PAPP-A and PSA digest of dBP4
Concentrated conditioned medium (20 pi) containing dBP4 was incubated with 2 pi 
recombinant PAPP-A (conditioned medium from HEK 293 ceils transfected with human 
PAPP-A) (a gift from Claus Oxvig, University of Aarhus, Denmark) and 4 pi IGF II (50 ng/pl) 
at 37°C overnight. For PSA digestion, 20 pi concentrated conditioned medium was 
incubated with 2 pi PSA (10 ng/pl) at 37°C overnight. dBP4 cleavage by PAPP-A or PSA 
was assessed by Western blot (2.7.6).
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2.9.6 Western blotting of proteins
Proteins were fractionated by electrophoresis through 4 -2 0  % (w/v) pre-cast SDS-PAGE 
(polyacrylimide gel electrophoresis) gel (Pierce, IL, USA). Gel rigs (Bio-Rad, MA, USA) were’ 
washed with distilled water and assembled according to manufacturer’s instructions. Gels 
were placed in the gel rig and chamber and then wells were rinsed with electrode buffer (0.1 
M Tris, 0.1 M HEPES, 3 mM SDS, pH 8, Pierce, IL, USA, Appendix 6). Once rinsed 40Ó ml 
of electrode buffer was poured into the chamber. Up to 50 pg of protein plus the appropriate 
amount of 6 x Laemmli buffer (Appendix 6) were denatured at 98°C for 10 min. Samples 
were loaded on to thè gel (35 pl/well) arid electrophoresis was carried out at 130 V for 45 
min or until the bromophenol dye front reached the end of the gel. Pre-stained protein 
markers (10-250 kDa) (Fermentas, Germany) were loaded on each gel alongside samples.
2.9.7 Silver staining of SDS-PAGE
Following section 2.7.4 and 2.7.5 a silver stain kit was obtained from GE Healthcare and the 
protocol was followed as per the manufacturer’s instructions. Following SDS-PAGE proteins 
were fixed for 30 minutes in 40% (v/v) EtOH while shaking. The 40% (v/v) EtOH was 
discarded and the gel was sensitised for 30 min using a sensitising solution (EtOH, 5% (w/v) 
sodium thiosulphate, sodium acetate, distilled water). The gel was washed-.3-times 5 r j^n 
each with water. . .
Silver nitrate solution (2.5 % w/v) was added to the gel for 20 min with shaking. The 
silver nitrate solution was discarded and the gel was washed twice for 1 min each with 
water. Developing solution (0.06 M sodium carbonate, 37% (v/v) formaldehyde) was 
incubated for 2-5 min depending on how quickly a colour change developed. When the 
bands of the gel reached the desired intensity the gel was transferred into stop solution (9.8 
mM Ethylene Diamine Tetraacetic Acid Disodium (EDTA)) for 10 min with gentle shaking. 
The stop solution was removed and the gel was washed 3 times for 5 min each. To preserve 
the gel, 87% (v/v) glycerol was added and incubated for 20 min with gentle shaking.
2.9.8 Western Blot transfer
A wet transfer apparatus (Bio-Rad, CA, USA) was used to transfer proteins to nitrocellulose 
membrane (Pall Gelman Laboratory, NY, USA). Nitrocellulose and Whatman filter paper 
were cut to the same size of the gel. The membrane, filter paper and transfer sponges were 
soaked in 1 x transfer buffer (made from 10 x solution: 1.5M glycine, 0.18M Tris, 0.1% (w/v) 
SDS; 1 x working solution: 100 ml 10 x solution, 200 ml methanol, made up to a litre with 
distilled water, Appendix 6 ) before assembling the transfer apparatus. The transfer sponges 
were placed within the cassette, which was then overlaid with filter paper, followed by the 
gel, nitrocellulose (0.2 pm), filter paper and finally another transfer sponge. Air bubbles were
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removed and cassettes were clipped together and placed into the wet transfer apparatus 
with nitrocellulose towards the cathode (-) and gel orientated towards the anode (+) with 1 L 
1 x transfer buffer and a cooling block. Proteins were transferred to nitrocellulose membrane 
for 1 hat 100V,
2.9.9 Ponceau S staining
To confirm efficient transfer of protein onto nitrocellulose membrane, the membrane was 
stained with Ponceau S staining solution (Sigma-Aldrich, MO, USA) for 2 min. Protein bands 
became visible upon de-staining with distilled water. Membranes were washed with 1 x 
TBST (25 mM Tris, 150 mM NaCI, 0.1 % Tween) for 5 min until stain was removed.
2.9.10 Antibody detection for Western blotting
Membranes were incubated with blocking solution (5 % (w/v) fat free dried milk protein,
Marvel, Premier Foods, UK) in 1 x TBST (Appendix 6) for 1 h on a shaking table at room 
temperature. Membranes were washed 3 times for 10 min each with 1 x TBST. The 
appropriate primary antibody was diluted in either 5 % (w/v) fat free dried milk protein or 5 %
(w/v) BSA in 1 x TBST according to the manufacturer’s specifications. Primary antibodies 
(Appendix 8) were incubated overnight at 45C. Membranes were washed:3 'times'' witli;f 'x  t~ , , ' v* 
TBST for 10 min each at room temperature. Horse-radish peroxidise (HRP)-corijugated goat 
anti-rabbit or rabbit anti-mouse antibody (Dako, Glostrup, Denmark) were diluted 1:2000 in 1 
x TBST with 5 % (w/v) fat free dried milk protein and incubated for 1 h on a shaking table at 
room temperature. Membranes were washed 3 times with 1 x TBST for 10 min, followed by
5 min incubation with a chemiluminescent HRP substrate (Pierce ECL Western blotting 
substrate, IL, USA). The membrane was placed beneath a clear plastic sheet within an 
X-ray cassette, before being exposed to X-ray film (Kodak Ltd, Herts, UK) for 30 s in the first 
instance in a dark room under red light. If necessary, the membrane was exposed to fresh 
film for a shorter or longer time. ,
2.9.11 IGF binding ELISA
To determine if dBP4 maintains its binding affinity for IGF, an ELISA based method was 
developed. A 96 well plate was coated with 50 ng/ml IGF I, IGF II and VEGF165 overnight at 
4°C. The plate was washed 3 times with 400 pl/well PBST (0.1 % (v/v) Tween) and blocked 
with 5 % (w/v) BSA in PBS for 1.5 h at 37°C. Blocking solution was removed and the plate 
was washed 3 times with 400 pl/well PBST. dBP4 (500 ng/ml) was added to each well and 
incubated for 1.5 h at 37°C. Again the plate was washed 3 times with PBST. Primary 
antibody, 1:10,000 His-tag HRP (100 pl/well) in 1 % fat free dried milk protein in PBS was
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incubated for 1 h at 37°C. The plate was washed 3 times with 400 pl/well PBST. As the 
primary antibody was HRP-conjugated, 100 pl/well of tetramethylbenzidine (TMB) substrate 
(Sigma-Aldrich, MO, USA) was added and incubated for 30 min at room temperature. Stop 
solution, 0.5 M sulphuric acid (100 pl/well) was then added. Absorbance was read at 450 nm 
on a Victor X Multilabel Plate reader (Perkin-Elmer, Oy, Finland).
2.9.12 VEGF165 ELISA
To determine VEGF165 expression by PC-3M-luc2, a VEGFies Sandwich ELISA was 
purchased from R&D Systems (R&D Systems, MN, USA) and was carried out according to 
the manufacturer’s instructions. Briefly, the VEGF165 ELISA contains an antibody to VEGF165 
immobilised in each well of the 96 well plate. Conditioned medium and VEGF165 standards (0 
- 1000 pg/ml) were added to each well for 2 h at room temperature. The 96 well plate was 
washed 3 times with 400 pl/well wash buffer and incubated with VEGF165 conjugate for 2 h at 
room temperature. The plate was washed 3 times with 400 pl/well wash buffer, before 
Substrate Solution (100 pl/well) was added and incubated for 20 min in the dark at room 
temperature. Stop Solution (100 pl/well) was then added (blue to yellow colour change) and 
absorbance at 570 nm was measured. The OD value for the blank control was subtracted 
from each sample. A standard curve was constructed which.allowed for unknown,sampjes to; 
be determined (Appendix 9). Total protein content was measured as per section 2.7,2 in cell 
lysates and VEGF165 levels were normalised to total protein content within the cell (pg/mg).
2.9.13 IGF I ELISA
IGF I in prostate cancer patient plasma samples (obtained from the Prostate Cancer 
Research Consortium), mouse serum and tumour lysates was measured by ELISA 
according to the manufacturer’s protocol (R&D systems, MN, USA). All samples were 
assayed in duplicate. Standards for human IGF I (6, 3, 1.5, 0.75, 0.375, 0.188, 0.094 ng/ml) 
and mouse IGF I (2, 1, 0.5, 0.25, 0.125, 0.062, 0.031 ng/ml) were prepared by serial 
dilutions of a 60ng/ml or 2 ng/ml stock, respectively. Prostate cancer plasma samples used 
for the IGF I ELISA were first pre-treated with an acidic dissolution solution, in order to 
release all IGF I bound to IGFBPs. The 96-well plate supplied was pre-coated with anti-IGF I 
antibody. Samples (or standard) (50 pl/well) were added in duplicate to each well and 
incubated for two hours at 4°C. The liquid was aspirated from each well and washed 4 times 
with 400 pl/well wash buffer supplied with the kit. Cold conjugate (100 pl/well) was added to 
each well and then incubated for 1 h at 4°C. The liquid was aspirated from each well and 
washed 4 times with 400 pl/well wash buffer. Substrate solution (100 pl/well) was added to 
each well and incubated for 30 min at room temperature, while ensuring the plate was 
protected from light. Stop solution (100 pl/well) was added and a colour change was
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observed (blue to yellow). The OD450 was then determined using a Victor X Multilabel Plate 
reader (Perkin-Elmer, Oy, Finland). A standard curve was plotted (A450 vs. concentration) 
and used to determine the IGF I concentration of the unknown samples (Appendix 10 & 11).
2.9.14 PAPP-A ELISA
PAPP-A levels were measured in prostate cancer patient plasma samples (obtained from 
the Prostate Cancer Research Consortium) by ELISA according to the manufacturer’s 
instructions (R&D Systems, MN, USA). All samples were assayed in duplicate. Standards 
for PAPP-A (50, 25, 12.5, 6.25, 3.12, 1.56, 0.78 ng/ml) were prepared by serial dilutions of a 
500 ng/ml stock. The supplied 96 well plate was pre-coated with a monoclonal antibody to 
PAPP-A. Samples and standards (50 pl/well) were added to the plate and incubated for 3 h 
at room temperature. The plate was washed 4 times with 400 pl/well wash buffer supplied 
with the kit. PAPP-A conjugate (100 pl/well) was added and incubated for 2 h at room 
temperature. The plate was washed 4 times with 400 pl/well wash buffer before Substrate 
solution (100 |jl/well) was added for 30 min at room temperature while protecting the plate 
from the light. Stop solution (100 pl/well) was added and a colour change from blue to yellow 
was observed. The OD450 was then determined using a Victor X Multilabel Plate reader 
(Perkin-Elmer, Oy. Finland) A standard curve was plotted (A450 vs. conoentra*ionXand used 
to determine the PAPP-A concentration of the unknown samples (appendix 12).
2.10. Measurement of cell proliferation
2.10.1 BrdU proliferation assay
A bromodeoxyuridine (BrdU) cell proliferation ELISA, which is a non-radioactive 
measurement of DNA synthesis (Roche Applied Sciences, Basel, SWI) based on the 
incorporation of BrdU into DNA was used to determine PC-3M-luc2 cell growth. Briefly, BrdU 
labelling reagent (20pl/well) was added to cells in a 96 well plate and incubated for 24 h. 
The BrdU labelling reagent was removed and FixDenat (200pl/well) was added for 30 min at 
room temperature to fix the cells in the plate. The FixDenat solution was removed, anti- 
BrdU-POD working solution was added (100|jl/well) and the plate was then incubated for 90 
min at room temperature. The antibody conjugate was removed and the wells were rinsed 3 
times with wash buffer (300pl/well). Substrate solution was added to each well (1 OOpl/well) 
and incubated until the colour development was sufficient for photometric detection (25 min). 
The absorbance was measured using the Victor X Multilabel plate reader (Perkin-Elmer, Oy, 
Finland) set to 490nm. The blank measurement was subtracted from each reading and the 
increase of cell proliferation was seen as the percentage increase in proliferation relative to 
the untreated controls, which were taken as 100 % proliferation.
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2.10.2 MTS Assay
The CellTiter 96® AQue0us Non-Radioactive Cell Proliferation Assay (Promega, Wl, USA) is a 
colorimetric method for determining the number of viable cells in proliferation, cytotoxicity or 
chemosensitivity assays. The CellTiter 96® AQue0us Assay is composed of solutions of a 
tétrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- 
sulfophenyl)“2H-tetrazolium, inner salt, MTS and an electron coupling reagent (phenazine 
methosulfate) PMS. MTS is reduced by cells into a formazan product that is soluble in tissue 
culture medium. The conversion of MTS into the aqueous soluble formazan product is 
accomplished by dehydrogenase enzymes found in metabolically active cells. The quantity 
of formazan product is measured at 490 nm, which is directly proportional to the number of 
living cells in culture. MTS was added to cells in a 96 well plate (20 | j l/100 pi medium) and 
incubated for 1.5 h at 37°C. The absorbance was measured using the Victor X Multilabel 
plate reader (Perkin-Elmer, Oy, Finland) set to 490nm. The blank measurement was 
subtracted from each reading, controls (untreated) were taken as 100 % proliferation and an 
increase or decrease in proliferation was relative to untreated controls.
2.11 In vivo experiments
2,11*1. Animals . - - _ :
i '
Animal experiments were carried out for 2 months in Dana Farber Cancer Institute, Boston, 
MA. 10-12 week old male NSG (NOD SCID Beige gamma) mice were used for all 
experiments. NSG mice were obtained from a breeding colony in Charles River (Charles 
River Laboratories, MA) and were housed in a licensed biomedical facility (Dana Farber 
Cancer Institute, Harvard Medical School, Boston, MA, USA) and had ad libitum access to 
animal chow, water and 12 h light 12 h darkness cycle. All procedures were subjected to 
institutional ethics review carried out under the Animal licence and guidelines from the 
Institutional Animal Care and Use Committee (IACUC) and in accordance with the USA 
Animal Welfare Act.
2.11.2 Preparation of cells for injection
PC-3M-luc2 dBP4 cells were grown to 80 % confluency in 20 cm2 dishes. Cells were 
washed with 5 ml of PBS pre-warmed to 37 °C. 3 ml of pre-warmed trypsin-EDTA was 
added to the cells and incubated at 37 °C until cells detached. 20 ml MEM Eagle containing 
10 % (v/v) FCS was added to neutralise the trypsin. Cells were pelleted at 1100 x g for 3 
min. Supernatant was removed and cells were resuspended in 5 ml MEM Eagle containing 
10 % (v/v) FCS. Cells were counted (section 2.2.5), pelleted at 1100 x g for 3 min and 
resuspended in the appropriate volume of PBS (without Mg2+/ Ca2+) to the correct 
concentration of cells for each animal model.
it. •ï
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2.11.3 Subcutaneous prostate cancer model
10-12 week old male NSG mice were anaesthetised in an anaesthetic chamber with 2 % 
(v/v) isoflurane using 1 L/min oxygen. Animals were placed on their side with an anaesthetic 
gas pipe covering their noses and mouths and anaesthesia was maintained at 2 % (v/v) 
isoflurane (Baxter, IL, USA) using 1 L/min oxygen. PC-3M-luc2 dBP4 cells were suspended 
in a 70 % (v/v) PBS: 30 % (v/v) Matrigel solution. Cells were kept on ice throughout the 
procedure in order to maintain the Matrigel (BD Biosciences, NJ, USA) in a liquid form. Cells* 
were drawn directly into a 1 cc BD syringe before attaching the 27 gauge needle to avoid 
shearing. The barrel was tapped to remove any air bubbles and the cell suspension was 
pushed through to remove all air present. An alcohol prep pad was used to disinfect the 
injection site. The needle was inserted subcutaneously near the top of the right leg muscle 
and gently moved from side-to-side to create a pocket for the cells to grow ¡n. 100 pi (5 x 106 
PC-3M-luc2 dBP4 cells) of the cell suspension was injected into the pocket created.
2.11.3.1 Measurement of subcutaneous tumours
Following implantation of PC-3M-luc2 dBP4 subcutaneously in male NSG mice, tumour 
measurements were carried out every 3 - 4  days using a caliper. The length and width of 
tumours .were measured in millimetres (mm), MTD was-calculated., using the equation 
Vlength x width. Treatment of mice with doxycycline chow (200 mg/kg, Bio-Serve, Laurel, 
MD) or TKI, NVP-AEW541 (50 mg/kg diluted in tartaric acid, given daily by oral gavage) was 
started when tumours reached a MTD of 7 - 8 mm (23 days post implantation of PC-3M-luc2 
dBP4 cells (treatment day 1)). NSG mice were treated for up to 42 days.
2.11.4 Orthotopic prostate cancer model
10-12 week old male NSG mice were anaesthetised in an anaesthetic chamber with 2 % 
(v/v) isoflurane (Baxter, IL, USA) using 1 L/min oxygen. Animals were placed on their back 
with an anaesthetic gas pipe covering their noses and mouths and anaesthesia was 
maintained at 2 % (v/v) isoflurane using 1 L/min oxygen. Under anaesthesia, a 1.5 cm skin 
incision was made directly anterior to the abdominal fat pad. Skin was gently dissociated 
from the underlying peritoneum using a surgical scissors. A similar incision was made in the 
peritoneum, directly under the original cut. The bladder was pulled through the incision, at 
which point the dorsal prostate was located and injected with 5 x 105 PC-3M-luc2 dBP4 cells 
in 50 pi 1:1 PBS: Matrigel solution using a 100 pi 1710 Hamilton syringe with a 27 gauge 
needle. PBS: Matrigel solution was kept on ice throughout the procedure to maintain the 
Matrigel in a liquid form. After injections, both incisions were sutured. The peritoneum was 
sutured using Ethicon 4.0 Chromic Gut (absorbable) sutures and the skin was sutured using 
Ethicon 4.0 SofSilk sutures. Mice received two analgesics, topical Marcaine (0.5 % (w/v)
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bupivacaine, Hospira Inc., TX, USA) directly on the incision site and an i.p. injectionv(100 |jl) 
of Buprenex (0.3 mg buprenorphine base/ml, Reckitt Benckiser Healthcare, NJ, USA) upon 
waking from anaesthesia. Mice were monitored daily until the surgical wound fully healed. 
Treatment with doxycycline chow (200 mg/kg) or TKI, NVP-AEW541 (50 mg/kg diluted in 
tartaric acid, given daily by oral gavage) was initiated 22 days post implantation of PC-3M- 
Iuc2 dBP4 cells (treatment day 1) and mice were treated for 26 days.
2.11.5 Intracardiac metastasis model
Ultrasound guided intracardiac injection of tumour cells was carried out using the Vevo 770 
High-Resolution Imaging System (VisualSonics, Toronto, Canada) with a 703 scan 
head (35 MHz). 10-12 week old NSG mice were anaesthetised in an anaesthetic chamber 
with 2 % (v/v) isoflurane (Baxter, IL, USA) using 1 L/mln oxygen. Animals were placed on 
their back on a stereotactic board with an anaesthetic gas pipe covering their noses and 
mouths and anaesthesia was maintained at 2 % (v/v) isoflurane using 1 L/min oxygen. PC- 
3M-luc2 dBP4 cells were drawn directly into a 1 cc BD syringe before attaching the 27 
gauge needle to avoid shearing. The barrel was tapped to remove any air bubbles and the 
cell suspension was pushed through to remove all air present. The syringe was placed into 
a stereotactic device and orientated toward the heart.. Ultrasound was used to locate theJeft 
ventricle. The needle was inserted between the ribs,„ once the ultrasound detected that the 
needle was at the left ventricle 100 |jl of 5 x 104 PC-3M-luc-2 dBP4 cells were injected. 
Doxycycline (200 mg/kg) treatment was initiated 42 days post injection of PC-3M-luc2 dBP4 
cells and mice were treated for up to 20 days.
2.11.6 Intravenous metastasis model
10-12 week old male NSG mice were injected via the lateral tail vein. PC-3M-luc2 dBP4 
cells were drawn directly into a 1 cc BD syringe before attaching the 27 gauge needle to 
avoid shearing. The barrel was tapped to remove any air bubbles and the cell suspension 
was pushed through to remove all air present Before injection each mouse was vasodilated 
by placing under a warming lamp for 1-2 min to increase blood flow through the area, before 
being placed in a tail vein restrainer (Braintree Scientific, MA). Prior to injection the entire tail 
vein was disinfected with an alcohol prep pad. 2 x 106 PC-3M-luc2 dBP4 cells in 250 pi PBS 
were injected into NSG mice via the lateral tail vein. After the needle was removed from the 
vein a 2 x 2 cm gauze pad was used to staunch bleeding from the injection site. Doxycycline 
(200 mg/kg) treatment was initiated 47 days post injection of PC-3M-luc2 dBP4 cells and 
mice were treated for up to 32 days.
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2.11.7 Bioluminescent imaging
The IVIS Spectrum (Caliper Life Sciences, MA, USA) was used to image mice injected with 
PC-3M-luc2 dBP4 cells. The PC-3M-luc2 dBP4 cells express luciferase so upon injection of 
luciferin light is emitted which is detected using the IVIS Spectrum. 250 pi of d-luciferin (75 
mg/kg, Caliper Life Sciences, MA, USA) was administered to mice by i.p. injection and mice 
were imaged 5 min later under 2% (v/v) isoflurane (Baxter, IL, USA) using 1 L/min oxygen. 
Bioluminescence was measured for 1 s at f/stop 1. Images were then analysed using Living 
Image 3.2 software. To allow direct comparison of images and quantification, images were 
recorded as p/s/cm2/sr (total photons per centimetre squared per steradian).
2.11.8 Blood Glucose measurement
Blood glucose levels were measured in mice using an AlphaTRAK glucose meter (Abbott, 
IL, USA). Before measuring blood glucose, a control solution was used to validate the test. 
A new test strip was inserted and 2-3 drops of blood were placed on the strip and glucose 
levels were read as mmol/L.
2.11.9 Removal of tumours
NSG mice were euthanised in a chamber with 100 % C02. Subcutaneous and prostate 
tumours were excised. For protein analysis each tumour was placed into a 1.5 ml tube and 
snap frozen in liquid nitrogen, then stored at -80°C. For the intracardiac and IV metastasis 
models mice were assessed for the presence of metastases in the abdominal cavity and the 
whole mouse was placed into 10 % (v/v) buffered formalin for 48 h. After 48 h fixed mice 
were transferred to 70 % (v/v) EtOH.
2.11.10 Serum collection
Blood was collected promptly after C02 asphyxiation via cardiac puncture and placed into
1.5 ml tube. The blood was mixed by gentle inversion and serum was separated by 
centrifugation at 3000 x g for 10 min at room temperature. Serum was then recovered and 
stored at -80°C.
2.12 Statistical Analysis
For statistical analysis of IGF IR staining in prostate TMAs, tumours were scored as low 
expression (0/1) (cores with negative or weak staining) or high expression (2/3), (cores with 
moderate and strong staining). Fisher’s Exact tests were performed on contingency tables 
using Graphpad INSTAT-3™ (Graphpad Software Inc, San Diego, USA) to analyse 
associations between prostate cancer samples, BPH/normal samples or Gleason grade and 
immunohistochemical score (negative (0/1) and positive (2/3)).
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Where means for more than two groups were compared, statistical comparison was 
carried out by One-Way ANOVA with Dunnett post hoc test to examine differences from the 
controls. To carry out multiple comparisons, LSD post hoc correction was used. Where the 
means of two data sets were compared an unpaired Student t-test was used. To compare 
two dependent data sets a paired t-test was used. To determine correlations between two 
groups, a Pearson’s correlation was carried out. A Kaplan-Meier curve was used in survival 
curves. Statistics was carried out using SPSS™ statistical package.
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C h a p t e r  3
I n v o l v e m e n t  o f  t h e  I G F  p a t h w a y  i n  p r o s i a t e
c a n c e r
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3.1 Introduction
PSA measurement is the most commonly used diagnostic tool for prostate cancer detection, 
as PSA is elevated in prostate cancer (Fall et a/., 2007). PSA velocity (doubling time) is also 
used in prostate cancer diagnosis and screening (Carter et aL, 2006). However, current 
opinion regarding the value of PSA velocity as a diagnostic tool is conflicting. It has been 
reported that PSA velocity is a significant independent clinical factor predicting relapse after 
radical prostatectomy and also predicts for larger, more aggressive and more locally 
advanced tumours (Patel et al., 2005). In contrast to Patel et a! (2005), no evidence to 
support the recommendation that men with high PSA velocity should be biopsied in the 
absence of other indications such as elevated PSA or positive digital rectal exam (DRE) was 
seen. This study showed that there is little evidence that PSA velocity adds to the predictive 
value of PSA alone (Vickers et al., 2011). Therefore, a new panel of biomarkers for prostate 
cancer are needed to enhance the sensitivity for prostate cancer detection. Upon diagnosis 
of biopsy-confirmed prostate cancer the tumour is assigned a stage and grade. Staging of 
prostate cancer gives information on the extent of the cancer and whether it has spread to 
other organs. The TNM (tumour, node, metastasis) staging system (described in TNM atlas) 
describes the extent of the primary tumour ( f ), the absence or presence of metastasis to 
nearby jymph no^es or, glands (N) and the absence or presence, of distant _meii?stasisA(M) 
(Wittekind et al (2005)). Stage T1 tumours are clinically unapparent and are not detected by 
DRE, stage T2 tumours are confined within the prostate, stage T3 tumours spread beyond 
the outer layer of the prostate on one or both sides and may have spread to the seminal 
vesicles and stage T4 tumours have spread beyond the seminal vesicles to nearby tissue or 
organs, such as the rectum, bladder, or pelvic wall (Shambaugh et al, (2003)). Staging can 
help in determining the optimum course of treatment required for each individual patient. 
The Gleason grade gives information on the tumour’s behaviour. Gleason grade is 
numbered 1 - 5, a tumour with a low-grade (1) is likely to be slow-growing while one with a 
high-grade (5) is more likely to be aggressive or have spread outside the prostate. The 
Gleason score is the sum of the two most common Gleason grade patterns in the prostate 
tissue. The Gleason score can range from 2 -10. A score of 2 - 4 is considered low-grade, a 
score of 5 - 7 an intermediate grade and 8-10, high-grade (Understanding Gleason grade 
(1997)).
The main risk factors for prostate cancer development are age, race, family history 
and diet (Giovannucci et al., 2007). The exact mechanism of prostate cancer development is 
complex as numerous signalling pathways are involved. One such pathway is the IGF 
pathway. Over the last number of years interest has grown in targeting the IGF pathway in 
prostate cancer. Stattin et al (2000) showed a statistically significant association between 
prostate cancer risk and increasing levels of circulating IGF I (odds ratio 1.57) particularly in
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younger men suggesting the involvement of IGF I in early stages of prostate cancer. Others 
have shown that the IGF IR is overexpressed in prostate cancer and commonly persists in 
metastatic disease (Hellawell et a/., 2002) further supporting the involvement of the IGF 
pathway in the pathogenesis of the disease. The PI3K/Akt and MAPK pathways are IGF IR 
main downstream targets. IGF I can inhibit apoptosis via activation of the PI3K or MAPK 
pathways (Parrizas et al., 1997b). Akt is a serine threonine kinase downstream of PI3K that 
regulates apoptosis and proliferation (Kim et al., 2001, Rossig et al., 2001). High levels of 
activated Akt (phospho Akt) in prostate cancer tissue are a strong predictor of elevated PSA 
post curative therapy (Ayala et a/., 2004). Immunohistochemical analysis of prostate cancer 
tissue using antibodies to phospho Akt and phospho MAPK showed an increase in activated 
Akt in high Gleason grade tumours, whereas activated MAPK was decreased relative to PIN 
(Malik et al.y 2002). This may imply that the PI3K pathway is the dominant pathway involved 
in prostate cancer progression. As well as changes in IGF I, IGF IR and downstream 
effectors, IGFBPs are known to be increased or decreased in prostate cancer relative to 
healthy individuals.
Circulating IGFBP 3 is the most abundant of the IGF binding proteins (Baxter et al., 
1989) is decreased in prostate cancer. This decrease in IGFBP 3 in combination with an 
increase in plasma IGF I is associated with advanced stage, prostate cancer. (Qhan ^ i  a/.,. ..
2002). IGFBP 2 is the second most abundant binding pjotein in the body (Wheatcroft and 
Kearney, 2009). Elevated serum IGFBP 2 levels have been noted in prostate cancer 
patients and are associated with PSA levels and tumour stage (Cohen et al., 1993). IGFBP
4 mRNA and immunostaining have shown IGFBP 4 to be elevated within epithelial cells of 
prostate adenocarcinoma relative to benign tissue (Tennant et al., 1996c). In vivo, 
overexpression of IGFBP 4 in androgen independent M12 prostate cancer cells implanted 
subcutaneously in male nude athymic mice markedly delayed tumour growth (Damon et al.,
1998). This suggests that increased IGFBP 4 may have an inhibitory role in prostate cancer 
tissue. However, PSA levels are elevated in the majority of prostate cancer patients and 
PSA cleaves IGFBP 4 (Rehault et al., 2001). Therefore, an increase in IGFBP 4 and PSA 
could trigger proteolysis of IGFBP 4 thus leading to increased IGF I to stimulate tumour 
growth. A protease resistant IGFBP 4 may be useful in tumour growth inhibition as it could 
not be cleaved by proteases, inhibiting IGF I proliferative effects.
As the major clinical challenge in prostate cancer patients is treatment of androgen 
independent disease an androgen independent cell line (PC-3M-luc2) was chosen for this in 
vitro and in vivo study. An in vivo model (SCID mice) of progression from androgen 
dependent to androgen independence using LAPC-9 and LNCaP prostate cancer cells has 
shown an increase in IGF I (60-fold and 28-fold, respectively) and IGF IR mRNA (2.5-fold 
and 5-fold, respectively) in the androgen independent model relative to androgen dependent
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neoplasms, suggesting IGF IR signalling may confer androgen independence (Nickerson et 
a 2001). Increased Akt activity has been seen in an androgen independent, PSA positive 
LNAI cell line relative to the parental androgen dependent LNCaP cells (Graff et al.t 2000). 
Literature suggests that the IGF pathway plays a role in the pathogenesis of prostate cancer 
and may provide a therapeutic target for this disease.
The main aims of this chapter were to assess the expression of the IGF IR in 
prostate cancer tissue and to determine the expression of components of the IGF pathway 
in an androgen independent prostate cancer cell line, PC-3M-luc2. In addition, to determine 
the suitability of these cells to assess the therapeutic potential of a protease resistant IGFBP
4 in an in vivo model of androgen independent prostate cancer.
The specific aims of this chapter were:
1: To investigate the expression of the IGF IR in prostate cancer tissue compared to normal 
tissue and to assess a correlation between IGF IR expression and Gleason grade.
2. To determine the expression of IGF pathway components in the human prostate cancer 
cell line PC-3M-luc2 in order to assess their suitability for use in vivo.
3. To examine whether the IGF IR interacts with IR and EGFR in PC-3M-luc2 cells.
* 4. To assess downstream activation of the IGF pathway following IGF stimulation, in PC-.3M-
iuc2.
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3.2 Results
3.2.1 IGF IR expression in prostate cancer TMAs
Tumour tissue was obtained from 45 prostate cancer patients with Gleason score ranging 
from 6 - 9 (average number of cores/patient = 7). The clinicopathological details of these 
patients are detailed in Table 3.1. Gleason grade is based on microscopic tumour patterns 
giving information on the tumour’s behaviour. The Gleason score is the sum of the two most 
common Gleason grade patterns in the prostate tumour. Gleason score is based on the 
degree of loss of normal glandular structure (de-differentiation). Figure 3.1 shows 
representative cores for benign prostatic hyperplasia (BPH) and Gleason grade 3 -5 . BPH 
tissue shows prostatic hyperplasia consisting of nodules of glands and intervening stroma, 
the glands vary in size with larger glands showing greater papillary folding (Figure 3.1 A). 
Gleason grade 3 tissue is well differentiated with normal gland unit similar to the normal 
prostate and glands vary in shape and invade into stroma (Figure 3.1 B). Gleason grade 4 
shows disruption and loss of normal gland structure (Figure 3.1 C). Gleason grade 5 is 
undifferentiated with no evidence of gland structure (Figure 3.1 D). Expression of the IGF 
IRp subunit was assessed in the prostate cancer TMAs (n=263 cores). Immunoreactivity 
was seen predominantly in epithelial cells surrounding the prostate glands and assigned a 
score of 0 - 3 based on intensity of staining.' Figure 3.2 shows representathx .^sections for■ * *• >
each of the immunoreactivity scores numbered 0 - 3. A representative Gleason grade 4 core 
shows negative IGF IRp staining (0, Figure 3.2 A), a representative Gleason grade 4 core 
shows weak IGF IRp staining (+ 1, Figure 3.2 B). A representative BPH core shows 
moderate IGF IRp staining (+ 2, Figure 3.2 C) and a representative Gleason grade 3 shows 
strong IGF IRp staining (+ 3, Figure 3.2 D).
Membrane and cytoplasmic staining was noted in prostate cancer tissue. Membrane 
and cytoplasmic staining were scored separately using the scoring system represented in 
Figure 3.2. Representative sections are shown (Figure 3.3) for membrane or cytoplasmic 
staining. In Figure 3.3 A, BPH IGF IRp membrane staining was predominantly around the 
membrane with no IGF IRp cytoplasmic staining, while cytoplasmic staining for IGF IRp was 
weak, but diffuse in the cytoplasm with no IGF IRp membrane staining. In Gleason grade 3,
IGF IRp membrane staining was strong with moderate cytoplasmic staining, while 
cytoplasmic staining was weak with no evidence of membrane IGF IRp staining (Figure 3.3 
B). In Gleason grade 4, membrane staining showed strong membrane IGF IRp staining with 
weak cytoplasmic staining, while cytoplasmic staining showed moderate IGF IRp staining in 
cytoplasm and negative for IGF IRp membrane staining (Figure 3.3 C) and in Gleason grade
5 membrane staining showed IGF IRp was weak with
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Table 3.1: Clinicopathological parameters of patients for TMA analysis
Parameters Data
Patients (n) 45
. Aqe (vrs)
Mean 58
Range 42 - 70
PSA levels (nq/ml)
Mean 8.6
Range 4^ 1 CO
Gleason qrade score
sum in)
Gleason score 6 25
Gleason score 7 17
Gleason score 8 2
Gleason score 9 1
Tumour Staoe in)
■ " T2 34" '
• T3 11
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Figure 3.1: Haematoxylin and Eosin (H&E) staining of prostate tissue. Prostate cancer 
tissue microarrays were stained with H&E (n=263 cores) to determine Gleason grade. 
Representative sections of (A) Benign Prostatic Hyperplasia (BPH). (B) Gleason grade 3, 
(C) Gleason grade 4 and (D) Gleason grade 5. (Original magnification 200 x).
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Figure 3.2: IGF IRp expression in prostate cancer TMAs. TMAs (n=263 cores) were 
stained with an anti-IGF IRp antibody. Representative sections illustrating the IGF IRp 
scoring (0-3). (A) 0, Gleason grade 4 core with no IGF IRp staining, (B) +1, Gleason grade 
4 core with weak IGF IRp staining, (C) +2, a BPH core with moderate IGF IRp staining and 
(D) +3, Gleason grade 3 core with strong IGF IRp staining. (Original magnification 200 x).
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weak cytoplasmic staining, while cytoplasmic staining showed weak cytoplasmic IGF IRp 
with no IGF IRp membrane staining (Figure 3.3 D). Membrane IGF IRp varied from weak- 
strong staining whereas IGF IRp cytoplasmic staining only varied from weak-moderate. 
Membrane IGF IRp staining was more prominent than cytoplasmic IGF IRp staining.
In order to establish the relationship between IGF IRp staining and Gleason grade in 
the prostate cancer patient TMAs, statistical analysis was carried out for either membrane or 
cytoplasmic staining. Tumour cores were categorised into negative (0/1) or positive (2/3) 
based on staining intensity. Table 3.2 shows the association between membrane IGF IRp 
staining and Gleason grade as determined by Fisher’s Exact Test. A p value <0.05 was 
taken as significant. Membrane IGF IRp expression was increased in tumour tissue relative 
to normal/BPH tissue (p<0.001). Membrane IGF IRp expression was higher in Gleason 
grade 3 (p<0.0004) and Gleason grade 4 (p<0.002) relative to normal tissue. Membrane IGF 
IRp staining was higher in Gleason grade 3 than Gleason grade 5 (p<0.005); there was no 
significant difference in membrane IGF IRp expression between BPH/normal tissue and 
Gleason grade 5 tissue.
Table 3.3 shows the association between cytoplasmic IGF IRp staining and Gleason 
grade as determined by Fisher’s Exact Test. A p value <0.05 was taken as significant. There 
was no significant difference in cytoplasmic IGF IRp between normal/BPH tissue and overall 
tumour tissue. Cytoplasmic IGF IRp expression increased in Gleason grade 3 relative to 
normal/BPH tissue (p<0.02). Gleason grade 3 expressed higher levels of cytoplasmic IGF 
IRp compared to Gleason grade 5 (p<0.02), but there was no significant difference in 
cytoplasmic IGF IRp expression between BPH/normal tissue and Gleason grade 4 or 5 
tissue. A Pearson’s correlation was carried out to assess if there was an association 
between membrane IGF IRp and cytoplasmic IGF IRp staining. A value close to 1 
represented a positive correlation and values close to -1 represented a negative correlation. 
A value of p<0.05 was taken as significant. A positive correlation was noted between 
membrane IGF IRp and cytoplasmic IGF IRp (p<0.01) (Table 3.4). Therefore, as membrane 
IGF IRp staining increased an increase in cytoplasmic IGF IRp was also seen.
3.2.2 Plasma IGF I and PAPP-A levels in BPH and prostate cancer patients
An IGF I ELISA was carried out on plasma samples (n = 33) obtained from the Prostate 
Cancer Research Consortium. After determining the IGF I levels from each sample, clinical 
information was obtained. Patient groups were categorised into BPH (n = 13), Gleason 
score 5 (n = 11) and Gleason score 7 (n = 9). Table 3.5 shows IGF I levels measured for 
each group. BPH patients were used as controls. A one-way ANOVA was used to compare 
IGF I levels between each group. No statistically significant difference was found in IGF I.
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Membrane Cytoplasmic
Figure 3.3: Total IGF1R0 staining in the membrane and cytoplasm of prostate cancer 
tissue. Prostate, cancer TMAs (n=263 cores) were stained with an anti-IGF IRp antibody. 
Membrane and cytoplasmic staining were scored separately using the 0 - 3 scheme illustrated in 
Figure 3.2. Representative images showing membrane and cytoplasmic staining are shown. (A), 
BPH tissue shows strong membrane IGF IRp and weak cytoplasmic staining. (B), Gleason grade 
3 tissue shows strong membrane IGF IRp and weak cytoplasmic IGF IRp staining. (C) Gleason 
grade 4 tissue shows strong membrane IGF IRp and moderate cytoplasmic IGF IRp and (D) 
Gleason grade 5 tissue shows weak membrane IGF IRp and weak cytoplasmic IGF IRp staining. 
(Original magnification 200 x).
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Table 3.2: Relationship between IGFIRp membrane staining and Gleason grade in 
prostate cancer TMAs (0/1= Negative, 2/3 = Positive). Tumour cores (n=263) were 
categorised as negative (0/1) or positive (2/3) based on staining intensity. The association 
between immunohistochemical score of the IGF IRp membrane staining and Gleason grade 
was determined by the Fisher’s Exact Test. A p value of < 0.05 was taken as significant, (ns 
= non significant).
TEST Histology Score of 
Membrane 
Total IGF 
IR (0/1)
Score of 
membrane 
Total IGF IR 
(2/3)
Normal vs. Normal/BPH 99 16
Tumour n = 115 (40 %) (6%)
p <0.001 Tumour 94 44
n = 138 (37 %) (17%)
Gleason ¡grade 3 Gleason grade 3 42 25
vs. Gleason grade 
r
n = 67 (46 %) (27 %)
p< 0.005 Gleason grade 5 23 2
n = 25 (25 %) (2 %)
Normal vs. Normal/BPH 99 .16 .
Gleason grade 3 n = 115 (54 %) (9%) '
p< 0.0004 Gleason grade 3 42 25
n = 67 (23 %) (14%)
Normal vs. Normal/BPH 99 16
Gleason grade 4 n = 115 (61 %) (10%)
p< 0.002
Gleason grade 4 29 17
n = 46 (18%) (11 %)
Normal vs. Normal/BPH 99 16
Gleason grade 5 n = 115 (7 %) (11 %)
ns
Gleason grade 5 23 2
n = 25 (16%) (14%)
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Table 3.3: Relationship between IGF1R0 cytoplasmic staining and Gleason grade in 
prostate cancer TMAs (0/1= Negative, 2/3 = Positive). Tumour cores (n=263) were 
categorised as negative (0/1) or positive (2/3) based on staining intensity. The association 
between immunohistochemical score of the IGF IRp cytoplasmic staining and Gleason 
grade was determined by the Fisher’s Exact Test. A p value of < 0.05 was taken as 
significant, (ns =non significant).
TEST Histology Score of 
cytoplasmic 
Total IGF IR 
(0/1)
Score of 
cytoplasmic 
Total IGF IR 
(2/3)
Normal vs. Normal/BPH 96 19
Tumour n = 115 (38 %) (8 %)
ns Tumour 102 36
n = 138 (40 %) (14%)
Gleason grade Gleason Grade 46 21
3 vs. Gleason 
grade 5
3.
n = 67
(50 %) (23 %)
p< 0.02 Gleason Grade 23 2
5
n = 25 *
(25 %) (2 %)
- Norma! vs; Normal/BPH 96- __
__
_
C
D ;ê
Gleason grade
o
’ n = 115 (53 %) (10%)
o
p< 0.02 Gleason Grade 46 21
3
n = 67
(25 %) (12%)
Normal vs. Normal/BPH 96 19
Gleason grade 
4
n= 115 (60 %) (12%)
ns Gleason Grade 33 13
4
n = 46
(20 %) (8 %)
Normal vs. Normal/BPH 96 19
Gleason grade
r
n = 115 (69 %) (14%)
ns Gleason Grade 23 2
5
n = 25
(16%) (1 %)
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Table 3.4 Pearson’s correlation coefficients between membrane IGF IRp and 
cytoplasmic IGF IRp staining. Pearson’s correlation was used to analyse the association 
of membrane IGF IRp with cytoplasmic IGF IRp staining. **p<0.01.
Membrane IGF IRp Cytoplasmic IGF IRp
staining staining
Membrane - 0.366**
IGF IRp
staining
Cytoplasmic 0.366** -
IGF IRp
staining
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levels between each group. A PAPP-A ELISA was carried out on the same plasma samples 
used for the IGF I ELISA. BPH patients were used as controls. Table 3.6 shows PAPP-A 
levels measured for each group. One-way AN OVA was used to compare PAPP-A levels 
between groups. A value of p<0.05 was considered as significant. Negative values were 
obtained for BPH and Gleason score 7 patients therefore a value of zero was given. This 
may be due to a lack of sensitivity with the PAPP-A ELISA assay. PAPP-A was significantly 
higher in Gleason score 5 patients relative to controls (p<0.0001 vs. BPH).
Pearson’s correlation was performed to determine whether there was a relationship 
between IGF I, PAPP-A, PSA levels, age and Gleason score (Table 3.7). A negative 
correlation was seen between PAPP-A levels and age (p<0.01). PAPP-A decreased with 
age. There was no correlation seen between PAPP-A and IGF I, PAPP-A and PSA, or 
PAPP-A and Gleason score. No correlation was seen between IGF I and PSA, age or 
Gleason score.
3.2.3 Expression of the IGF pathway in PC-3M-luc2 cells
IGF IR expression was assessed by immunoblotting for the p subunit of the IGF IR. PC-3M- 
luc 2 and MCF-7 whole cell lysate was fractionated by 4 - 20 % (w/v) SDS-PAGE. Proteins 
were transferred to nitrocellulose membrane and probed with anti-IGF IRp antibody (Figure 
3.4). The.predicted molecular weight of IGF IRp is 95 kDa. IGF IRp was expressed by MCF- 
7 (positive control, lane 1) and PO-3M-luc2 cells (lane 2).
IGFBPs and IGF l/ll expression were determined using a. multiplex RT-PCR, which 
allows multiple binding proteins to be assessed within one sample at the same time. PCR 
products were fractionated on a 2 % (w/v) agarose gel (Figure 3.5). Amplification of the 18S 
ribosomal subunit was a control for loading and sample integrity. PC-3M-luc2 cells express 
IGFBP 3 (lane 3). To further validate IGFBP 3 expression in PC-3M-luc2 cells, Western blot 
analysis was carried out. After culturing in serum-free medium for 48 h, PC-3M-luc2 
conditioned medium was collected and concentrated using 3 kDa Centricon YM-3 filter tube. 
PC-3M-luc2 conditioned medium and whole cell lysate along with MIA PaCa2 cell lysate 
(pancreatic cell line), which are known to express IGFBP 3, were fractionated by 4 - 20 % 
(w/v) SDS-PAGE, transferred to nitrocellulose membrane and probed with anti-IGFBP 3 
antibody (Figure 3.6 A). Predicted size of IGFBP 3 is 30 kDa. IGFBP 3 was expressed in 
PG-3M-luc2 cell lysate (lane 1) and conditioned medium (lane 2). Cell lysate from MIA 
PaCa2 cells used as a positive control is shown in lane 3.
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Table 3.5: Plasma IGF I in BPH and prostate cancer patients. Plasma levels of IGF I 
were measured in duplicate by ELISA in BPH and prostate cancer patients. IGF I levels 
were compared between the groups using one-way ANÒVA,(SEM= standard error of the 
mean) (p = ns).
Patient Age 
(Mean +SEM)
IGF 1 (ng/ml) 
(Mean + SEM)
Pre-op PSA (ng/ml) 
(Mean + SEM)
BPH (n= 13) 71+2.2 67.2 + 5.5 7.1+ 1.2
Gleason score 5 59 + 1.3 52.8 + 5.8 7.9+1.6
(n = 11)
Gleason score 7 62 + 1.5 70.7 + 8.7 10.8+1.8
(n = 9)
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Table 3.6: Plasma PAPP-A in prostate cancer patients. Plasm a levels of P A P P -A  were 
measured in duplicate by E L IS A  in. BPH  and prostate cancer patients. P A P P -A  levels were 
compared between the groups using one-way AN O VA followed by Dunnet post hoc 
procedure. ***p<0.001 vs BPH. (SEM  = standard error of the mean).
Patient Age 
(Mean +SEM)
PAPP-A (ng/ml) 
(Mean + SEM)
Pre-op PSA 
(ng/ml) (Mean + 
SEM)
BPH '(n=13) 71 + 2.2 0 7.1 + 1 .2
Gleason score 5 59 + 1.3 19.4+10.5*** 7 .9 + 1 .6
(n = 1 1 )
Gleason score 7 62 + 1.5 0 1 0 .8 + 1 . 8
(n = 9)
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Table 3.7 Pearson’s correlation coefficients between measured IGF I and PAPP-A 
levels. Pearson’s correlation was used to analyse the association of IG F  I and P A P P -A  with 
PSA , age and Gleason score. **p<0.01.
IGF I PAPP-A Pre-op
PSA
Age Gleason 
score 
(5 & 7)
IGF 1 -0.092 -0.148 * 0.075 0.385
PAPP-A -0.092 - 0.186 -0.599** -0:314
Pre-op
PSA
-0.148 0.186 - 0.097 0.266
Age 0.075 -0.599** 0.097
.......
0.398
Gleason 
score 
(5 & 7)
0.385 -0.314 0.266 0.398
-
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Figure 3.4: IGF1R ft is expressed by PC-3M-luc2 cells. Cell lysate was fractionated by 4 - 
20 %  (w/v) S D S -P A G E , transferred to nitrocellulose and probed with anti-IGF IRp. Lane 1 
shows cell lysate from M CF-7 cells used as a positive control. Lane 2 shows cell lysate from 
PC-3M -luc2 cells. Position of molecular weight marker is indicated (kDa). Western blot is 
representative of three independent experiments.
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Figure 3.5: PC-3M-luc2 cells express IGFBP 3 mRNA. Expression of IG FB P s and IG Fs  
was determined by multiplex R T -P C R . Amplification of the 18S ribosomal subunit was used 
as a control for equal loading and sample integrity. P C R  products were fractionated on a 
2%  (w/v) agarose gel. Lane 1 shows 100 bp DNA ladder, lane 2 shows P C R  products from 
the positive control (provided with the kit) and lane 3 shows P C R  products from PC-3M -luc2 
mRNA. Amplification of P C R  products in the positive control is indicated. Position of 
molecular weight marker is shown (bp).
IG FB P  4 was not included in the multiplex R T -P C R  kit; therefore Western blot analysis was 
performed to a sse ss  its expression in PC-3M -luc2 cells. PC-3M -luc2 conditioned medium, 
whole cell lysate and recombinant human IG FB P  4 were fractionated by 4 - 20 % (w/v) S D S -  
P A G E, transferred to nitrocellulose membrane and then probed for IG FB P  4 expression with 
anti-IG FBP 4 antibody (Figure 3.6 B). Predicted molecular weight of IG FB P  4 is 28 kDa. P C -  
3M-luc2 conditioned medium expressed IG FB P  4 (lane 2) with a faint band present in the 
cell lysate (lane 1). The majority of IG FB P  4 was secreted into the conditioned medium. A  
size difference was seen between IG FB P  4 in conditioned medium and cell lysate. This 
difference is due to cleavage of the signal peptide upon IG FB P  4 secretion. Therefore, 
IG FB P  4 in conditioned medium is smaller in molecular weight compared with IG FB P  4 in 
cell lysate. Recombinant IG FB P  4 was used as a positive control (lane 3) (Figure 3.6 B). 
P A P P -A  was assessed  by R T -P C R . P C R  products were fractionated on a 2 % (w/v) agarose  
gel (Figure 3.7). cDNA from H E K  293 cells were used as a positive control for P A P P -A  
m RNA expression (lane 2). p-actin was used as a control for equal loading and sample 
integrity (lane 4 & 5). PC-3M -luc2 cells express P A P P -A  (lane 3).
3.2.4 Cell proliferation and VEGF expression in response to IGF I
As PC-3M -luc2 cells express the IG F IR, cel! proliferation in response to. IG F  !■ ligandawss 
measured by Brdll assay (Figure 3.8). PC-3M -luc2 cells (3 x 103 cells/well) were treated in 
triplicate with 0 - 1 0 0  ng/ml IG F I for 48 h. As PC-3M -luc2 cells express IG FB P  3 and IG FB P
4 (Figure 3.6) cells were also treated with IG F (E3R ) (0 -1 0 0  ng/ml) for 48 h. IG F (E3R ) is a 
70 amino acid IG F I analogue with reduced affinity for IG FB P s. Control cells were treated 
with the vehicle concentration P B S  containing 0.1 %  (w/v) B SA  (IG F  I) or P B S  containing 10 
mM HCI with 0.5 % (w/v) B SA  (IG F (E 3 R )) equivalent to that of the highest dose of IG F I or 
IG F (E3R). Proliferation is expressed as %  of control where control is taken as 100 %. IGF  
(E 3 R ) significantly increased cell proliferation at doses of 20 ng/ml (p<0.004), 40 ng/ml 
(p<0.005) and 60 ng/ml (p<0.026), whereas, IG F I had no effect on cell proliferation (Figure 
3.8). A s PC-3M -luc2 cells express IG FB P  3 and IG FB P  4, it is possible that these IG FB P s  
could have blocked IG F I action in this assay.
The effect of IG F I ligand on the expression of the angiogenic factor, V E G F 165 was 
assessed  by E LISA . PC-3M -luc2 cells (5 x 104 cells/well) were treated in triplicate with IG F I 
or IG F (E 3 R ) (0 - 100 ng/ml) for 48 h. Controls were treated with the vehicle concentration 
(P B S  containing 0.1 %  (w/v) B SA  (IG F  I) or P B S  containing 10 mM HCI with 0.5 % (w/v) 
B SA  (IG F  (E 3 R )) equivalent to the highest dose of IG F I or IG F (E3R). Conditioned medium 
was collected from the cells and V E G F i65 levels were measured by E LISA . V E G F i65 was 
expressed as pg/mg cell protein.
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Figure 3.6 A and B: PC-3M-luc2 cells express IGFBP 3 and IGFBP 4 protein. Whole cell 
lysate or conditioned medium was fractionated by 4 - 20 %  (w/v) S D S -P A G E , transferred to 
nitrocellulose and probed with anti-IG FBP 3 (A) or anti-IG FBP 4 (B) antibodies. In A, lane 1 
shows PC-3M -luc2 cell lysate, lane 2 shows conditioned medium from PC-3M -luc2 cells 
and lane 3 shows MIA P a C a 2 cell lysate (pancreatic cell line) which was used as a positive 
control. In B, lane 1 shows PC-3M -luc2 cell lysate, lane 2 shows conditioned medium from 
PC-3M -luc2 cells and lane 3 shows recombinant IG FB P  4 as a positive control. Position of 
molecular weight marker is indicated (kDa). Western blots are representative of three 
independent experiments.
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Figure 3.7: PAPP-A mRNA is expressed by PC-3M-luc2 cells. P A P P -A  expression was 
assessed  by R T -P C R . cDNA from H E K  293 cells was used as a positive control for PA P P -A  
expression. Lane 1 shows 1 kb DNA ladder. Lanes 2 and 3 show P A P P -A  m RNA transcript 
from H E K  293 cells and PC-3M -luc2 cells, respectively. Lanes 4 and 5 show p-actin 
amplified from H E K  293 cells and PC-3M -luc2 cells, respectively as a control for equal 
loading and sample integrity. Position of molecular weight marker is indicated (bp). Gel 
shown is representative of three independent experiments.
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Figure 3.8: PC-3M-luc2 cells proliferate in response to IGF (E3R). 3 x 103 PC-3M -luc2  
cells were treated in triplicate with IG F I or IG F (E 3 R ) for 48 h and proliferation was assayed  
by BrdU incorporation. Proliferation is expressed as %  of control where control is taken as  
100 %. Controls were treated with the vehicle concentration equivalent to the highest dose  
of IG F I or IG F (E3R ). Data (n = 3) are expressed as mean + SEM  and analysed by one­
way AN O VA with Dunnets post hoc procedure.*p<0.05 vs. Control, **p<0.01 vs. Control.
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Treatment with IG F (E 3 R ) had a significant effect on V E G F 165 expression at doses of 60 
ng/ml (p<0.017), 80 ng/ml (p<0.035) .and 100 ng/ml (p<0.031) whereas IG F I had no 
statistically significant effect on V E G F 165 production. As PC-3M -luc2 cells express IG FB P  3 
and IG FB P  4 this may have inhibited the effects of IG F I (Figure 3.9).
3.2.5 Activation of IGF signalling by IGF I in PC-3M-luc2 cells
Activation of the IG F IR and downstream signalling molecules Akt and MAPK were 
assessed  by Western blotting following IG F I or IG F  (E 3 R ) treatment. PC-3M -luc2 cells (1.5 
X 105 cells/well) were treated with 100 ng/ml IG F I or IG F (E 3 R ) for 0 - 60 min. PC-3M -luc2  
whole cell lysates were fractionated by 4 - 20 %  (w/v) S D S -P A G E , transferred to 
nitrocellulose membrane and probed with anti-IGF IRp, anti-plGF IR  (Tyr 1131) and anti-p- 
actin antibodies (Figure 3.10 A & B). Figure 3.10 A  and 3.10 B show no phosphorylation of 
the IG F  IR at zero timepoint. However, following stimulation with IG F I (A) or IG F  (E 3 R ) (B) 
IG F IR activation is seen after 10 min and remains up to 60 min after stimulation, p-actin 
shows equal loading in all lanes.
To a sse ss  expression of Akt, PC-3M -luc2 cells (1.5 x 105 cells/well) were treated 
with 500 nM wortmannin (P I3K  inhibitor) for 1 h followed by treatment with 100 ng/ml IG F I 
(Figure 3 .1 T A ) or IG F (E3R)(Figure 3.11 B) for 0 - 6 G min. PC-3M -luc2 .whole ce!! lysates 
were fractionated by 4 - 20 %  (w/v) S D S -P A G E , transferred to nitrocellulose-membrane and 
probed with anti-Akt, anti-phospho Akt (Ser 473) and anti-p-actin antibodies (Figure 3.11 A  & 
B). Total Akt is unaffected by wortmannin treatment (Figure 3.11 A & B) and pAkt is absent 
at the zero timepoint. In cells treated with IG F I Akt is phosphorylated after 10 min of IG F I 
treatment, but is undetectable after 60 min. PC-3M -luc2 cells treated with IG F (E 3 R ) showed 
phosphorylation of Akt after 5 min and this was maximal at 15 min. Therefore, IG F  I 
stimulation of Akt at 10 min compared with 5 min in IG F (E 3 R ) stimulated cells may be due 
to binding of IG F I to IG FB P  3 and IG FB P  4. Wortmannin inhibited the phosphorylation of 
Akt at all timepoints following stimulation with IG F I or IG F  (E 3 R ) (Figure 3.11), suggesting 
that activation of Akt occurs via a P I3K dependent pathway.
To a sse ss  expression and activation of ER K , PC-3M -luc2 cells (1.5 x 105 cells/well) 
were treated with 100 ng/ml IG F I or IG F (E 3 R ) for 0 - 6 0  min. PC-3M -luc2 whole cell lysates 
were fractionated by 4 - 20 % (w/v) S D S -P A G E , transferred to nitrocellulose membrane and 
probed with anti-ERK (p44/p42), anti-phospho E R K  (Thr202/Tyr204) and anti-a tubulin 
antibodies. Figure 3.12 A shows PC-3M -luc2 cells stimulated with IG F I had no change in 
total ER K . There was no difference in p E R K  at any timepoint.
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Figure 3.9: IGF (E3R) stimulates VEGF165 production in PC-3M-luc2. PC-3M -luc2 cells 
were treated with IG F I or IG F (E 3 R ) for 48 h in triplicate and V E G F 165 was measured by 
ELISA . Controls were treated with the vehicle concentration equivalent to the highest dose  
of IG F I or IG F (E3R). Total cell protein was assessed  by Bio-Rad D C  protein assay. Data 
(n = 3) are expressed as mean + SEM  and analysed by one-way AN O VA with Dunnet 
procedure post hoc correction. *p< 0.05 vs. Control.
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Figure 3.10 A & B: IGF treatment activates phosphorylation of the IGF IR. 1.5 x 1 0 5
cells/well PC-3M -luc2 cells were treated with IG F I (100 ng/ml) (A) or IG F  (E 3 R ) (100 ng/ml) 
(B) at different time points (0 - 60 min). 25 pg of cell lysate was fractionated by 4 - 20 %  
(w/v) S D S -P A G E , transferred to nitrocellulose and then probed for IG F IRp or p IG F IR (Tyr 
1131). p-actin was probed as a loading control. Position of molecular weight marker is 
indicated (kDa). Western blots are representative of three independent experiments.
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Figure 3.11 A and B: IGF (E3R) induces phosphorylation of Akt mediated by PI3K.
1 . 5  x 1 0 5 cells/well of PC-3M -iuc2 Were pre-treaied with the PI3K inhibitor, vvorlmannin 
(500 nM) for 1 h. Cells-with (+) or without (-) wortmannin were stimulated with 100 ng/ml 
IG F I (A) or IG F (E 3 R ) (B) from 0 - 60 min. Cells were lysed and 25 jjg of total cell protein 
was fractionated by 4 - 20 %  (w/v) S D S -P A G E , transferred onto nitrocellulose and probed 
with anti-Akt, anti-phospho Akt (Ser 473) or p-actin antibody. Position of molecular weight 
marker is indicated (kDa). Western blots are representative of three independent 
experiments.
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Similarly, PC-3M -luc2 cells treated with IG F (E3R ) showed no change in total E R K  and no 
difference in p E R K  at any timepoint following IG F (E 3 R ) treatment (Figure 3.12 B). a-tubulin 
was used as a loading control as p-actin is a similar molecular weight as ER K .
t
3.2.6 IGF IR forms heterodimers with EGFR and Insulin R in PC-3M-luc2 cells
The IG F IR has the ability to form heterodimers with other tyrosine kinase receptors. The  
interaction of the IG F  IR with E G F R  or IR following IG F  (E3R ) treatment was assessed  by 
immunoprécipitation (IP) followed by Western blotting (Figure 3,10). PC-3M -luc2 cells (1 x 
106 cells/dish) were treated (+) for 10 min with 100 ng/ml IG F (E 3 R ) or left untreated (-). Cell 
lysates were incubated with Sepharose G beads pre-incubatèd with antibodies to pIGF IR, 
IG F IR, p EG FR , E G F R , pIR and IR. Immunoprecipitates were fractionated by 4 - 20 % (w/v) 
S D S -P A G E , transferred to nitrocellulose membrane and probed with the above mentioned 
antibodies. Cell lysates from untreated (-) and treated (+) PC-3M -luc2 cells were used as 
controls for protein expression. Cell lysate incubated with Sepharose G beads only were 
used as a negative control (N). IG F  IR and pIGF IR pulldown showed that the IG F IR  
interacted with the E G F R . IG F (E 3 R ) had no effect on levels of total or phosphorylated 
E G F R . When the E G F R  and p E G F R  were used to pulldown the IG F IR and p IG F IR no 
increase in ¡G F JR  or p IG FR  was seen. The IG F  IR was also shown to interact with the. IR ;-1 
Upon stimulation with IG F (E3R), an increase in pIR was seen whereas-total IR levels 
remained constant. When the IR and pIR were used to pulldown the IG F IR and p IG FR , an 
increase in p IG FR  was seen (Figure 3.13).
3.2.7 Proliferation of PC-3M-luc2 cells in response to EGF
As PC-3M -luc2 cells express the E G F R , which can form heterodimers with the IG F IR, cell 
proliferation in response to E G F  ligand was examined using BrdU assay (Figure 3.14). P C -  
3M-luc2 cells (3 x 103 cells/well) were treated in triplicate with E G F  ( 0 -1 0 0  ng/ml) for 48 h. 
Controls were treated with the vehicle concentration equivalent to the highest dose of E G F  
(P B S  containing 0.1 % (w/v) BSA). Proliferation is expressed as %  of control where control 
Is taken as 100 %. E G F  did not have a statistically significant effect on cell proliferation.
3.2.8 EGFR and IGF IR activation following EGF treatment in PC-3M-luc2 cells
As IG F IR forms heterodimers with E G F R , PC-3M -luc2 cells (1.5 x 105 cells/well) were 
treated with 100 ng/ml E G F  for 0 - 6 0  min to determine if the E G F R  cross activated the IG F  
IR. PC-3M -luc2 whole cell lysates were fractionated by 4 - 2 0  %  (w/v) S D S -P A G E , 
transferred to nitrocellulose membrane and probed with anti-EG FR, anti-pEG FR (Tyr 1173), 
anti-IGF IRp, anti-plGF IR (Tyr 1131) and anti-p-actin antibodies (Figure 3.15).
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Figure 3.12 A & B: Phosphorylation of ERK is not induced by IGF. 1.5 x 105 cells/well of 
PC-3M -luc2 cells were treated with 100 ng/ml IG F I (A) or IG F (E 3 R ) (B) for 0 - 6 0  min. 
Cells were lysed and 25 pg of total cell protein was fractionated by 4 - 20 % S D S -P A G E ,  
transferred onto-nitrocellulose and probed with an anti-plVospho E R K  (Thr2G2/Tyr 204), 
anti-ERK or an anti a-tubulin antibody. Position of molecular weight marker is indicated 
(kDa). Western blots are representative of two independent experiments.
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Figure 3.13: IGF IR forms heterodimers with the EGFR and IR. PC-3M-luc2 cells were 
treated with 100 ng/ml IGF (E3R) for 10 min. Heterodimers were immunoprecipitated with 
the relevant antibody coupled to Sepharose G beads for 2 h at 4°C. Immunoprecipitates 
(IP) were fractionated by 4 - 20 % (w/v) SDS-PAGE and transferred to nitrocellulose. 
Heterodimers were identified by Western blotting (WB) with antibodies indicated. 
Immunoprecipitates (IP) of untreated (-), treated (+) cells and a negative control (N) 
incubated with Sepharose G beads only are shown. Cell lysates from untreated (-) and 
treated (+) cells are shown as controls. Position of molecular weight marker is indicated 
(kDa). IP and Western blots are representative of three independent experiments.
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Figure 3.14: PC-3M-luc2 cells do not proliferate in response to EGF. 3 x 103 PC-3M- 
Iuc2 cells were treated in triplicate for 48 h with EGF and proliferation was assayed by BrdU 
incorporation. Proliferation is expressed as % of control where control is 100 %. Controls 
were treated with the vehicle concentration equivalent to the highest dose of EGF. Data (n = 
3) expressed as the mean + SEM and analysed by one-way ANOVA (p = ns).
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E G F  stimulated E G F R  activation after 20 min and E G F R  remained activated up to 60 min 
post E G F  stimulation (Figure 3.15). However, E G F  did not activate the IG F IR (Figure 3.15). 
Total E G F R  and IG F IR levels did not change following stimulation with E G F . p-actin shows 
equal loading in all lanes.
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Figure 3.15: EGF activates the EGFR but not the IGF IR. 1.5 x 105 cells/well of PC-3M - 
Iuc2 cells were treated with E G F  (100 ng/ml) for 0 - 6 0  min. 25 pg lysate was fractionated 
by 4 - 20 % (w/v) S D S -P A G E , transferred to nitrocellulose and then probed for E G F R , 
p E G F R  (Tyr 1173), IG F IRp, p IG F IR  (Tyr 1131) or p-actin as a loading control. Position of 
molecular weight markers is indicated (kDa). Western blots are representative of three 
independent experiments.
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, 3.3 Discussion
The IG F IR is a tyrosine kinase receptor involved in cell growth, differentiation and 
proliferation (Kiepe et a/., 2005). In this study; staining of prostate cancer TM As with an IG F  
IR antibody showed IG F IR staining in the membrane and cytoplasm of prostate cancer 
tissue. Membrane and cytoplasmic staining has been noted previously in human prostate 
tumours (Liao et al., 2005), but the significance of cellular localization in relation to clinical 
parameters remains unknown. In the current study, membrane IG F IR levels were increased 
in prostate tumours relative to B PH  tissue or normal tissue. Membrane IG F IR  levels were 
highest in Gleason grade 3, but decreased in Gleason grade 5 prostate cancer tissues. This 
pattern of IG F IR expression was also seen by Liao et al (2005), where IG F IR  expression 
was high in low Gleason grade tissue and low in high Gleason grade tissue. However, other 
groups have shown that IG F IR levels remain elevated in primary prostate and metastatic 
disease (Hellawell et al., 2002). Down-regulation of the IG F IR has been seen in advanced 
breast cancer relative to control tissue (Schnarr et a/., 2000). An exact reason for down- 
regulation of the IG F IR in advanced cancers remains unclear. One explanation may be the 
role of IG F IR in differentiation. Early grade tumours are well differentiated whereas more 
aggressive tumours are poorly differentiated. IG F IR m RNA and protein decreased  
significantly as prostate epithelial cells underwent transformation to ma!ignari^^iTe,nnanJ-e^ 
a/., 1996a). Plymate et al (1.997) examined the effect of re-expression of the IG F IR in the 
highly malignant androgen independent M12 subclone of the P 69SV 40T  immortalised 
prostate tumour cell line. Expression of the IG F IR in this M12 cell line reduced anchorage  
independent growth In vitro and tumour growth in vivo, but these cells had increased 
proliferative response to IG F I in vitro. The authors suggested that the IG F IR  may have a 
dual function in tumours. High IG F IR expression may inhibit tumour growth, but induce 
differentiation. Whereas, low receptor number may induce proliferation (Plymate et al., 
1997). This may explain the high level of membrane IG F IR seen in Gleason grade 3, which 
is well differentiated, relative to Gleason grade 5 which is poorly differentiated. Low levels of 
IG F IR seen in Gleason grade 5 may imply a more malignant phenotype. A  second 
explanation for decreased IG F IR expression in higher grade prostate cancer may be due to 
invasiveness of cancer cells. It has been shown in colorectal neoplasia that decreased IG F  
IR was found at invasive foci along with loss of cell adhesion (Allison et al.t 2007). 
Knockdown of the IG F IR in IG F IR overexpressing M CF-7 breast cancer cells led to an 
increase in motility and decreased ability to form aggregates in culture (Pennisi et al., 2 0 0 2 ).
IG F IR cytoplasmic staining was also seen in prostate cancer TMAs. No significant 
difference in cytoplasmic IG F IR was seen between tumour tissue and BPH/normal tissue, 
whereas cytoplasmic staining in Gleason grade 3 tumours was higher than in BPH/normal 
tissue or Gleason grade 5. The relevance of cytoplasmic IG F IR in prostate cancer
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progression has not been investigated. In TM As constructed of benign breast biopsies 
stained for IG F IR there was a positive association between cytoplasmic IG F IR and 
subsequent risk of breast cancer (odds ratio: 2.47) (Tamimi et a/., 2011). However, the 
association between cytoplasmic IG F IR and prostate cancer risk has not been investigated. 
The IG F IR can be internalised and recycled to the cell surface following activation by IG F I 
(Romanelli et al, 2007), leading to regulation of activation of Shc/M APK signalling (Chow et 
a/., 1998). In Gleason grade 3 prostate cancer tissue, the high level of cytoplasmic IG F IR 
may be associated with overexpression of membrane IG F IR which may then lead to an 
increased level of receptor recycling whereas in the higher Gleason grade due to down- 
regulation of the IG F IR, cytoplasmic IG F IR may not be detected. This is further supported 
in this study where a positive association between membrane IG F IR and cytoplasmic IG F  
IR staining was noted (p<0.01). Therefore, an increase in membrane IG F IR staining leads 
to an increase in cytoplasmic IG F IR staining: Membrane IG F IR shows a stronger 
relationship with Gleason grade than cytoplasmic IG F IR in prostate cancer (membrane 
staining p<0001 vs. p<0.05 cytoplasmic staining), suggesting membrane IG F IR may be 
more important in prostate tumour development and growth rather than cytoplasmic IG F IR.
In addition to increased IG F IR levels in prostate tumour tissue elevated plasma IG F  
I levels are associated with increased risk of prostate cancer. In this study,. IG F I was. 
measured in the plasma of BPH, Gleason score 5 and Gleason score 7 patients, but no 
difference in IG F I levels were seen, possibly due to the small number of patient samples 
(n=33) compared with other studies. Stattin et al (2000) measured plasma IG F I levels in. 
men (n=149) with a diagnosis of prostate cancer between 1 month and 10 years after blood 
collection. The risk associated with increased IG F I was higher in subjects under the age of 
59 years at the time of blood collection, suggesting that elevated IG F I levels may be 
involved in early pathogenesis of prostate cancer (Stattin et al., 2000). However, it was 
found that elevated plasma IG F I levels were associated with advanced prostate cancer 
(Chan et al., 2002). BPH patients may not have been suitable controls for this study as BPH  
results in enlargement of the prostate due to chronic inflammation, but no association 
between IG F I levels and BPH has been previously shown (Mantzoros et al., 1997). No 
correlation was seen between IG F I and P S A  or IG F I and Gleason grade which was also 
reported by Shariat et al (2000) in patients (n=120) who had undergone radical 
prostatectomy. P A P P -A  levels were also measured in the sam e patient cohort. P A P P -A  is a 
metalloproteinase that cleaves IG FB P  4 (Lawrence et al., 1999) thus modulating IGF  
availability. In lung cancer, P A PP-A  levels are higher in lung cancer patients (n=83) relative 
to controls (n=33) (Bulut et al, 2009). P A PP-A  is expressed in normal prostate epithelium 
and in seminal fluid as measured by immunoperoxidase and radioimmunoassays (Sjoberg J  
et al, 1985), but the importance of P A P P -A  expression in the male reproductive tract has
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not been elucidated. In the current study, plasma P A P P -A  measured in BPH, Gleason score
5 and 7 patients showed a significant increase in P A P P -A  levels in the Gleason score 5 
cohort relative to controls. P A P P -A  levels have never been measured in relation to prostate 
cancer. However, larger numbers would be required to further validate the differences seen  
in P A P P -A  levels. P A P P -A  levels were negatively correlated with age, suggesting that 
measurement of P A P P -A  levels in younger men may be a prognostic marker for prostate 
cancer.
In order to select an in vivo model of prostate cancer to evaluate the therapeutic 
potential of IG F blockade, an appropriate cell line was required. The cell line chosen was the 
PC-3M -luc2 cells, a human androgen independent cell line derived from a liver metastasis 
following PC -3  cell injection into the spleen of a mouse (Kozlowski et a/., 1984). PC-3M -luc2  
cells have been transfected with luciferase to allow non-invasive imaging when growing in 
mice (IV IS imaging system). Before using the PC-3M -luc2 cells in vivo (Chapter 5) they were 
characterised with respect to expression and activation of IG F  pathway components as the 
protease resistant IG FB P  4 targets the IG F pathway. Therefore, if the PC-3M -luc2 cells were 
not IG F responsive PC-3M -luc2 tumour growth may not be inhibited by IG F blockade in vivo. 
PC-3M -luc2 cells expressed the IG F IR, which was phosphorylated in response to IG F I 
treatment. PG-3M-!uc2 cells were previously shown to pro d u ceJG FB P  3 (Bindukumar ef.ai.t , 
2005) and multiplex P C R  analysis confirmed IG FB P  3 expression in this study. IG FB P  4 
was detected in PC-3M -luc2 cells at a low level, the majority of which is secreted into the 
medium. P A P P -A  levels were also measured in the PC-3M -luc2 as P A P P -A  cleaves IG FB P  
4. R T -P C R  was used as there is currently no specific antibody for P A P P -A  available. The  
PC-3M -luc2 cells expressed P A P P -A  at the m RNA level, but this may not directly reflect 
protein levels of PAPP-A. P A P P -A  protein has been detected in prostate epithelium and in 
seminal fluid from healthy men (Sjoberg et a/,, 1985). Serum P A P P -A  was measured by 
E L IS A  and was shown to be elevated in chronic stable angina. Patients with high levels of 
P A P P -A  had . a poorer prognosis compared with those with low levels of the protein 
(Consuegra-Sanchez et a/., 2008). Even though P A P P -A  is expressed by men, its role in the 
male reproductive tract is unknown. Since the PC-3M -luc2 cells are derived from prostate 
epithelial cells which have been shown to express P A P P -A  in men (Sjoberg et ai., 1985) this 
may explain why P A P P -A  was detected in these cells. However, this finding has not been 
previously reported.
Since PC-3M -luc2 expressed the IG F IR, cell proliferation and V E G F 165 expression 
was assessed  in response to IG F I or IG F (E3R). As PC-3M -luc2 cells express IG FB P s  
which can bind IG F I and inhibit its actions, IG F (E3R ), which is unable to be bound by 
IG FB P s, was also used. V E G F  is an important mediator of angiogenesis, which plays a 
major role in prostate tumour development and growth by supplying tumour cells with
*
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oxygen and nutrients (Ackerstaff et al., 2004, Kitagawa et al., 2005, Mazzucchelli et a/.,
2000). There are at least six isoforms of V E G F , V E G F 12 i, V E G F 145i V E G F 165t V E G F 183i 
V E G F 189 and V E G F 206. V E G F  production is stimulated by hypoxia and IG F I (Levy et al., 
1996, Menu et al., 2004, Poulaki et al., 2003, Warren et al., 1996). IG F (E 3 R ) stimulation of 
PC-3M -luc2 cells significantly increased V E G F 165(most abundant V E G F  isoform) relative to 
controls, whereas IG F I had no effect possibly due to IG F I being sequestered by IG FB P  3 
and IG FB P  4 rendering it inactive and unable to bind the IG F IR. Similarly, IG F (E3R ) 
stimulated PC-3M -luc2 cell proliferation whereas wildtype IG F I had no effect.
In order to determine whether the IG F IR was responsive to IG F I and activated 
downstream signalling molecules, PC-3M -luc2 cells were stimulated with either IG F I or IG F  
(E3R). Both IG F I and IG F (E 3 R ) activated the IG F IR. To further investigate the activation of 
the IG F I pathway, Akt activation was also analysed. High levels of phospho Akt are a strong 
predictor of biochemical recurrence in prostate cancer (Ayala et a/., 2004). By using 
wortmannin, a P I3K inhibitor which was previously shown to inhibit Akt activation (Powis et 
al., 1994), it was shown that both IG F I and IG F (E 3 R ) activated Akt specifically via PI3K. 
Activation occurred rapidly (10 min with IG F I, 5 min with IG F (E3R )) and after 15 minutes 
the levels of phospho Akt began to decrease. The difference in Akt activation between IG F  
IG F (E 3 R ) and I may be attributed to IG F I inhibition by. IG FB P s. PCr3M-luc2^ cells pre­
treated with wortmannin showed complete inhibition of Akt phosphorylation following IG F I 
or IG F (E3R ) stimulation. As Akt is involved in stimulating cell proliferation, inhibition of Akt 
leads to apoptosis (Sekine et a/., 2008).
The MAPK pathway is another pathway activated downstream of the IG F IR. Six  
distinct groups of MAPK have been characterised. The E R K  pathway is the most studied, 
consisting of E R K  1 (p 44) and E R K  2 (p 42) which are linked with cell proliferation and 
differentiation (Li et al., 2006). Phospho E R K  was present in unstimulated PC-3M -luc2 cells 
and was not increased following IG F I or IG F  (E 3 R ) treatment. This suggests that in PC-3M - 
Iuc2 cells Akt is the main mediator of IG F signalling via IG F IR. PC-3M -luc2 cells are also 
P T EN  negative (Vlietstra et a l 1998). P T EN  inhibits Akt activity, therefore in P T E N  negative 
cells a key regulator of Akt activity is absent which may lead to an Akt dominant pathway. 
Malik et al (2002) have shown that in high Gleason score tumours, phospho Akt 
predominates relative to phospho ER K . Phospho E R K  was elevated in normal and PIN 
tissue samples. This suggests that progression of normal prostate tissue to cancerous 
disease may rely on an increase in Akt and decrease in ER K . This was further supported by 
protein microarrays, which characterised disease progression at the cancer invasion front in 
normal, PIN and prostate cancer tissue. Phospho Akt was increased and phospho E R K  was 
suppressed in invasive prostate cancer relative to PIN (Paweletz et al., 2001).
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This may explain why no increase in phospho E R K  was seen upon IG F I treatment as active 
E R K  decreases in prostate cancer progression.
The IG F IR can form homodimers and heterodimers with other receptors such as the 
IR (Treadway et al., 1991) and E G F R  (Riedemann et al., 2007). IG F (E 3 R ) was used to 
stimulate the PC-3M -luc2 cells. In PC-3M -luc2 cells, the IG F IR heterodimerised with the IR 
and E G F R . There was an increase in the interaction between phosphorylated IG F IR and 
phosphorylated IR following treatment with IG F (E 3 R ) relative to untreated PC-3M -luc2 cells, 
suggesting that IG F (E3R ) also activates the IR in these cells. Johansson et al (2006) have 
reported IG F IR-IR  heterodimers in vascular smooth muscle cells, whereby IG F I increased 
glucose metabolism and DNA synthesis. Although E G F R -IG F  IR heterodimers were 
identified in PC-3M -luc2 cells, no increase in phosphorylated E G F R  was seen upon 
stimulation with IG F (E3R ). Riedemann et al (2007) carried out co-immunoprecipitations in 
the MDA-MB-468 breast cancer cell line and clinical samples of breast cancer and found 
that the E G F R  interacts with the IG F IR and regulates its stability. Knockdown of the E G F R  
led to ubiquitinylation (degradation) of the IG F IR in MDA-MB-468 breast cancer cell line. In 
response to IG F IR blockade, the E G F R  pathway may become overactivated in order to 
overcome the IG F IR inhibition. This effect has been seen upon inhibition of the IG F IR in 5 
hepatocellular carcinoma cells (HepG2, Hep3B, HuH7, HuH6  and PLC/PRF5.,cells) treated 
with AVE1642 (mAb), whereby a resistance mechanism is induced via increased 
phosphorylation of the E G F R  and H ER 3  receptors (Desbois-Mouthon et a/., 2009). 
Therefore, combination therapy to inhibit IG F IR and E G F R  may be of value in tumours that 
develop resistance to IG F IR blockade via E G F R  signalling.
The E G F R  was shown to be expressed by the PC-3M -luc2 cells and formed 
heterodimers with the IG F IR. E G F R  has also been implicated in prostate cancer growth 
(Marks et al., 2008). However, PC-3M -luc2 cells did not proliferate in response to E G F. This 
concurs with a study where P C -3  cells, parental cells of PC-3M  did not proliferate in 
response to E G F  treatment. The authors found that phosphorylation of both E G F R  and 
ER B B 2  are predictive of prostate cancer cell proliferation in response to E G F  (Sheikh et al., 
2004). ER B B 2  was undetectable in PC-3M  cells (Wang et a/., 2001). Therefore, proliferation 
in response to E G F  in PC-3M -luc2 cells may be attributed to low levels of E R B B 2  as Sheikh 
et al (2004) suggest that quantifying the sum of E G F R  and ER B B 2  phosphorylation may 
identify prostate cancers that grow in response to E G F. E G F R  has previously been shown 
to potentiate the metastatic behaviour of PC-3M  cells in vitro (Uysal-Onganer and Djamgoz,
2007). Therefore, E G F R  expression in PC-3M -luc2 cells may not be involved in cell 
proliferation, but in metastatic potential. As the E G F R  forms heterodimers with the IG F IR, 
activation of the IG F IR was assessed  following E G F  treatment. Contrary to a study where 
E G F  activated the IG F IR in rat hepatocytes (Hallak et ai, 2002), E G F  treatment did not
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activate the IG F IR  in PC-3M -luc2 cells. Conversely, IG F  I has been shown to activate the 
E G F R  in C O S -7  cells (Roudabush et a/., 2000). However, in this study, IG F (E 3 R ) did not 
activate the E G F R .
The key findings from this chapter are that IG F IR expression is important in prostate 
cancer progression and may be useful in determining early Gleason grade and late Gleason  
grade prostate cancer tissue as seen in the prostate tumour TM As as IG F IR levels were 
higher in Gleason grade 3 prostate tissue and decreased in higher Gleason grade 5. This 
difference in staining may help in deciding therapeutic strategies for individuals based on 
receptor status. PC-3M -luc2 cells were selected as suitable for in vivo studies to test 
protease resistant IG FB P  4 as a strategy to inhibit prostate tumour growth as they express 
the IG F IR, are IG F (E 3 R ) responsive, express IG FB P  3 and IG FB P  4, the IG FB P  4 
protease P A PP-A  and Akt signalling is activated downstream of the IG F IR following IG F I 
treatment. Since the PC-3M -luc2 cells express components of the IG F signalling pathway 
and proliferate in response to IG F (E3R), utilising a protease resistant IG FB P  4 may inhibit 
IG F I induced proliferation of these cells in vivo.
C h a p t e r  4
P u r i f i c a t i o n  a n d  i n  v i t r o  e v a l u a t i o n  o f  p r o t e a s e  
r e s i s t a n t  I G F B P 4  i n  p r o s t a t e  c a n c e r  c e l l s
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4.1 In troduction
Due to the su ccess of targeting the H E R 2  receptor with the monoclonal antibody 
Herceptin™ (Trastuzumab), focus has turned towards inhibition of the IG F IR. However, 
there are concerns about targeting the IG F IR due to its importance in normal physiology 
and its ubiquitous distribution throughout the body. As the IG F IR shares 60 % homology 
with the IR (Ullrich et a/., 1986), blocking the IG F IR can inhibit the IR leading to toxicity 
issues or side effects such as hyperglycaemia which has been reported following treatment 
with CP-751,871 (IG F IR monoclonal antibody) in patients with refractory solid tumours 
(Haluska et a/., 2007). Numerous pharmaceutical companies have developed molecular 
targeted reagents to inhibit the IG F IR. The primary drugs being developed involve mAbs 
and TKIs. In pre-clinical trials, mAbs have shown good results in inhibiting tumour growth in 
vivo. IMC-A12, a fully humanised monoclonal antibody against the IG F IR developed by 
ImClone systems, inhibited growth of androgen dependent (Lu C a P  35) and androgen 
independent (Lu C a P  V5) prostate cancer cells implanted subcutaneously in S C ID  mice (Wu 
et al., 2005). 1MC-A12 is currently in Phase II trials in patients with mesothelioma 
(www.clinicaltrials.gov). T K Is  or small molecule inhibitors exploit the subtle differences in the 
kinase domains between the IG F IR and IR, therefore making these drugs more specific for 
the IG F IR compared with mAbs NVP-AEW 541 was designed by Novartis as an IG F IR  
specific TKI. In vitro and in vivo NVP-AEW 541 down-regulated IG F IR activation in a panel 
of 10 neuroblastoma cell lines (Tanno et al., 2006), similar to the mAb, IMC-A12 (Rowinsky 
et al., 2007). NVP-AEW 541 in combination with Herceptin™ enhanced the anti-proliferative 
effect of both drugs compared with either alone in H ER 2  overexpressing breast cancer cells 
(MDA-MB-231, BT474, S K B R 3  and M CF-7 cells) (Esparis-O gando et al., 2008). However, 
NVP-AEW 541 did not progress into clinical trials and the reasons for this have not been 
published.
Targeting the IG F I ligand is an alternative approach to inhibit IG F I induced effects 
and avoid unwanted effects on insulin signalling. IG FB P s may prove useful as therapeutics 
for cancer. The IG FB P s are naturally produced within the body, reducing the likelihood of an 
immune response upon administration. Protease resistant IG FB P s would decrease IG F I 
bioavailability resulting in inhibition of IG F I activity. IG FB P  4 is the smallest of the binding 
proteins and contains an N-linked glycosylation site which causes IG FB P  4 to exist in two 
forms, a 24 kDa non-glycosylated and 28 kDa glycosylated form (Ceda et al., 1991). IG FB P  
4 is purely inhibitory to IG F I and does not have any IGF-independent effects compared with 
other binding proteins. Numerous cancer cell lines have been shown to secrete IG FB P  4. 
The production of inhibitory IG FB P s by cancer cells or tumours may increase the local 
reservoir of IG F I thus increasing bioavailability of IG F I in tissues or tumours where P A P P -A  
is present.
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17p estradiol increased IG FB P  4 expression in M CF-7 breast cancer cells (Pratt and Poliak, 
1993). Prostate carcinoma cells (androgen independent P C -3  cells) have also been shown 
to secrete IG FB P  4 (Conover et a/., 1995b). As IG FB P  4 inhibits IG F I it suggests an 
interesting therapeutic approach for blockade of IG F  I. Overexpression of wildtype IG FB P  4 
in androgen receptor negative M1 2  prostate cancer cells delayed tumour onset in a 
subcutaneous prostate cancer model relative to controls (Damon et a/., 1998). In a 
subcutaneous animal model of colon cancer, peritumoural injection of a mammalian vector 
(pcDNA3) containing wildtype IG FB P  4 cDNA increased apoptosis and decreased the 
mitotic rate of colon cancer cells (HT-29) relative to controls which received empty vector 
(Durai et a/., 2007). Proteolysis of IG FB P  4 is a regulatory mechanism to control IG F I 
release and activity. P A P P -A  was identified as an IG F dependent IG FB P  4 protease 
(Lawrence et a/., 1999) and cleaves IG FB P  4 into two fragments of 18 kDa and 14 kDa 
which have decreased affinity for IG F I. P S A  can also cleave IG FB P  4 (Rehault et a/., 2001), 
but very little is known about the P S A  cleavage site in IG FB P  4. The P A PP-A  cleavage site 
has been well established (Chelius et a/., 2000). Zhang et a/. (2002a) mutated the P A P P -A  
cleavage site of rat IG FB P  4 from 119-KH M A KV RD R SKM K-133 to 119- 
AAM AAVADASAM A-133 and demonstrated it was resistant to cleavage by a fibroblast 
/-. produced protease. This protease resistant IG FB P  4 was^ used Jn -a  .porcine modeL o f -  ■■ 
neointimal hyperplasia where infusion of protease resistant IG FB P  4 into 
hypercholesterolemic pigs inhibited cell proliferation and neointimal expansion relative to 
controls (Nichols et a!., 2007).
In the Harmey group the equivalent murine protease (PA PP-A ) resistant form of 
IG F B P  4 was constructed using site directed mutagenesis (Appendix 13). The mutated 
sequence was cloned into a pTriEx4 Neo plasmid which contains a C-ter His-tag coding 
sequence, N-ter signal sequence to ensure secretion of the cloned protein and a neomycin 
resistance allowing selection of stable clones (Figure 4.1). Previously, mouse 4T1.2 breast 
cancer cells were transfected with rat wildtype IG FB P  4, rat protease resistant IG FB P  4 or 
empty vector and implanted into the mammary fat pad of female BALB/c mice. 
Overexpression of protease resistant IG FB P  4 in the mice showed a reduction in tumour 
growth and increased survival relative to controls as well as anti-angiogenic effects (Ryan et 
a/., 2009).
An advantage of using a protease resistant IG FB P  4 to block IG F I is that it is a small 
molecule compared with other IG FB P s and antibodies and can cross endothelial barriers 
(Boes et a/., 1992). As protease resistant IG FB P  4 cannot be cleaved by P A P P -A  it may 
have a long serum half-life. It has been shown that insertion of 12-mer peptides selected 
from protective motifs structures (capable of preventing the access of proteases to defined 
cleavage sites without affecting ligand binding) between a FLA G  epitope motif and a
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thrombin cleavage site led to peptides resistant to thrombin. The observed resistance to 
thrombin, resulted in increased resistance to plasma proteases in vitro and to an increase in 
circulating half-lives in rats (Eldridge et a/., 2009). As the protease resistant IG FB P  4 was 
previously shown to inhibit tumour growth in breast cancer and IG F I has been implicated in 
prostate cancer, its effects on prostate cancer growth and metastasis were evaluated. The  
aims of this chapter were to purify protease resistant IG FB P  4 to evaluate it in vitro.
The specific aims of this chapter were:
1. To purify dBP4 protein from H E K  293 cells transfected with dBP4 construct.
2. To determine dBP4 sensitivity to P A P P -A  and P S A  cleavage.
3. To determine IG F I and IG F II binding affinity of dBP4.
4. To compare the effects of IG F IR  T K Is  (AG1024 and N VP-AEW 541) and dBP4 on 
proliferation of PC-3M -luc2 cells.
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S  N-ter P A P P -A  C-ter E K  H IS
A  A M  A A V  A  D A S  A M  A  V  (d B P 4 sequence) 
from
K H M A K I  R D R S K M K V  (wildtype sequence)
Figure 4.1 Protease resistant mouse IGFBP 4 (dBP4) construct. PA P P -A  cleavage site 
was mutated by site directed mutagenesis to produce a P A P P -A  resistant IG FB P  4. The  
P A P P -A  cleavage site is located at residues 119-KHM AKIRDRSKM KV-133. A 6  residue 
His-tag (H IS) was added at the C-terminus of P A P P -A  cleavage site with an enterokinase 
(E K ) site located before the histidine tag (H IS) to allow removal of the His-tag. S  represents 
the signal peptide, which is cleaved upon secretion of dBP4. Amino acid sequence of the 
full construct is shown in Appendix 13.
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4.2 Results
4.2.1 Isolation of protease resistant IGFBP 4 expressing HEK 293 single cell clones
To obtain high levels of protease resistant IG FB P  4 (dBP4) from H E K  293 cells transfected 
with dBP4, single cell clones were isolated by serial dilution. Single cell clones were 
incubated in serum free medium for 72 h. Conditioned medium was collected and 
fractionated by 4 - 20 % (w/v) S D S -P A G E , transferred to nitrocellulose membrane and 
probed with anti-His-tag antibody (Figure 4.2). The predicted molecular weight of dBP4 is 34 
kDa. Clones 5 - 2 0  expressed dBP4. However, clones 5 - 8  expressed the highest level of 
dBP4 compared with other clones (Figure 4.2). Clones 5, 6 , 7 and 8  were further expanded 
for dBP4 protein purification.
4.2.2 Purification of dBP4 from HEK 293 single cell clones
Nickel agarose column was used to purify dBP4 protein. dBP4 is a 6  x  His-tagged protein 
allowing for dBP4 to interact with nickel ions covalently linked to the agarose beads. Flow 
through from each step of the column was retained in order to determine dBP4 recovery. 
Sam ples from flow through of conditioned medium, wash buffer, binding buffer, elution 
buffer and concentrated elution buffer were fractionated by 4 - 20 %  (w/v) S D S -P A G E , 
transferred to nitrocellulose membrane ^nd probed with anti-IG FBP 4 or anti-H is-t^  
antibody (Figure 4.3 A & B, respectively). Figure 4.3 A & B show that dBP4 was not present 
in the conditioned medium flow through (lane 1 ), wash buffer (lane 2 ) and binding buffer 
(lane 3). dBP4 was only present in the elution buffer and concentrated elution buffer (lane 4
& 5, respectively) indicating that the dBP4 loaded bound to nickel agarose and did not elute 
with the washes. In order to remove any other impurities that may be present Fast Protein 
Liquid Chromatography (F P L C ) was used to further purify dBP4. A Superdex 200 column 
was used which purifies proteins based on size exclusion. Based on the size of dBP4 (28 - 
34 kDa), it was predicted that dBP4 should be eluted after 12 - 13ml (Figure 4.4). dBP4 was 
dialysed into a running buffer (10 mM H E P E S , 150 mM NaCI and 1 mM C a C I2, pH 7.5) to 
remove imidazole from elution buffer. 500(jl of running buffer containing dBP4 was injected 
into the F P L C  and sam ples were collected and kept on ice for further analysis using 
Western blot. Figure 4.4 represents the chromatogram obtained from the F P L C , an increase 
in absorbance at 280 nm is seen when protein has eluted from the column. Peak 
absorbance at 280 nm was seen after 1 2  ml volume.
To identify sam ples containing dBP4, samples from the F P L C  were pooled in pairs 
and fractionated by 4 - 20 % (w/v) S D S -P A G E , transferred to nitrocellulose membrane and 
probed with anti-His-tag antibody (Figure 4.5). A His-tagged protein Masi (E3  ubiquitin 
ligase) (provided by Dr. Heidi Daxeckler), was used as a positive control.
1 0 6
kDa 1 10
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Figure 4.2: dBP4 is expressed by HEK 293 single cell clones. Single cell clones 1 - 20 
were isolated by serial dilution. Concentrated, conditioned medium was collected after 72 h. 
Conditioned medium was fractionated by 4 - 20 %  (w/v) S D S -P A G E , transferred to 
nitrocellulose and then probed for dBP4 expression with anti-His-tag antibody. Position of 
molecular weight maker is indicated (kDa).
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Figure 4.3: Nickel agarose purification of dBP4. dBP4 was isolated from conditioned 
medium of dBP4-transfected H E K  293 cells by nickel agarose chromatography. Sam ples  
were fractionated by 4 - 20 %  (w/v) S D S -P A G E , transferred to nitrocellulose and probed 
with anti-His-tag (A) or anti-IG FBP 4 antibody (B). In A & B, lane 1 shows conditioned 
medium flowthrough, lane 2 shows wash buffer flowthrough, lane 3 shows binding buffer 
flowthrough, lane 4 shows elution buffer and lane 5 shows concentrated elution buffer (20 
x ) .  Position of molecular weight marker is indicated (kDa).
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column purification, dBP4 was further purified using size exclusion F P L C . dBP4 was 
dialysed into a running buffer (10 mM H E P E S , 150 mM NaCI and 1 mM C a C l2, pH 7.5) 
using Centricon YM-3 filters to a volume of 500 pi and applied to Superdex 200 column and 
eluted with 10 mM H E P E S , 150 mM NaCI and 1 mM C a C I2, pH 7.5 in 1 ml fractions. The x- 
axis represents the elution volume and the y-axis represents the UV absorbance (A2eo)-
-E" 290 —n
300 —
Figure 4.4: Chromatogram from FPLC purification of dBP4. Following nickel agarose
109
dBP4 was present in fractions 1 4 - 1 9  (Figure 4.5). In order to check whether impurities from 
the nickel agarose column had been removed by F P L C , silver staining was carried out. 
Fractions from F P L C  containing dBP4 were pooled, fractionated by S D S -P A G E  and silver 
stained (Figure 4.6). Purified dBP4 was present in the pooled fractions 1 4 - 1 9  (lane 1). A  
band at approximately 6 6  kDa (lane 1) was also present in the commercially available 
IG FB P  4 (lane 2 ) and is probably indicative of serum albumin contamination.
4.2.3 Cleavage of dBP4 by PAPP-A and PSA
The P A P P -A  cleavage site of mouse IG FB P  4 was mutated from 119-KHM AKVRDIRSKM K- 
133 to 119-AAM AAVADASAMA-133. To test dBP4 resistance to P A P P -A  and P S A  
cleavage, dBP4 was incubated with P A P P -A  (a gift from Dr. Claus Oxvig) or P S A  overnight 
at 37°C. Recombinant human IG FB P  4 was used as a positive control for protein cleavage. 
Intact IG FB P  4/dBP4 and cleavage fragments were identified with anti-IG FBP 4 antibody 
(Figure 4.7). P A P P -A  cleavage of IG FB P 4  generates fragments of 18 kDa and 14 kDa. In 
the presence of PAPP-A, dBP4 was not cleaved. Recombinant IG FB P  4 was cleaved by 
P A P P -A  (18 kDa and 14 kDa) (Figure 4.7). In the presence of PSA , dBP4 was cleaved into 
two fragments of approximately 17 and 10 kDa in size whereas recombinant IG FB P  4 was 
cleaved Jnto one fragment (~ 26 kDa). Untreated dBP4 and recombinant IG FB R -4 remained 
intact. Since P S A  cleavage of dBP4 generated different sized fragments compared with 
recombinant IG FB P  4, this may suggest that mutation of the P A P P -A  site has increased 
P S A  cleavage due to either a change in amino acid sequence or a change in conformation.
4.2.4 IGF binding to dBP4
An IGF-binding E L IS A  method was developed to test the binding capacity of dBP4 for IG F I 
and IG F II. A  96 well plate was coated with 50 ng/ml IG F I, IG F II or V E G F 165. To  
demonstrate specificity of dBP4, binding to V E G F i65 was assayed as a non-specific ligand 
as dBP4 does not bind V E G F 16s- A s an additional control, dBP4 was pre-incubated with IG F  
I/ll for 30 min. Pre-incubation with IG F I/ll prevented dBP4 binding to IG F I/ll coated wells 
further demonstrating specificity of IGF/dBP4 interaction. dBP4 (500 ng/ml) binding was 
detected by incubation with H R P  substrate and absorbance read at 450 nm (Figure 4.8). An 
increase in absorbance was not seen following addition of dBP4 to IG F I or IG F II coated 
wells. Therefore, dBP4 did not bind IG F I or IG F II using this assay. Statistical analysis could 
not be carried out on data as it is only representative of n = 2 .
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Figure  4.5: d B P 4  in F P L C  fractio n s. Following size exclusion chromatography, paired 
fractions were pooled, concentrated and fractionated by 4 - 20 % (w/v) S D S -P A G E ,  
transferred to nitrocellulose and dBP4 was detected using anti-His-tag antibody. Masi 
(RN181) is a His-tagged E3 ubiquitin ligase used as a positive control. Position of molecular 
weight marker is indicated (kDa).
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Figure  4.6: S ilv e r stain  of purified dBP4. F P L C  purified dBP4 was fractionated by 4 - 20 
%  (w/v) S D S -P A G E  and silver staining carried out to a sse ss  protein purity. Lane 1 shows 
purified dBP4 and lane 2 shows commercially available recombinant IG FB P  4 (20 pg, 28 
kDa). Position of molecular weight marker is indicated (kDa).
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Figure 4.7: dBP4 sensitivity to PAPP-A and PSA. dBP4 or recombinant IG FB P  4 (20 pg) 
were incubated overnight at 37 °C  with either P A P P -A  (2 pi) or P S A  (20 ng). Sam ples were 
fractionated on 4 - 20 % (w/v) S D S -P A G E  and transferred to nitrocellulose. dBP4 and 
recombinant IG FB P  4 cleavage was analysed by anti-IG FBP 4 antibody. Recombinant 
IG F B P  4 was used as a positive control for protein cleavage. Position of molecular weight 
marker is indicated (kDa). Western blots are representative of three independent 
experiments.
dBP4 IGFBP 4 dBP4 IGFBP 4
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Figure  4.8: d B P 4  b inds IG F  I. An E L IS A  based method was used to determine dBP4  
binding affinity for IG F I and IG F II. A 96 well plate was coated with 50 ng/ml IG F I, IG F  II or 
V E G F 165 as a non-specific ligand. dBP4 was pre-incubated with either IG F I (50 ng/ml) or 
IG F II (50 ng/ml) for 30 min prior to addition to the plate as a second control for dBP4  
binding. V E G F 165 was used as a non-specific control. dBP4 binding to IGF-coated wells was 
detected by incubation with HRP-labelied anti His-tag antibody and bound antibody was 
detected using H R P  substrate and absorbance read at 450 nm (A^o). Uncoated wells were 
incubated with dBP4 or buffer alone. Data (n =2) expressed as the mean. Statistical 
analysis was not carried out.
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4.2.5 Effect of tyrosine kinase inhibitors on PC-3M-luc2 proliferation
To determine whether blockade of the IG F pathway inhibits cell proliferation tyrosine kinase 
inhibitors AG 1024 (Figure 4.9) (Merck, Nottingham, UK) and NVP-AEW 541 (Figure 4.10) 
(provided by Dr. Andrew Kung, D F C l, MA, U SA ) were used to test if IG F IR inhibition blocks 
PC-3M -luc2 proliferation. AG 1024 inhibits both the IR and IG F IR (Parrizas et a/., 1997a) 
whereas NVP-AEW 541 is an IG F IR specific Inhibitor (Garcia-Echeverria et a/., 2004). P C -  
3M-luc2 (5 x 103 cells/well) were treated with AG 1024 or NVP-AEW 541 ( 0 - 5  pM) in the 
absence or presence of IG F I (.100 ng/ml) or IG F (E 3 R ) (100 ng/ml) for 48 h. Cell 
proliferation and cytotoxicity was assayed by M TS assay. Controls were treated with the 
vehicle concentration equivalent to the highest dose of IG F and/or drug (DM SO (5 pM) and 
P B S  / 0.1 % (w/v) B SA  (IG F I) or P B S  / 10 mM HCI / 0.5% (w/v) B SA  (IG F  (E3R )) and 
DM SO (5 pM) or DM SO (5 pM) alone), IG F  I or IG F (E 3 R ) alone (100 ng/ml). Proliferation is 
expressed as % of control where control is taken as 100 %. PC-3M -luc2 cells treated with 
AG 1024 alone showed a significant decrease in proliferation at 0.5 pM (p<0.002), 1 pM 
(p<0.001) and 5 pM (p<0.0001) relative to controls. Treatment of PC-3M -luc2 cells with IG F
I or IG F (E3R ) caused a significant increase in proliferation relative to controls (p<0.017 and 
p<0.05, respectively). AG 1024 significantly inhibited IGF-induced proliferation at 0.1 pM 
(p<0.007), 0.5 pM (p<0;002), 1 pM (p<0.002) and 5 pM (p<Q,0001) relative to PQ-3M-luc2 
cells treated with IG F I alone. AG 1024 significantly inhibited IG F (E3R ) induced proliferation 
at doses of 0.1 pM (p<0.006), 0.5 pM (p<0.0001), 1 pM (p<0.0001) and 5 pM '(p<0.0001) 
relative to PC-3M-luc2 cells treated with IG F (E 3 R ) alone. AG 1024 inhibited IGF-induced 
proliferation at a dose of 0.1 pM.
Figure 4.10 shows treatment of PC-3M -luc2 cells with IG F I or IG F (E 3 R ) and NVP- 
AEW 541. PC-3M -luc2 cells treated with NVP-AEW 541 alone showed a significant reduction 
in proliferation at a dose of 5 pM relative to controls (p<0.001). IG F I or IG F (E3R ) 
significantly increased proliferation of PC-3M -luc2 cells relative to controls (p<0.045 and 
p<0.031, respectively). NVP-AEW 541 significantly inhibited IGF-induced proliferation at 1 
pM (p<0.021) and 5 pM (p<0.001) relative to PC-3M -luc2 cells treated with IG F I alone. 
Similarly, NVP-AEW 541 significantly inhibited IG F (E 3 R ) induced proliferation at doses of 1 
pM (p<0.017) and 5 pM (p<0.001) relative to PC-3M -luc2 cells treated with IG F (E 3 R ) alone. 
Therefore, NVP-AEW 541 inhibited IGF-induced proliferation at a dose of 1 pM. Previously, it 
was shown by BrdU (Figure 3.8) that PC-3M -luc2 cells do not proliferate in response to IG F
I, however the M TS assay showed an increase in proliferation following IG F I treatment 
(Figure 4.9 and Figure 4.10). This difference may be attributed to seeding density as the 
BrdU required 3 x 1 0 3 cells vs. 5 x 103 cells in the M TS assay.
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Figure 4.9: AG1024 inhibits IGF-induced proliferation in PC-3M-luc2 cells. 5 x 103
cells/well PC-3M-luc2 cells were treated with tyrosine kinase inhibitor AG1024 (0.1 - 5 pM) 
with or without 100 ng /ml IGF I and IGF (E3R) in triplicate for 48 h and proliferation 
assayed by MTS assay. Proliferation is expressed as % of control where control is taken as 
100 %. Controls were treated with the vehicle concentration equivalent to the highest dose 
of IGF and/or drug Data (n = 3) expressed as the mean + SEM and analysed by one-way 
ANOVA followed by LSD post hoc correction. *p<0.05 vs Control, ***p <0.001 vs Control, 
$$p<0.01 vs. IGF I, $$$p<0 .0 0 1  vs. IGF I, t+p<0.01  Vs. IGF (E3R) and tn p<0 .0 0 1  vs. JGF
(E3R).
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In addition, the M TS assay is based on metabolic activity, therefore IG F I may affect 
metabolic activity as well as DNA synthesis (BrdU assay).
4.2.6 Effect of dBP4 on PC-3M-luc2 cell proliferation
dBP4 was used to block IG F I induced proliferation in PC-3M -luc2 cells. PC-3M -luc2 (5 x 
103 cells/well) were treated with dBP4 (2.5 pg/ml) in the absence or presence of IG F I (50 
ng/ml) for 48 h and cell proliferation and cytotoxicity was assayed by M TS assay. Controls 
were treated with vehicle (P B S). Proliferation is expressed as %  of control where control is 
taken as 100 %. Treatment of PC-3M -luc2 cells with dBP4 or dBP4 plus IG F I had no 
significant effect on inhibiting proliferation (Figure 4.11). However, it was technically 
impossible to show an effect of dBP4 on proliferation in vitro as IG F I had no effect on P C -  
3M-luc2 cell proliferation in the first instance. Previously, IG F  (E 3 R ) increased proliferation, 
but it cannot be bound by IG FB P s therefore it could not be used for this experiment. A lower 
dose of IG F I was used in this experiment compared with Figure 4.9 and Figure 4.10, this 
may have contributed to IG F I having no effect on proliferation.
4.2.7 Effect of dBP4 on angiogenesis in human endothelial cells
An Angiokit was purchased from T C S  Cell Works (Buckingham, UK) which contained a 24- 
well plate of early stage tubule forming human endothelial cells. The effect of dBP4 on 
angiogenesis (tubule formation) was assessed  by staining the cells for C D 31+ (work carried 
out by Dr. Constanze Schadow). Human endothelial cells were treated in triplicate for 10 
days with V E G F  (10 ng/ml, positive control), an angiogenesis inhibitor, Suramin (20 |j M, 
negative control), IG F I (100 ng/ml) or IG F I (100 ng/ml) pre-incubated with dBP4 (2.5 pg/ml) 
for 30 min. Control wells were untreated. Medium was changed every 3 days along with 
fresh treatments. Figure 4.12 A shows untreated endothelial cells with multiple tubules 
formed. VEGF-treated endothelial cells showed a greater number of tubules (Figure 4.12 B). 
Suramin-treated endothelial cells showed a decrease in tubule formation relative to 
untreated controls and VEGF-treated cells (Figure 4.12 C). IG F  I treated endothelial cells 
showed tubule formation, but tubule formation was less than that seen in VEGF-treated  
endothelial cells (Figure 4.12 D) and IG F I pre-incubated with dBP4 showed a large 
decrease in tubule formation relative to all other treatments (Figure 4.12 E).
Images from 3 different fields of view were taken from each triplicate and the 
Angiosys software was used to determine the number of tubules formed following each 
treatment. Dr. Silvia Napoletano carried out statistics, which were performed between each 
biological triplicate for each treatment group.
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Figure 4.10: NVP-AEW541 inhibits IGF-induced proliferation in PC-3M-luc2. 5 x 103
cells/well PC-3M -luc2 cells were treated with tyrosine kinase inhibitor, NVP-AEW 541 (0.1 - 
5 pM) with or without 100 ng/ml IG F I and IG F (E 3 R ) in triplicate for 48 h and proliferation 
assayed by M TS assay. Proliferation is expressed as % of control where control is taken as 
100 %. Controls were treated with the vehicle concentration equivalent to the highest dose 
of IG F and/or drug. Data (n = 3) expressed as the mean + SEM  and analysed by one-way 
AN O VA followed by L S D  post hoc correction. *p<0.05 vs. Control, ***p <0,001 vs. Control, 
$p<0.05 vs. IG F I, $$$p<0-001 vs. IG F  I, fp<0.05 vs. IG F  (E 3 R ) and m p<0 .0 0 1  Vs. IG F
(E 3 R )
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Figure 4.11: Effect of dBP4 on PC-3M-luc2 proliferation. 5 x 103 cells/well PC-3M -luc2  
cells were treated with dBP4 (2.5 (jg/ml) with or without 50 rig /ml IG F I in triplicate for 48 h 
and proliferation assayed by M TS assay. Proliferation is expressed as % of control where 
control is taken as 100 %. Data (n = 3) are expressed as the mean + SEM  and analysed by 
one-way AN O VA (p = ns).
if-
119
Figure 4.12: dBP4 inhibits tubule formation by human endothelial cells. Early stage  
tubule forming human endothelial cells were treated in triplicate for 10 days with V E G F  
(positive control, 10 ng/ml), angiogenesis inhibitor, Suramin (negative control, 20 pM), IG F I 
(100 ng/ml) or IG F I (100 ng/ml) pre-incubated with dBP4 (2.5 pg/ml) for 30 min. Controls 
were untreated. Tubule formation was assessed  following staining for C D 31+. 
Representative images from each treatment are shown. (A) shows untreated endothelial 
cells, (B) shows V E G F  (positive control, 10 ng/ml) treated endothelial cells, (C ) shows 
Suramin (negative control, 20 | jM )  treated endothelial cells, (D) shows IG F I (100 ng/ml) 
treated endothelial cells and (E ) shows IG F I (100 ng/ml) and dBP4 (2.5 ng/ml) treated 
endothelial cells. (Original magnification 200 x )
120
A  significant increase in tubule number was noted following treatment with V E G F  (10 ng/ml, 
positive control) relative to untreated controls (278 + 16 vs. 165.8 + 13.9, p<0.001). No 
significant difference in tubule number was seen between controls or IG F I treated wells. It is 
likely that the growth factor cocktail provided with the Angiokit already contained IG F I so the 
addition of further IG F I may have had no effect. However, T C S  Cellworks could not confirm 
the absence or presence of IG F I in the cocktail. Suramin (20 jjM, negative control) 
treatment significantly reduced tubule number relative to untreated controls (81.6 + 5.2 vs.
165.8 + 13.9, p<0.01). IG F I (100 ng/ml) and dBP4 (2.5 }jg/ml) treatment significantly 
reduced tubule number relative to untreated controls (11.4 + 2.2 vs. 165.8 + 13.9, p<0.001). 
IG F I (100 ng/ml) and dBP4 (2.5 pg/ml) treatment significantly decreased tubule number 
relative to IG F I (100 ng/ml) treated endothelial cells (11.4 + 2.2 vs. 140.3 + 17.8, p<0.001) 
(Figure 4.13). These results further support IG F I presence in the growth factor cocktail as  
dBP4 significantly reduced tubule formation relative to controls.
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Figure 4.13: dBP4 decreases tubule number in endothelial cells relative to untreated 
controls or VEGF-treated endothelial cells. A 24-well plate of early stage tubule forming 
human endothelial cells were, treated in triplicate for 5 days with V E G F  (positive control, 10 
ng/ml)f an angiogenesis inhibitor, Suramin (negative control, 20 pM), IG F I (100 ng/ml) or 
IG F I (100 ng/ml) pre-incubated with dBP4 (2.5 pg/ml) for 30 min. Controls were untreated. 
Tubule formation was assessed  following staining for C D 3 1 +. 3 fields of view were taken for 
each triplicate well and AngioSys Software was used to calculate the number of tubules. 
Data are expressed (n=3) as mean + SEM . A one-way AN O VA was carried out on 
triplicates followed by Tukey post hoc correction. **p<0.01 vs. Control, ***p<0.001 vs. 
Control, $$$p<0.001 vs. IG F  I.
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4.3 Discussion
The IG F pathway plays a central role in transformation and tumourigenesis (Kaleko et a/., 
1990). Due to the involvement of the IG F pathway in cancer it has proved an attractive 
therapeutic target. Numerous therapeutics have been developed against the IG F IR, but the 
IG F  IR forms hybrid receptors with the IR (Johansson and Arnqvist, 2006) and shares 60 %  
homology with this receptor (Ullrich et a/., 1986). Inhibition of the IG F IR can also inhibit the 
IR leading to complications such as the clinical syndrome of insulin resistance which can 
lead to diabetes (Araujo et al.t 2005). New therapies are required to overcome the issue of 
IR blockade. In this study, the ligand IG F I was chosen as the target. IG FB P s are naturally 
occurring regulators of IG F I/ll activity. Exploiting the ability of the IG FB P s to inhibit IG F I led 
to the development of a P A P P -A  resistant form of IG FB P  4 (dBP4).
H E K  293 cells were chosen for dBP4 production as they are a mammalian cell line 
which do not produce endogenous IG FB P  4 and would allow for correct folding, 
glycosylation and secretion of dBP4 facilitating protein purification. The addition of a C-ter 
His-tag allowed differentiation of dBP4 vs. endogenous IG FB P  4 and facilitated purification 
by nickel-agarose affinity chromatography. The nickel column was an efficient method of 
purifying dBP4 from the conditioned medium, as none of the protein was lost during each 
step. F P L C  was .used to ,further purify dBP4. The F P L C  purification can be monitored 
allowing for the detection of proteins eluting from the column. Sam ples correlating to an 
increase in absorbance were further analysed using Western blot to confirm the presence of 
dBP4. The silver stained gel allowed us to a sse ss  the purity of the samples. The band that 
appeared at 6 6  kDa was that of albumin which was also seen in the commercially available 
IG FB P  4. The presence of albumin in the dBP4 sample is indicative of residual serum in 
medium and the commercially available IG F B P  4 is reconstituted in P B S  containing 0.1 %  
BSA. This method of purification has been used previously to purify His-tagged proteins 
(Overgaard et a/., 2001).
P A P P -A  is the main IG FB P  4 protease (Lawrence et a!., 1999). To a sse ss  that dBP4  
was resistant to P A PP-A  a cleavage assay was carried out. P S A  which is elevated in 
prostate cancer patients was also tested as it is known to cleave IG FB P  4 (Rehault et a/.,
2001). dBP4 was resistant to P A P P -A  cleavage but was cleaved by PSA . Therefore, P SA  
cleaves dBP4 at a different site to P A PP-A  with the major fragment occurring at 10 kDa. The  
P S A  cleavage site in IG FB P  4 has not been established. The P S A  cleavage site in IG FB P  3 
is known to occur at Tyr 159 (Okabe et a/., 1999) in the mid region of the protein which differs 
between each binding protein. The substrate specificity of P S A  has been investigated to 
determine preferred sequences for P S A  cleavage. Tyrosine was reported as a preferred site 
of hydrolysis. The consensus sequence S S (Y / F )Y jS G  was determined as the sequence for 
most efficient peptide hydrolysis by P S A  (Coom bs et a/., 1998), but this consensus
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sequence is not found in dBP4 (see Appendix 13). However, P S A  cleavage of dBP4 led to 
an increased number of fragments relative to recombinant IG FB P  4. Therefore, mutation of 
the P A PP-A  sequence may have introduced more cleavage sites for P S A  due to either the 
change in amino acid sequence or a change in conformation. Further mutation of dBP4 to 
generate a P A P P -A  and P S A  resistant variant could be pursued as a therapeutic in prostate 
cancer if the mutation did not affect IG F binding capacity. However, the cells used in this 
study, PC-3M -luc2 cells, do not produce PSA.
dBP4 binding of IG F  I and IG F II was assessed  to determine if mutation of the P A P P - 
A cleavage site altered binding to IG F I and IG F II. dBP4 was not shown to bind IG F or IG F
II in E L IS A  based assay. However, Dr. Anthony Chubb previously carried out Biacore 
analysis of dBP4 to determine the binding affinity of dBP4 to IG F I relative to wildtype IG FB P
4. The binding affinity for IG F I by wildtype IG FB P  4 or dBP4 was comparable (3.9 x 10'9 M 
vs. 3.5 x  10‘9 M, respectively) (Chubb and Harmey, unpublished data). IG FB P  4 binds IG F I 
and IG F II with equal affinity (Kiefer et a/., 1992). The IG F binding domain for IG FB P  4 
consists of the N-terminal Leu 72 - Ser 91and the C-terminal C ys 205 - Val 214. They are 
important for correct folding and high affinity binding of IG Fs (Qin et a/., 1998). The PA P P -A  
cleavage site is located at Lys 119 - Lys 133 therefore mutation of the P A PP-A  site should not 
alter the IG F binding domain as it Is outside the IG F binding-domains. Molecular modelling 
predicted that dBP4 should therefore bind both IG F I and IG F II.
dBP4 was compared with the commercially available IG F IR tyrosine kinase 
inhibitors AG 1024 and NVP-AEW 541. AG 1024 is a tyrphostin, a synthetic protein tyrosine 
kinase inhibiting receptor autophosphorylation. AG 1024 dose dependently inhibited cell 
proliferation of LN C a P  cells, an androgen dependent prostate cancer cell line (Thom as et 
a/., 2009). NVP-AEW 541 is an IG F IR  tyrosine kinase inhibitor. IG F  I or IG F (E 3 R ) increased 
proliferation of PC-3M -luc2 cells relative to controls. Following treatment of PC-3M -luc2 with 
AG 1024 alone a significant decrease in proliferation was reported at doses 0.5 - 5 pM 
relative to controls. However, when AG 1024 and IG F I was compared with IG F I alone, 
AG  1024 and IG F I significantly inhibited IG F I induced proliferation at 0.1 - 5 pM. Therefore, 
AG 1024 inhibited IG F I induced proliferation at a dose of 0.1 pM. In PC-3M -luc2 cells 
treated with IG F (E 3 R ) and AG1024, a significant decrease in proliferation was reported at 
doses of 0.1 - 5 pM compared with doses of 0.5 pM - 5 pM AG 1024 vs. controls. Therefore, 
AG 1024 inhibited IG F (E3R ) induced proliferation at a dose of 0.1 pM. In NVP-AEW 541  
treatments, IG F I or IG F (E3R ) significantly increased proliferation of PC-3M -luc2 cells. 
NVP-AEW 541 alone inhibited proliferation at 5 pM relative to controls. However, when IG F I 
and NVP-AEW 541 was compared with IG F I alone a significant decrease in proliferation was 
reported at 1 pM and 5 pM. A similar effect was seen when IG F (E 3 R ) and NVP-AEW 541  
was compared with IG F (E 3 R ) alone. NVP-AEW 541 inhibited IGF-induced proliferation at a
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dose of 1 pM. Previously, it was shown by BrdU that IG F  I did not induce proliferation of P C -  
3M-luc2 cells (Chapter 3) whereas in the M TS assay a significant increase in proliferation 
was seen following IG F I treatment. The difference in the effect of IG F I may have been 
attributed to a higher seeding density used in the M TS assay (5 x 103 cells) compared with 
the BrdU assay (3 x 103 cells). Although the M TS assay is useful for quantification of viable 
cells this assay has a number of limitations. Cells with low metabolic activity must be used in 
high numbers to detect changes in viability in response to treatments. The assay assum es  
that metabolic activity is proportional to cell viability, which may not be the case, as 
treatments may increase, or decrease metabolic activity without affecting cell number. 
However, this assay is widely used to estimate proliferation (Marrero et a/., 1997, Ono et a/., 
2004, Helguero et al., 2005) and is an accepted technique to a sse ss  cytotoxicity, drug 
sensitivity and cell activation. The M TS assay has advantages over other assays i.e. BrdU 
incorporation, as it requires less cell manipulation and therefore may reduce errors. The  
M TS is also based on a metabolic reaction compared with the BrdU assay which directly 
measures DNA synthesis, therefore IG F I may increase metabolic activity of the PC-3M -luc2  
and/or DNA synthesis.
dBP4 binds the IG F I ligand rather than blocking the IG F IR receptor. PC-3M -luc2  
cells were treated with IG F I instead of IG F  (E 3 R ) as IG F (E3R )xan no t be bound to IG FB P s, 
therefore dBP4 would not have inhibited it. dBP4 should inhibit IGF-induced proliferation. A 
lower dose of IG F I (50 ng/ml) was used compared with AG 1024 or NVP-AEW 541  
experiments (100 ng/ml) as a 5:1 molar excess of dBP4 was used (50 ng/ml IG F 1:2.5 [jg/ml 
dBP4) and due to a limited amount of protein the higher dose of IG F I was not used.
IG F (E3R ) significantly increased V E G F  production in PC-3M -luc2 cells suggesting  
that dBP4 could have anti-angiogenic effects. In this study, the anti-angiogenic effect of 
dBP4 is supported by a significant reduction in tubule formation following treatment of 
human endothelial cells with dBP4 in the presence of IG F I relative to untreated controls or 
IG F  I treated endothelial cells (p<0.001). dBP4 increased apoptosis of endothelial cells 
within mammary 4 T 1 .2 breast cancer tumours (Ryan et al., 2009).
Assessm ent of colony formation and invasion of PC-3M -luc2 cells may have 
provided additional information on the anti-metastatic effect of dBP4 in vitro. Wildtype 
IG FB P  4 inhibits colony formation and invasion through Matrigel in colon cancer cells 
sensitive (LS1034 cells) and insensitive to IG F I (lsreco-1 cells) (Diehl et al., 2004). Given 
the effect of dBP4 on tubule formation and the potential role for it as an anti-angiogenic 
molecule, future in vitro work should also include the assessm ent of these parameters.
The key findings from this chapter were dBP4 was effectively purified from H E K  293 
single cell clones using nickel column purification followed by F P L C . However, ~ 30 pg/ml of 
dBP4 was purified, which was insufficient for use in vivo, but was shown to work in vitro.
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dBP4 remained insensitive to P A P P -A  cleavage, but was cleaved by P S A  at different sites 
to the recombinant IG FB P  4. dBP4 maintained its binding capacity to IG F I. Inhibition of the 
IG F pathway caused a decrease in PC-3M -luc2 cell proliferation, as seen with two T K Is  
A G 1024 and NVP-AEW 541. dBP4 significantly inhibited tubule formation in human 
endothelial cells suggesting an anti-angiogenic effect. The effect of dBP4 on PC-3M -luc2 
cells could not be fully assessed  in vitro suggesting that other parameters such as 
angiogenesis, apoptosis and colony formation may give a better insight into dBP4 effects in 
vitro.
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5.1 Introduction
Pre-clinical models of cancer have proven to be essential in further understanding human 
cancer and in the development of novel therapeutics. Animal models should recapitulate 
many aspects of human cancer such as hormone dependency, angiogenesis and tumour- 
stromal interactions. Advances within the field of molecular and cellular imaging have now 
allowed researchers to non invasively measure tumours at serial timepoints from the same 
individual subject leading to smaller cohorts of experimental animals (Dickson et al., 2007).
One of the most important aspects of testing new therapies pre-clinically is selecting 
an appropriate model. Transgenic mice and xenografts are commonly used as prostate 
cancer models. Transgenic mice have been engineered to develop prostate cancer with 
prostate specific transforming agents in combination with prostate specific promoters. The  
most commonly used transforming agent is the SV 40 T  antigens. SV 40 oncoproteins 
inactivate the tumour suppressor p53 thus allowing transformation of the mouse prostate to 
occur (Mietz et al., 1992). Xenografts allow implantation of human tissue or cells into 
immunodeficient mice. Nude mice in which a genetic mutation leads to absence of a thymus 
thus leading to a repressed immune system lacking T  cells have long been used for 
xenograft models of cancer (Rygaard and Poulsen, 1969). NOD S C ID  Gamma mice are 
more immunodeficient than nucfe mice. Subcutaneous. ..injection of human cells has 
commonly been used to test drugs pre-clinically due to ease of use and large amount of 
data obtained. However, one drawback to subcutaneous xenograft models is they do not 
accurately represent clinical cancer as the tumours are growing in a different tissue with a 
different microenvironment (Stephenson et a/., 1992). Orthotopic implantation of human 
cells is becoming more common where human cancer cells are implanted into the 
appropriate anatomical site. Orthotopic xenograft models allow investigation of human 
cancer to determine the influence of microenvironment on growth, behaviour of human 
tumour cells and metastasis formation (Wang et al., 2005). However, the cell-cell 
interactions involved within the microenvironment are between the murine host cells and the 
human tumours cells, which may affect the behaviour of human tumours. The orthotopic 
prostate cancer model is a better representation of human prostate cancer than 
subcutaneous models (Stephenson et al.t 1992). Interaction of tumour cells with the 
microenvironment is crucial in tumour development (Liotta and Kohn, 2001).
Bone metastasis is a common feature of advanced stage prostate cancer (Dai et al.,
2008). Orthotopic prostate models have been shown to metastasise previously (Yang et al., 
1999), but not all animal prostate cancer models develop metastases. In order to establish 
bone metastases, experimental metastasis models have been established, the most 
common of which is intracardiac injection of tumour cells via the left ventricle which gives 
rise to bone metastases (Jenkins et al., 2003, Sasaki et a/., 1995).
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A second method involves IV injection of tumour cells via the lateral tail vein, which gives 
rise to either lung or less frequently bone and liver metastases (Lu et a/., 2010, Nemeth et 
ai., 1999).
In this study, a xenograft model was chosen. Human prostate cancer cells PC-3M - 
Iuc2 dBP4, were implanted into immunodeficient NOD S C ID  Gamma (N SG ) mice to 
examine the efficacy of dBP4 against prostate cancer. NOD mice were established from 
inbreeding of cataract prone mice (cataract shionogi mice), which spontaneously exhibited 
polyuria and glucosuria accompanied by rapid weight loss. Mating pairs were selected and 
offspring showing spontaneous diabetes and reproductive abilities were further mated. 
Following 6  generations a stable diabetic strain was established (Makino et a/., 1980).
N SG  mice are double homozygous for S C ID  mutation and lnterleukin-2 R  gamma 
(IL -2 R y ) allelic mutation and were established following 8  back backcross matings between 
C57BL/6J ynu" mice with NOD/Shi-sc/d mice resulting in N SG  mice with no active T-cells, B- 
cells, natural killer cells, reduced complement activity and macrophage and dendritic cell 
dysfunction. N SG  mice are therefore a more appropriate mouse strain for xenograft 
implantation compared with nude mice as the reduced immunogenicity improves 
transplantability of human tissue or cells. N SG  mice have been shown to be an excellent 
recipient for human cell:engraftment (!to et ai., 2 0 0 2 ).
: A Tet-On inducible system was chosen to block IG F I effects in vivo using dBP4. The  
Tet-On inducible system allows the dBP4 protein to be induced within tumours once 
established whereas previously dBP4 was constitutively expressed in a 4T1.2 breast cancer 
model (Ryan et a/., 2009). The principle of the Tet-On system is that the gene of interest is 
only expressed in response to doxycycline. The first component of the Tet-On system is a 
regulatory protein, which is based on the Tet repressor protein (TetR) produced by E. coii, 
which negatively regulates expression of genes of the tetracycline-resistance operon. The  
regulatory protein for the Tet-Off system is based on the TetR  protein which is fused to the 
C-terminal of Herpes simplex virus VP16 domain that converts TetR  from a transcriptional 
repressor to a transcriptional activator (Triezenberg et ai., 1988). The resulting hybrid protein 
is known as tetracycline-controlled transactivator (tTA). The tTA protein is produced by the 
pTet-Off regulator plasmid. The Tet-On system is similar to the Tet-Off system, but the 
regulatory protein is a reverse Tet repressor (rTetR) which contains a 4 amino acid change  
(Gossen et ai., 1995). rtTA is encoded by the pTet-On regulator plasmid: Both Tet-Off and 
Tet-On plasmids contain a neomycin-resistance gene. PC-3M -luc2 cells were initially 
transduced with the pTet-On plasmid and a stable cell line was established under selection 
with genetlcin (G418). The second component of the Tet-On System Is the response  
plasmid, which expresses the gene of interest, in this case dBP4, cloned under control of 
the Tet response element (T R E). The plasmid that dBP4 was cloned into is pLV X Tight Puro
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which contains a puromycin resistance gene, allowing for selection of stable cell line 
expressing dBP4. Ultimately, a cell iine was established containing the regulatory and 
response plasmids where addition of doxycycline turned on dBP4 expression. The  
advantages of using the Tet-On inducible system for this study is that it allows tumours to 
grow and become established before induction of dBP4, which mimics the clinical situation. 
Other advantages of the Tet-On system are high expression levels (Yin et a/., 1996) and no 
pleiotropic effects as rtTA binds specifically to its target sequences (Harkin et a/., 1999). The  
effect of dBP4 expression on tumour growth in vivo was assessed  using subcutaneous, 
orthotopic and experimental metastasis prostate cancer models.
Tumour growth and metastasis was monitored by bioluminescent in vivo imaging 
(B LI) as PC-3M -luc2 dBP4 cells express luciferase, which converts Iuciferin to oxyluciferin 
and light, which is detected by the IVIS imaging system. Individual mice can be imaged over 
a defined time course leading to a reduction in animal numbers. Tight correlations between 
tumour burden and photon emission have been demonstrated (Jenkins et a/., 2003). A s A TP  
and oxygen are required along with luciferin for light emission, luciferase provides a 
quantitative measure of viable cells (Jenkins et a/., 2003, Rehemtulla et a/., 2000). BLI is 
quick and relatively inexpensive. Image acquisition time can vary from 1 s - 60 s making it 
p o s s ib le s  image numerous treatment cohorts in a single session,, . ;. ...
The increased availability of small animal imaging technology has facilitated rapid 
progress in understanding tumour biology and evaluation of novel therapeutics (Chinnaiyan 
et a/., 2000). The overall aim of this chapter is to subclone the dBP4 construct into the Tet 
inducible system and transduce PC-3M -luc2 with the Tet inducible system (PC-3M -luc2  
dBP4). The effect of dBP4 expression on PC-3M -luc2 dBP4 prostate tumour growth and 
metastasis was assessed in N SG  mice.
In Chapter 4, dBP4 inhibited tubule formation in vitro therefore; anti-angiogenic 
effects are anticipated in vivo. IG F  (E 3 R ) increased PC-3M -luc2 cell proliferation in vitro. 
Therefore, in vivo dBP4 may target PC-3M -luc2 tumour growth in two ways - by blocking 
tumour cell growth and proliferation directly and indirectly by inhibiting angiogenesis within 
the tumours.
The specific aims of this chapter were:
1. To clone dBP4 construct into Tet inducible system (PC-3M -luc2 dBP4 cells).
2. To transduce PC-3M -luc2 cells with Tet inducible system and to test the effects of dBP4  
expression following addition of doxycycline when tumours were palpable.
3. To test the effect of dBP4 expression on PC-3M -luc2 dBP4 tumour growth in 
subcutaneous, orthotopic and experimental metastasis models of prostate cancer.
4. To compare the effects of dBP4 expression (mice fed on doxycycline chow) with controls 
(fed on normal chow) and mice treated with a known tyrosine kinase inhibitor against the 
IG F IR, N VP-AEW 541.
5. To determine the effect of dBP4 expression on serum and tumour IG F I levels, blood 
glucose and the IG F signalling pathway in vivo compared with controls or NVP-AEW 541  
treated mice.
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5.2 Results
5.2.1 Cloning of dBP4 into pLVX Tight Puro lentiviral vector
In order to subclone dBP4 from the pTriEx4 Neo plasmid into the doxycycline inducible 
p LV X Tight Puro (lentiviral) vector, restriction enzyme sites for BamH\ (5’ end) and EcoRI (3’ 
end) were added onto dBP4 construct using dBP4-specific P C R  primers. The pLV X Tight 
Puro vector contains a restriction site for each of these enzymes. P C R  products were 
fractionated on a 0.8 %  (w/v) agarose gel (Figure 5.1). Lanes 1 - 1 0  all contain amplified 
d BP4 (847 bp); bands were excised and purified using the GeneJet purification kit.
Following purification of amplified dBP4, dBP4 and pLV X Tight Puro were digested 
with BamH\ and Eco R I restriction enzymes. Digested dBP4 was fractionated on a 0.8 %  
(w/v) agarose gel (Figure 5.2). Double digests were carried out on dBP4 (lane 2) and pLVX  
Tight Puro vector (Lane 3). Single digests were carried out using BamH\ and Eco R I on 
dBP4 (lane 4 & 5, respectively) or pLV X Tight Puro (lane 7 & 8 , respectively). Single digests 
were carried out to demonstrate that each restriction enzyme was working efficiently. 
Linearised plasmid DNA migrates more slowly through the gel than supercoiled plasmid 
DNA. Lane 8  shows pLVX Tight Puro vector digested with BamH\ and EcoR I and 
undigested vector is shown in lane 9. As both enzym es effectively digested pLV X Tight 
Puro, the double digest of the dBP4 construct should also be complete. BamH\ and EcoRI 
digested insert and vector bands were excised and purified using the GeneJet purification 
kit.
Gel purified BamH\ and EcoRI digested dBP4 was ligated into BamH\ and EcoR I 
digested pLV X Tight Puro vector. Ligation controls were set up; vector with no insert, vector 
and insert with no ligase, single digested vector with or without ligase to a sse ss  self-ligation 
and that ligase was working. One Shot® T O P IO  competent E.coli were transformed with 
ligations. Once ampicillin resistant colonies were established, 28 colonies were picked and 
streaked onto a fresh agar plate and a portion added to Triton X-100 (5 % v/v) and heated to 
95 °C  to release DNA. P C R  amplification with dBP4-specific primers (2.4.4) was carried out 
to screen for the insert (dBP4) in the bacterial colonies. P C R  products were fractionated on 
0.8 %  (w/v) agarose gel (Figure 5.3 A & B). pTriEx4 Neo dBP4 (+) was used as a positive 
control for dBP4 P C R  (Figure 5.3 A, (+)), with the correct band size seen at 827 bp. Two 
bands were seen in the positive control. This may have been due to coiled pTriEx4 Neo 
plasmid. The negative control contained no DNA (-) and no P C R  product was generated 
(Figure 5.3 A, (-)). A band at 827 bp was amplified from colonies 23, 24 and 28 (Figure 5.2
B, lane 11, 12 and 14, respectively). Colony P C R  is a crude method for determining the 
presence of the selected insert and non-specific amplification was seen in many of the 
colonies; this may be due to the composition of the primers which required a low annealing 
temperature (50 °C ) and the quality of DNA isolated by this method is “quick and dirty”.
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Figure 5.1: Addition of BamH\ and EcoRI restriction sites to dBP4 insert. Recognition 
sites for BamW\ (5’ end) and Eco R I (3’ end) were added to dBP4 using dBP4-specific P C R  
primers with restriction enzyme sites at the 5’end of forward (Bam HI) and reverse (Eco R I) 
primers. P C R  products (847 bp) were fractionated on a 0.8 %  (w/v) agarose gel (lanes 1 - 
10), were excised and purified using the GeneJet gel purification kit.* Position of the 
molecular weight marker is indicated (bp).
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Figure 5.2: Restriction digest of dBP4 insert and pLVX Tight Puro vector. Plasm ids 
and digested products were fractionated on a 0.8% (w/v) agarose gel. Lane 1 shows 10 kB 
DNA ladder, lane 2 shows BamH\ and Eco R I digested dBP4, lane 3 shows BamHI and 
Eco R I digested vector (pLV X Tight Puro), lane 4 shows BamH\ digested insert, lane 5 
shows Eco R I digested insert, lane 6  shows undigested insert, lane 7 shows BamH\ digested 
vector (pLVX Tight Puro), lane 8  shows Eco R I digested vector and lane 9 shows undigested 
vector. Position of molecular weight marker is indicated (bp).
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Figure 5.3 A & B: Screening for dBP4 insert by colony PCR. Following transformation of 
One Shot® T O P IO  E.coli with pLVX Tight Puro dBP4 ligations, colonies were picked onto a 
fresh agar replica plate and dBP4-specific P C R  was carried out on 28 colonies. P C R  
products were fractionated on a 0.8 %  (w/v) agarose gel. 1 ng pTriEx4 Neo dBP4 (+) was 
amplified as a positive control (A, (+)) and the negative control (-) contained no template 
DNA (A, (-)j' Clone number is indicated above each iane and position of molecular weight 
marker is indicated (bp).
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DNA was isolateci from colonies 23, 24 and 28 and was sent for sequencing (L G C  
Genomics, Germany) to confirm the orientation of the insert from each clone and to check  
that no mutations occurred within the insert. Clone 24 was found to contain the dBP4 in the 
correct orientation and was used to inoculate 250 ml LB  broth. Clone 23 and 28 did not 
contain the full-length dBP4 insert. pLV X Tight Puro dBP4 plasmid was purified from clone 
24 grown in LBAm p 100 broth using the Qiagen Endofree Maxi Prep system for transduction 
of PC-3M -luc2 cells. Endotoxin free plasmid was fractionated on 1 %  (w/v) agarose gel to 
ensure plasmid integrity (Figure 5.4).
5.2.2 Transduction of PC-3M-luc2 and HEK 293 cells with pTet-On Advanced vector
H E K  293 and PC-3M -luc2 cells were transduced with pTet-On Advanced vector, which 
produces rtTA that binds to the tetracycline response element (T R E  mod) switching on 
dBP4, by use of the CM V promoter in the presence of doxycycline in thè pLV X Tight Puro 
vector. The efficacy of the transduction was assessed  by transfection of pTet-On H E K  293 
cells with a reporter plasmid pLV X Tight Puro-luc that expressed luciferase in response to 
doxycycline or p16-luc, which expressed luciferase constitutively. The PC-3M -luc2 cells 
could not be tested in this way as they already express luciferase. A G F P  plasmid was used 
as control for the transfection in H E K  293 cells. pTet-On H EK  293 cells were treated for 72 h 
with (+) or without (.-) doxycycline (0.1 pM). Following addition of d-luciferin, cells were 
imaged using the IVIS imaging system, which detects bioluminescence (Figure 5.5). In 
Figure 5.5, wells 1 and 4 show pTet-On H E K  293 cells transfected with the inducible pLV X  
Tight Puro-luc plasmid. No bioluminescence was seen in the absence of doxycycline 
treatment (well 1), but with doxycycline, bioluminescence was observed (well 4). 
Bioluminescence in pTet-On H E K  293 cells transfected with a vector constitutively 
expressing luciferase (p16-luc, well 2 and 5) and treated with (well 5) or without (well 2) 
doxycycline was similar. In pTet-On H EK293 cells transfected with G F P -F 8 , no 
bioluminescence was detected with (well 6 ) or without doxycycline (well 3). This confirmed 
that pTet-On H E K  293 cells were transduced with pTet-On Advanced plasmid and from this 
we assumed that PC-3M -luc2 cells were also transduced.
5.2.3 Expression of rtTA and dBP4 in doxycycline induced expression system
Expression of rtTA by PC-3M -luc2 cells was demonstrated by Western blot. Whole cell 
lysate from pTet-On PC-3M -luc2 cells and PC-3M -luc2 (negative control) were fractionated 
by 4 - 20 %  (w/v) S D S -P A G E , transferred to nitrocellulose membrane and probed with anti- 
rtTA and anti-p-actin antibodies. The predicted molecular weight of rtTA is 30 kDa. Figure
5.6 A shows that rtTA is expressed by PC-3M -luc2 cells transduced with pTet-On Advanced
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Figure 5.4: Purified pLVX Tight Puro dBP4 plasmid. Plasmid DNA was purified from 
clone 24 using Qiagen endotoxin free maxi prep and fractionated on a 1 %  (w/v) agarose  
gel. Lane 1 shows 10 kB DNA ladder and lane 2  shows endotoxin free maxi prep pLV X  
Tight Puro dBP4 plasmid (1 |jg). Position of molecular weight marker is indicated (bp).
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Figure 5.5: Doxycycline induced luciferase activity in pTet-On Advanced HEK 293 
cells. H E K  293 cells transduced with the pTet-On vector were transfected with either pLVX  
Tight Puro-luc (wells 1 and 4, doxycycline inducible luciferase), p16-luc (wells 2  and 5, 
constitutively expressed luciferase) or G F P -F 8  (wells 3 and 6 , negative control) and 
incubated with (+) or without (-) doxycycline (0.1 pM) for 72 h then imaged using the I V IS  
Spectrum.
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vector (lane 1) and not expressed in untransduced PC-3M-luc2 cells (lane 2) were negative 
for rtTA. Following selection of stable pTet-On PC-3M-luc2 cells in G418 (400 Mg/ml) for 4 
weeks, cells were transduced with pLVX Tight Puro dBP4, then selected in puromycin (2 
pg/ml) for 10 days, placed in serum free medium with or without doxycycline (0.1 pM) for 72
h. Whole cell lysate and conditioned medium were fractionated by 4 - 20 % (w/v) SDS- 
PAGE, transferred to nitrocellulose and dBP4 expression was assessed using anti-His-tag 
antibody (Figure 5.6 B). The His-tag differentiates between exogenous dBP4 and 
endogenous wildtype IGFBP 4. Figure 5.6 B shows that His-tagged dBP4 was only 
expressed in the cell lysate (lane 2) and conditioned medium of PC-3M-luc2 dBP4 cells 
treated with doxycycline (lane 4). dBP4 was at a lower molecular weight in conditioned 
medium compared with cell lysate due to cleavage of the signal sequence on secretion of 
dBP4. dBP4 was not detected in cell lysate (lane 3) or conditioned medium (lane 5) from 
untreated PC-3M-luc2 dBP4 cells. Thus, the doxycycline inducible system is under tight 
control and does not ‘leak’ in the absence of doxycycline.
5.3 Effect of inducible vector expressed dBP4 on prostate tumour growth in vivo
5.3.1 Expression dBP4 in a subcutaneous prostate cancer model
A pilot study was carried out to demonstrate doxycycline inducible dBP4 expression in vivo. 
PC-3M-luc2 cells transduced with pTet-On and pLVX Tight Puro dBP4 were implanted 
subcutaneously into the right flank of NSG mice (n=15). When tumours reached a mean 
tumour diameter (MTD) of 7 - 8 mm mice were randomised into 3 groups. dBP4 expression 
was induced by feeding chow containing doxycycline (200 mg/kg) (n=5). Controls were 
given normal chow (n=5). The IGF IR TKI, NVP-AEW541 (50 mg/kg) was administered daily 
by oral gavage (n=5). After 3 days or 7 days treatment, 2 mice from each group were 
sacrificed and IGF I levels were measured by ELISA on both serum and tumour tissue. 
Tumour IGF I was expressed as ng/mg of total tumour protein. As there was only n = 2 
statistics could not be carried out (Figure 5.7 A & B). There was no difference in serum IGF I 
levels between the treatment groups at day 3 or day 7 (Figure 5.7 A). From day 3 - day 7 
tumour IGF I levels increased in controls, but not in dBP4-expressing or NVP-AEW541- 
treated tumours. Tumour IGF I levels were higher in NVP-AEW541-treated tumours relative 
to controls or dBP4-expressing tumours. The effect of dBP4 or NVP-AEW541 on tumour 
growth was not monitored as the study was only carried out for 7 days. dBP4 expression in 
the tumours was assessed by Western blotting using anti-His-tag antibody. Tumour lysates 
(50 pg) were fractionated by 4 - 20 % (w/v) SDS-PAGE, transferred to nitrocellulose and 
dBP4 expression was assessed by anti-His-tag antibody (Figure 5.8). The anti HiS-tag 
antibody allows for identification of vector-expressed dBP4 vs. wildtype IGFBP 4.
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Figure 5.6 A & B: rtTA and dBP4 are expressed by PC-3M-luc2 cells. PC-3M-luc2 cells 
were transduced with pTet-On plasmid which produces the regulatory protein, reverse 
tetracycline-controlled transactivator (rtTA). Cell lysates from PC-3M-luc2 cells transduced 
with pTet-On vector (A, lane 1) and untransduced cells (A, lane 2) were fractionated on 4 - 
20 % (w/v) SDS-PAGE, transferred to nitrocellulose and probed with an antibody to the Tet 
induced rtTA. p-actin was used as a loading control. Following selection of transduced cells 
in G418, the pTet-On PC-3M-luc2 cells were transduced with the response plasmid (pLVX 
Tight Puro dBP4) containing dBP4. Western blot carried out on the PC-3M-luc2 dBP4 cells 
treated with or without doxycycline (0.1 pM doxycycline, B) for 72 h. Cell lysate and 
conditioned medium were fractionated on 4 - 20 % (w/v) SDS-PAGE, transferred to 
nitrocellulose and probed with anti His-tag antibody (B). Lane 1 shows positive control 
(his-tagged protein ladder), lane 2 shows cell lysate from doxycycline treated PC-3M-luc2 
dBP4 cells, lane 3 shows cell lysate from untreated PC-3M-luc2 dBP4 cells, lane 4 shows 
conditioned medium from doxycycline treated PC-3M-luc2 dBP4 cells and lane 5 shows 
conditioned medium from untreated PC-3M-luc2 dBP4 cells. Position of molecular weight 
marker is indicated (kDa).
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Following addition of doxycycline chow to dBP4 mice, dBP4 expression was induced at day
3 (lanes 3 & 9) and remained expressed at day 7 (lanes 4 & 10). Controls or NVP-AEW541 
treated tumours showed low levels of dBP4 expression (lanes 8, 11 and 12 respectively).
5.3.2 Long-term effect of inducible vector expressed dBP4 in a subcutaneous model
of prostate cancer
Following a pilot study showing that doxycycline-induced dBP4 expression in the 
subcutaneously implanted PC-3M-luc2 dBP4 tumours in vivo, PC-3M-luc2 dBP4 cells (5 x 
106 cells/100 fjl) were implanted subcutaneously in male NSG mice (n=24). Tumour growth 
was monitored by caliper measurement every 3 -4  days. When tumours reached a MTD of 
7 - 8 mm mice were randomised into 3 groups. dBP4 expression was induced by feeding 
chow containing doxycycline (200 mg/kg) (n=8). Controls were given normal chow (n=8). 
The IGF IR TKI, NVP-AEW541 (50 mg/kg) was administered daily by oral gavage (n=8). 
Along with caliper measurement, tumour growth was monitored by bioluminescent imaging 
as the PC-3M-luc2 cells express luciferase, upon injection of luciferin light is emitted from 
the PC-3M-luc2 cells, which is then detected by the IVIS imaging system. Mice received an
i.p. injection of luciferin (75 mg/kg) and were imaged 5 min later while kept under 2% (v/v) 
isoflurane. Imaging was carried out every 3 -4  days up to day 20 of treatment (Figure 5.9). 
Following day 20 tumours began to become visibly necrotic therefore BLI was not used 
thereafter as luciferase is only expressed in viable cells and BLI would therefore under 
estimate tumour burden. In addition, BLI was not used in large subcutaneous tumours 
because the superficial location results in saturation of signal and non-linear correlation with 
tumour size.
Figure 5.9 shows IVIS images from controls, dBP4-expressing or NVP-AEW541- 
treated PC-3M-luc2 dBP4 subcutaneous tumour bearing mice. Controls showed an increase 
in tumour growth and BLI by treatment day 20. dBP4-expressing tumours also showed an 
increase in tumour growth and BLI. NVP-AEW541-treated tumours showed a rapid increase 
in tumour growth and BLI. Using Living Image 3.2 software, bioluminescence (ph/s/cm2/sr) 
was calculated for each tumour within all treatment groups. Photons are a measurement of 
radiance on the surface of the mouse. This measurement automatically takes into account 
the camera settings. Images of subjects acquired in the same session have the same signal 
amplitude as the radiance of the animal surface does not change. Therefore, this allows 
direct comparison of mice imaged throughout the study. No significant difference in 
bioluminescence was seen between each treatment group (Figure 5.10 A). However, from 
treatment day 14 - day 20 dBP4-expressing tumours were significantly smaller in MTD 
relative to controls (10.1 + 0.27 mm vs. 11 + 0.28 mm, p<0.05 (day 14),
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Figure 5.7 A & B: Serum and tumour IGF I levels in mice with subcutaneously 
implanted PC-3NMuc2 dBP4 cells. Serum and tumours were collected from NSG mice 
implanted with PC-3M-luc2 dBP4 subcutaneous tumours following treatment with normal 
chow (controls, 3 days (n=2/group) or 7 days (n=2/group)), doxycycline chow (200 mg/kg, 3 
days (n=2/group) or 7 days (n=2/group)) or NVP-AEW541 (50 mg/kg, 3 days (n=2/group) or 
7 days (n=2/group)). IGF I levels were measured in duplicate by ELISA ¡n serum (A) and 
tumour lysates (B). Total tumour protein was assessed by Bio-Rad DC protein assay. 
Tumour IGF I was expressed as ng IGF l/mg total protein Data (n=2 mice/group) are 
expressed as mean.
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Figure 5.8: dBP4 is expressed in subcutaneously implanted PC-3M-luc2 dBP4 cells 
following doxycycline treatment. 5 x 106 PC-3M-luc2 dBP4 cells were implanted 
subcutaneously into the right flank of NSG mice (n=15). Following treatment of NSG mice 
with normal chow (controls), doxycycline chow (200 mg/kg) or NVP-AEW541 (50 mg/kg 
daily by oral gavage), two mice from each group were sacrificed after day 3 and day 7 to 
test for dBP4 expression. Tumour lysates (50 pg) were fractionated by 4 - 20 % SDS- 
PAGE, transferred to nitrocellulose and probed with anti-His-tag antibody. Lanes 1 and 2 
show tumour lysates from control mice at day 3 and day 7, respectively. Lanes 3 and 4 
show tumour lysates from doxycycline treated mice at day 3 and day 7, respectively. Lanes 
5 and 6 show tumour lysates from NVP-AEW541 treated mice at day 3 and day 7, 
respectively. Lanes 7 and 8 show tumour lysates from control mice at day 3 and day 7, 
respectively. Lane 9 and 10 show tumour lysates from doxycycline treated mice at day 3 
and day 7, respectively. Lanes 11 and 12 show tumour lysates from NVP-AEW541 treated 
mice at day 3 and day 7, respectively. Position of molecular weight marker is indicated 
(kDa).
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Figure 5.9: Bioluminescent imaging of PC-3M-luc2 dBP4 implanted subcutaneous 
tumours expressing dBP4 or treated with NVP-AEW541. PC-3M-luc2 dBP4 cells (5 x 
106 cells) were implanted subcutaneously into the right flank of NSG mice (n=24). When 
tumours reached 7 - 8  mm MTD mice were randomised into groups. Controls received 
normal chow, dBP4 mice received doxycycline chow (200 mg/kg) or NVP-AEW541 (50 
mg/kg, daily by oral gavage) (n=8 mice/group). Tumour growth was monitored every 3 -4  
days by I VIS imaging and caliper measurements. Day 0 represents 16 days post 
implantation of PC-3M-luc2 dBP4 cells before treatment and treatment was started on day 1 
(23 days post PC-3M-luc2 dBP4 cell implantation). Mice received an i.p. injection of luciferin 
(75 mg/kg) and were imaged 5 min later under 2% (v/v) isoflurane. Mice were imaged for 1 
s at f stop 1 from day 0 - day 20 of treatment.
Day 20
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11 + 0.41 mm vs. 12.22 + 0.38 mm, p<0.041 (day 18) and 11.8 + 0.41 mm vs. 13.1 + 0.49 
mm, p<0.05 (day 20)) or NVP-AEW541-treated tumours (10.1 + 0.27 mm vs. 11.5 + 0.41 
mm, p<0.008 (day 14), .11 + 0.41 mm vs. 13.3 + 0.39 mm, p<0.0001 (day 18) and 11.8 + 
0.41 mm vs. 14.2 + 0.96 mm, p<0.001 (day 20)) (Figure 5.10 B). NVP-AEW541 did hot 
inhibit tumour growth in this experiment. The MTD further supports the IVIS images where 
dBP4-expressing tumours were smaller than controls or NVP-AEW541-treated tumours, but 
the average bioluminescence for each group did not reflect that of the MTD, which may 
have been attributed to necrotic regions in larger tumours. Percent survival as length of time 
to sacrifice was calculated for all groups. In this experiment, mice were sacrificed when 
tumours reached a MTD of 20 mm or when mice began to show signs of discomfort. 
Assessing the mice for illness was carried out blind in order to alleviate bias based on 
treatment groups. The majority of mice did not reach 20 mm MTD due to discomfort or leg 
paralysis. The Kaplan-Meier curve shows mice bearing dBP4-expressing tumours survived 
longer than controls (37 + 2.4 days vs. 27.8 + 2.4 days, p<0.04) or NVP-AEW541-treated 
mice (37 + 2.4 days vs. 27.3 + 2.1 days, p<0.04) (Figure 5.11).
The main side effect reported with other strategies or inhibitors of the IGF pathway is 
hyperglycaemia (Crouthamel et a/., 2009). For this reason, blood glucose was measured 
from non-fasting, mice before treatment initiation (pre-treatment) and upon sacrifice of mice 
(post-treatment). Mice were not fasted as hyperglycaemia should be apparent as a glucose 
reading >200 mg/dL or 11 mmol/L (Kobayashi et a/., 2003) and IGF I levels decrease upon 
fasting, which could interfere with the study (Frystyk et a/., 1999). Blood glucose was 
measured using AlphaTRAK glucose meter. A paired t-test was carried out to compare pre­
treatment glucose levels to post-treatment levels in all 3 groups. Post-treatment glucose 
levels were significantly higher than pre-treatment glucose levels in mice bearing 
subcutaneous dBP4-expressing tumours, (8.08 + 0.43 mmol/L vs. 9.95 + 0.9 mmol/L, 
p<0.019). Controls (7.7 + 0.3 mmol/L vs. 9.55 + 0.8 mmol/L) or NVP-AEW541-treated mice 
(7.67 + 0.4 mmol/L vs. 9.71 + 0.7 mmol/L) showed no significant change in glucose levels 
post-treatment (Figure 5.12). As NVP-AEW541 treatment showed no effect on tumour 
growth, a change in glucose was not expected. As IGFBP 4 inhibits IGF I, IGF I levels were 
measured in duplicate by ELISA in serum and subcutaneous tumours. The majority of IGF I 
within the body is bound to IGFBPs (Poffenbarger et a/., 1968), therefore IGF I bound to 
IGFBPs and unbound IGF I (total IGF I) was measured. Tumour IGF I was measured as 
ng/mg total tumour protein. Serum IGF I was increased in mice with subcutaneous dBP4- 
expressing tumours relative to controls (808.4 + 23 ng/ml vs. 647.8 + 53.8 ng/ml, p<0.033) 
or NVP-AEW541 -treated mice (808.4 + 23 ng/ml vs. 635.4 + 65.5 ng/ml, p<0.018) (Figure 
5.13 A).
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Figure 5.10 A & B: Inducible vector expressed dBP4 reduces growth of 
subcutaneously implanted PC-3M-luc2 cells. PC-3M-luc2 dBP4 (5 x  106 cells) cells were 
implanted subcutaneously into the right flank of NSG mice (n=24). Mice were randomised 
into groups when tumours reached a MTD of 7 - 8 mm. Controls received normal chow, 
dBP4 mice received doxycycline chow (200 mg/kg) or NVP-AEW541 (50 mg/kg, daily by 
oral gavage) (n=8 mice/group). Tumour growth was monitored every 3 - 4  days by I VIS 
imaging (A) and caliper measurements (B). Luciferin was delivered i.p. at 75 mg/kg and 
mice were imaged 5 min later while kept under 2% (v/v) isoflurane. Living Image 3.2 
software was used to calculate the bioluminescence of each individual subcutaneous 
tumour. Data (n=8 mice/group) is expressed as mean + SEM. Data was analysed by One 
way ANOVA followed by LSD post hoc correction test. *p<0.05 vs. Control, $$p<0.01 vs. 
dBP4, $$$p<0.001 vs. dBP4.
149
100*
-  50-
c
8 k.
<D 
CL
dBP4
Control
NVP-AEW541
% i L
"T"
10
- I —
20
—r-
40
~i
500   30
Days o f Treatm ent
Figure 5.11: Inducible vector expressed dBP4 increases survival o f mice with PC-3M- 
Iuc2 dBP4 implanted subcutaneous tumours. Kaplan-Meier plot showing increased time 
to sacrifice in NSG mice bearing PC-3M-luc2 dBP4 implanted subcutaneous tumours 
expressing dBP4 (doxycycline chow, n=8) relative to controls fed normal chow (n=8) and 
NVP-AEW541 treated mice (50 mg/kg, daily by oral gavage, n=8) (x2 = 6.17, p<0.05). Time 
to sacrifice was based on tumours reaching a MTD of 20 mm or signs of impaired mobility 
(leg paralysis) and discomfort.
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Figure 5.12: Non-fasting blood glucose levels increased post-treatment in mice 
bearing dBP4-expressing subcutaneous tumours. Blood glucose was measured in 
controls fed normal chow (n=8), dBP4-expressing mice fed doxycycline chow (200 mg/kg) 
n=8) or NVP-AEW541-treated (50 mg/kg, daily by oral gavage, n=8) mice using AlphaTRAK 
glucose meter. Pre-treatment and post-treatment blood glucose was measured from the 
lateral tail vein and upon sacrifice of mice by cardiac" puncture, respectively. Data (n=8 
mice/group) are expressed as mean + SEM. A paired t-test was carried out to test for 
differences between pre-treatment glucose and post-treatment glucose for each group 
(*p<0.05).
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However, tumour IGF I was decreased in dBP4-expressing tumours relative to controls (0.6 
+ 0.05 ng/mg vs. 0.79 + .07 ng/mg,• p<0.024) or NVP-AEW541-treated tumours (0.6 + 0.05 
ng/mg vs. 0.93 + 0.03 ng/mg, p<0.012) (Figure 5.13 B). This suggests that dBP4 is having 
an effect locally. Subcutaneous tumours were lysed and 4 tumours each from controls, 
dBP4-expressing tumours or NVP-AEW541-treated tumours were assessed for expression 
of dBP4 and components of the IGF I signalling pathway including IGF IRp, pIGF IR, Akt, 
pAkt, ERK and pERK. 50 jjg of protein was fractionated by 4 - 20 % SDS-PAGE, transferred 
to nitrocellulose and probed for the aforementioned proteins. dBP4 was not expressed in 
control tumour lysates (lanes 1 - 4). In lanes 5 - 8 dBP4 remained expressed in 3 out of 4 
doxycycline treated tumours up to time of sacrifice (32 - 34 days). NVP-AEW541 -treated 
tumours showed no dBP4 expression (lanes 9-12)  (Figure 5.14 A). As IGF I activates the 
PI3K and MAPK pathways (Valentinis et al., 1999), activation of both of these pathways was 
assessed in tumour tissue following dBP4 induction and treatment with NVP-AEW541. In 3 
out of 4 dBP4-expressing tumours (lanes 5 - 7) a decrease in IGF IR activation (pIGFR) was 
seen relative to controls (lanes 1 - 4) (Figure 5.14 B). The tumour shown in lane 8 did not 
express dBP4 despite doxycycline treatment and pIGFR was not reduced. However, no 
change in pIGFR was seen in NVP-AEW541 -treated tumours (lanes 9 - 1 2 )  relative to 
controls indicating that NVP-AEW541 (50 mg/kg) was inactive or ineffective at the dose 
used, a-tubulin was lower in lanes 3-4,  however a decrease in phospho Akt (Ser 473) was 
seen between controls (lanes 1 and 2) and dBP4-expressing tumours (lanes 5 - 7). Phospho 
Akt (Ser 473) was higher in 3 out of the 4 NVP-AEW541-treated tumours (lanes 9-11)  
relative to controls or dBP4-expressing subcutaneous tumours. The loading control a-tubulin 
shows unequal loading. However, densitometry was carried in order to normalise protein 
bands to a-tubulin (data not shown). Total Akt levels did not change in all treatment groups. 
No change in phospho ERK (Thr 202/Tyr204) was reported in dBP4-expressing tumours 
(lanes 5-8) relative to controls (lanes 1 - 4). However, phospho ERK (Thr 202/Tyr204) was 
decreased in NVP-AEW541 treated tumours (lanes 9-12) relative to controls (lanes 1 - 4) 
or dBP4-expressing tumours (lanes 5 - 8) although NVP-AEW541 had no effect on growth 
or survival or IGF IR activation (Figure 5.10 and Figure 5.11, respectively). Total ERK did 
not change in all 3 groups (Figure 5.14 B).
The effect of dBP4 on the angiogenic factor, VEGF was assessed by Western blot. 
The antibody detects the VEGF isoforms, VEGF12i (15-18 kDa), VEGF165 (24 kDa) and 
VEGF189 (28 - 30 kDa). However, VEGF may also be produced from host cells (mouse). 
Therefore, VEGF isoforms, VEGF120(14 kDa), VEGF164 (23 kDa) and VEGF188(27 kDa) may 
also be present VEGF164/165 was expressed in 3 of 4 control tumours (lanes 1 - 4), but was 
not expressed in the dBP4-expressing tumours (lanes 5 - 8) or NVP-AEW541-treated 
tumours (lanes 9-12).
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Figure 5.13 A & B: Serum IGF I increased in NSG mice bearing dBP4-expressing 
subcutaneous tumours whereas IGF I was decreased in dBP4-expressing 
subcutaneous tumours. Serum and tumours were collected from NSG mice with PC-3M- 
Iuc2 dBP4 implanted subcutaneous tumours treated with doxycycline chow (200 mg/kg, 
n=8), controls fed normal chow (n=8) or NVP-AEW541-treated (50 mg/kg daily by oral 
gavage, n=8). IGF I levels were measured in duplicate by ELISA in serum (A) and tumour 
lysates (B). Total tumour protein was assessed by Bio-Rad DC protein assay. Tumour IGF I 
was expressed as ng IGF l/mg total protein. Data (n=8 mice/group) are expressed as mean 
+ SEM. Data was analysed by one-way ANOVA followed by LSD post hoc correction 
(*p<0.05 dBP4 vs. Control).
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Two of 4 NVP-AEW541 -treated tumours expressed VEGF188/189 (lanes 9 - 12) whereas 
neither controls (lanes 1 - 4) nor dBP4-expressing tumours (lanes 5 - 8) expressed this 
isoform. VEGF12o/i2i was not expressed by any of the treatment groups (Figure 5.14 C).
5.3.3 Effect of inducible vector expressed dBP4 in an orthotopic model of prostate 
cancer
Tumour microenvironment is important in tumour growth and development. To represent 
human prostate cancer PC-3M-luc2 dBP4 (1 x 105 cells / 50 pi) cells were implanted into the 
prostate of NSG mice (n=20). This study was run in parallel to the subcutaneous prostate 
cancer model. Tumour growth was monitored by I VIS imaging every 3 - 4 days. Mice 
received an i.p. injection of luciferin (75 mg/kg) and were imaged 5 min later while kept 
under 2% (v/v) isoflurane. Once tumours were established mice were randomised into 3 
groups. dBP4 expression was induced by feeding chow containing doxycycline (200 mg/kg) 
(n=7). Controls were given normal chow (n=7). The IGF IR TKI, NVP-AEW541 (50 mg/kg) 
was administered daily by oral gavage (n=6). IVIS images of prostate tumours up to 
treatment day 19 are shown (Figure 5.15). Control prostate tumours show an increase in 
tumour size and BLI. dBP4-expressing prostate tumours did not increase significantly in size 
over the 19 days and BLI is lower compared with controls. Two control mice and dBP4- 
expressing mice were sacrificed before day 19. NVP-AEW541-treated tumours grew rapidly 
from day 4 - day 19, one mouse treated with NVP-AEW541 was sacrificed before day 14 
and 2 mice were sacrificed before day 19. Bioluminescence was measured for each 
prostate tumour within each group by Living Image 3.2. software. Readings were measured 
as photons/sec. At day 19 of treatment dBP4-expressing prostate tumours showed a 
significant decrease in bioluminescence relative to controls (2.74 x 109 + 6.9 1 08 p/s/cm2/sr 
vs. 48 x 109 + 1.2 x 109 p/s/cm2/sr, p<0.0097) (Figure 5.16). Only 2 mice were left in the 
NVP-AEW541 group at day 19, therefore they were not included in the statistical analysis. 
BLI was not used after day 19 as mice were too sick to anaesthetise and were euthanised. 
Percent survival as length of time to sacrifice was calculated for all groups. In this 
experiment mice were sacrificed when a sign of illness including depressed activity, unkept 
haircoat, hunched posture or decreased food/water intake was noted. Figure 5.17 shows 
the Kaplan Meier plot, neither dBP4 expression nor NVP-AEW541 treatment did not 
significantly increase survival in prostate tumour bearing mice relative to controls (22.3 + 3.4 
days vs. 18.8 + 1.9 days, 18.5 + 3.7 days vs. 18.8 +1.9 days, respectively). This conflicts 
with the BLI data where dBP4-expressing tumours showed decreased bioluminescence, an 
increase in survival may not have been seen due to the location of the tumours as the 
prostate tumours may have impinged on other organs.
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Figure 5.14 A, B & C: dBP4 is expressed in PC-3M-luc2 dBP4 implanted subcutaneous 
tumours and inhibits IGF IR activation. Subcutaneous tumours were collected from control 
(normal chow, n=8), dBP4-expressing (doxycycline chow, n=8) or NVP-AEW541-treated (50 
mg/kg, daily by oral gavage, n=8) mice (32 - 34 days post treatment) and snap frozen. Tumour 
lysates were made from 4 tumours from each group. 50 pg protein was fractionated by 4 - 20 
% SDS-PAGE, transferred to nitrocellulose and probed with the above antibodies. In A, B & C, 
lanes 1 - 4 show tumour lysates from control mice, lanes 5 - 8 show tumour lysates from 
dBP4-expressing mice and lanes 9 - 1 2  show tumour lysates from NVP-AEW541-treated 
mice. VEGF expression may have originated from either PC-3M-luc2 cells (human) or host 
cells (mouse). Human and mouse VEGF isoforms differ in size. The human isoforms are 
VEGF12i (15- 18 kDa), VEGF165 (24 kDa), VEGF189 (28 kDa). The mouse isoforms are 
VEGF12o (14 kDa), VEGF164 (23 kDa) and VEGF188 (27 kDa). Blots were probed with anti-a 
tubulin as a loading control. Position of molecular weight marker is indicated (kDa).
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Figure 5.15: Bioluminescent imaging of PC-3M-luc2 dBP4 prostate tumours 
expressing dBP4 or treated with NVP-AEW541. PC-3M-luc2 dBP4 (1 x 105 cells) cells 
were implanted into the prostate of NSG mice (n =20). Mice were randomised into groups. 
Controls received normal chow (n=7), dBP4 mice received doxycycline chow (200 mg/kg) 
(n=7) or NVP-AEW541 (50 mg/kg), given daily by oral gavage (n=6). Tumour growth was 
monitored every 3 - 4 days by IVIS imaging. Day 0 represents 16 days post implantation of 
PC-3M-luc2 dBP4 cells before treatment and treatment was initiated on day 1 (22 days post 
implantation of PC-3M-luc2 dBP4 cells). Mice received an i.p. injection of luciferin (75 
mg/kg) and were imaged 5 min later while kept under 2% (v/v) isoflurane. Mice were 
imaged for 1 s at f-stop 1 from day 0 - day 19.
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Figure 5.16: dBP4-expressing prostate tumours show a decrease in BLI compared to 
controls and NVP-AEW541 treated tumours. PC-3M-luc2 dBP4 (1 x 105 cells) cells were 
implanted into the prostate of NSG mice (n =20). Mice were randomised into groups; 
controls received normal chow (n=7), dBP4 mice received doxycycline chow (200 mg/kg, 
n=7)) and IGF IR TKI, NVP-AEW541 (50 mg/kg, n=6), was given daily by oral gavage. 
Prostate tumour growth was monitored every 3 - 4  days by IVIS imaging. Luciferin was 
delivered i.p. at 75 mg/kg and mice were imaged 5 min later while kept under 2% (v/v) 
isoflurane. Living Image 3.2 software was used to calculate the bioluminescence of each 
individual prostate tumour. Data (n=6/7 mice/group) are expressed as mean + SEM. Data 
was analysed by student t-test to compare dBP4 to controls at day 19 (**p<0.01). dBP4 vs. 
Control.
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Figure 5.17: Inducible vector expressed dBP4 or an IGF IR TKI, NVP-AEW541 had no 
effect on survival in mice bearing PC-3M-luc2 dBP4 prostate tumours. Kaplan-Meier 
plot showing percent survival (time to sacrifice) in mice with PC-3M-luc2 dBP4 prostate 
tumours. Controls fed normal chow (n=7), dBP4-expressing mice fed doxycycline chow 
(n=7), or NVP-AEW541 treated (50 mg/kg given daily by oral gavage, n=6) mice. Time to 
sacrifice was based on signs of illness including depressed activity, unkept haircoat, 
hunched posture or decreased food/water intake (p = ns).
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Non-fasting blood glucose levels were measured using the AlphaTRAK glucose meter 
before treatment initiation (pre-treatment) and before mice were sacrificed (post-treatment).
A paired t-test was carried out to compare pre-treatment glucose to post-treatment glucose 
levels in all groups. Control mice showed a significant decrease in post-treatment glucose 
compared to pre-treatment glucose levels (7.28 + 0.3 mmol/L vs. 4.86 + 0.29 mmol/L, 
p<0.003). Decrease in blood glucose may have been due to hypoglycaemic effect seen in 
tumour bearing mice (Takeda et al., 1984) as controls were below 5 mmol/L (4.86 nimol/L). 
Glucose levels were unchanged post-treatment in the dBR4-expressing mice (8.25 + 0.6 
mmol/L vs. 7.11 +1 mmol/L) or NVP-AEW541-treated mice (7.98 + 0.4 mmol/L vs. 7.6 + 0.7 
mmol/L) (Figure 5.18). IGF I levels were measured in serum and prostate tumours in 
duplicate by ELISA. Tumour IGF I was measured as ng/mg of total tumour protein, There 
was no significant difference in serum IGF I levels in mice bearing dBP4-expressing tumours 
relative to controls (670.4 + 104.4 ng/ml vs. 614.2 + 70.8 ng/ml) or NVP-AEW541-treated 
mice (670.4 + 104.4 ng/ml vs. 658.2 + 64.1 ng/ml) (Figure 5.19 A). However, a significant 
decrease in IGF I was seen in dBP4-expressing prostate tumours relative to controls (0.52 + 
0.07 ng/mg vs. 0.83 + 0.07 ng/mg, p<0.028). No significant difference in tumour IGF I was 
seen between NVP-AEW541 and controls (0.71 + 0.2 ng/mg vs. 0.83 + 0.07 ng/mg) or 
„ dBP4-expressing tumours (0.71 + 0.2 ng/mg vs. 0.52 + 0.07.-ng/mg) (Figure.5.19-B).
Prostate tumours were harvested from mice in each treatment group; controls, dBP4- 
expressing. tumours and NVP-AEW541 treated tumours. Prostate tumours were lysed, 3 
tumours each from controls, dBP4-expressing mice or NVP-AEW541 treated mice were 
assessed for expression of dBP4 and components of the IGF I signalling pathway including 
IGF IRp, pIGF IR, Akt, pAkt, ERK and pERK. 50 pg of protein was fractionated by 4 - 20 % 
SDS-PAGE, transferred to nitrocellulose and probed for the aforementioned proteins. dBP4 
was not expressed in tumours from controls (lanes 1 - 3) or NVP-AEW541 treated mice 
(lanes 7 - 9). dBP4 was expressed in all 3 tumours from mice fed doxycycline chow (lanes 4
- 6) up to the time of sacrifice (~ 20 days of treatment) (Figure 5.20 A). Activation of the Akt 
and MAPK pathways were assessed in prostate tumour tissue following treatment with 
dBP4 or NVP-AEW541 (Figure 5.20 B). Two of the 3 dBP4-expressing tumours (lanes 5-6) 
showed a decrease in IGF IR activation (pIGFR) relative to controls (lanes 1 - 3). NVP- 
AEW541-treated tumours showed a decrease in pIGFR (lanes 7-9)  relative to controls or 
dBP4-expressing tumours. Phospho Akt (Ser 473, pAkt) was higher in dBP4-expressing 
tumours (lanes 4 - 6 )  relative to controls (lanes 1 - 3) or NVP-AEW541-treated tumours 
(lanes 7 - 9). The loading control a-tubulin was higher in dBP4-expressing tumours. 
However, densitometry was carried in order to normalise protein bands to a-tubulin (data not 
shown). One of the 3 NVP-AEW541-treated tumours showed a decrease in phospho Akt
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Figure 5.18: Non-fasting blood levels decreased in orthotopic prostate cancer 
controls. Blood glucose levels were measured in controls fed normal chow (n=7), dBP4- 
expressing mice fed doxycycline chow (200 mg/kg, n=7) or NVP-AEW541-treated (50 
mg/kg, daily by oral gavage, n=6) mice using AlphaTRAK glucose meter. Pre-treatment and 
post-treatment blood glucose was measured from the lateral tail vein and upon sacrifice of 
mice by cardiac puncture, respectively. Data (n=6/7 mice/group) are expressed as mean + 
SEM. A paired t-test was carried out to test for differences between pre-treatment glucose 
and post-treatment glucose levels for each group (**p<0.01).
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Figure 5.19 A & B: IGF I levels decreased in dBP4-expressing prostate tumours.
Serum and tumours were collected from NSG mice (n=20) with PC-3M-luc2 dBP4 
prostate tumours treated with doxycycline chow (200 mg/kg, n=7), controls fed normal 
chow (n=7) or NVP-AEW541 -treated (50 mg/kg given daily by oral gavage, n=6). IGF I 
levels were measured in duplicate by ELISA in serum (A) and tumour lysates (B). Total 
tumour protein was assessed by Bio-Rad DC protein assay. Tumour IGF I was 
expressed as ng IGF l/mg total protein. Data (n=6/7 mice/group) are expressed as mean 
+ SEM. Data was analysed by one-way ANOVA followed by LSD post hoc correction 
(*p<0.05) dBP4 vs. Control.
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(pAkt, lane 8). Total Akt levels did not change in all groups. No difference in phospho ERK 
(Thr 202/Tyr204) was seen between all groups. In all groups no change in total ERK was 
seen (Figure 5.20 B). NVP-AEW541 had no effect on tumour growth or IGF signalling 
suggesting that it did not work in this study.
5.3.4 Effect of inducible vector expressed dBP4 in models of experimental metastasis
Bone is the most common site of metastases in prostate cancer patients (Bubendorf et a/., 
2000). In order to test the effect of dBP4 on metastasis formation two models were utilised. 
The intracardiac model involved injection of tumour cells into the left ventricle which gives 
rise to bone metastases and IV injection of tumour cells which leads to bone, lung and liver 
metastases. However, with the PC-3M-luc2 dBP4 cells few mice developed bone 
metastases in either model with the majority of metastases formed in the liver. The PC-3M 
cells are derived from a liver metastasis of parental PC-3 cells (Kozlowski et a/., 1984).
5.3.4.1 Effect of inducible vector expressed dBP4 following intracardiac injection of 
PC-3M-luc2 dBP4 cells
PC-3M-luc2 dBP4 (5 x 105 cells/100 pi) cells were injected into the left ventricle of NSG 
mice (n=12). Metastasis formation was monitored by IVIS imaging. Mice received an i.p. 
injection of luciferin (75 mg/kg) and were imaged 5 min later while kept under 2% (v/v) 
isoflurane. Once metastases were growing, mice with bioluminescent deposits (metastases) 
were randomised into 2 treatment groups. Six out of 12 mice developed metastases after 35 
days. dBP4 expression was induced by feeding chow containing doxycycline (200 mg/kg) 
(n=3). Controls were given normal chow (n=3). Metastasis growth was monitored every 3 - 4 
days. Mice were sacrificed once any sign of illness was seen. Figure 5.21, shows BLI 
images for controls and mice bearing dBP4-expressing liver metastases. Mice were 
monitored for 8 days by BLI as after day 8 bioluminescence decreased in both controls and 
dBP4-expressing mice suggesting that the metastases were becoming necrotic in both 
groups. Two of the control mice showed an increase in tumour burden by treatment day 8, 
with the majority of the liver containing tumour cells. One of the control mice showed a small 
deposit of tumour cells, which were not present by day 8. However, when mice were 
sacrificed all mice bore tumours. This suggests that the metastases in the control mouse 
may have become necrotic thus not detectable by BLI. dBP4-expressing liver metastases 
remained localised within the liver and did not diffuse throughout the liver relative to 
controls. However, dBP4-expressing mice showed a larger tumour burden on day 0 relative 
to controls. Percent survival as length of time to sacrifice was calculated for both groups. In 
this experiment mice were sacrificed when a sign of illness including depressed activity, 
unkept haircoat, hunched posture or decreased food/water intake was noted.
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Figure 5.20 A & B: dBP4 is expressed in PC-3M-luc2 dBP4 prostate tumours and 
inhibits IGF IR activation. Prostate tumours were collected from controls fed normal chow 
(n=7), dBP4-expressing mice fed doxycycline chow (200 mg/kg, n=7) or NVP-AEW541- 
treated (50 mg/kg daily by oral gavage, n=6) mice (20 days post treatment) and snap 
frozen. Tumour lysates were made from 3 tumours from each group. 50 pg protein was 
fractionated by 4 - 20 % SDS-PAGE, transferred to nitrocellulose and probed with the above 
antibodies. In A & B, lanes 1 -3  show tumour lysates from control mice, lanes 4 -6  show 
tumour lysates from dBP4-expressing mice and lanes 7 - 9 show tumour lysates from NVP- 
AEW541 treated mice. Blots were probed with anti-a tubulin antibody as a loading control. 
Position of molecular weight marker is indicated (kDa).
166
Day 0
Controls
;°‘ n=3
Figure 5.21: Bioluminescent imaging of PC-3M-luc2 dBP4 cells following intracardiac 
injection and induction of dBP4. PC-3M-luc2 cells (5 x 104 cells) were injected via 
intracardiac injection in NSG mice (n=12). Mice were randomised into groups. Controls 
received normal chow and dBP4-expressing mice received doxycycline chow (200 mg/kg) 
(n=3 mice/group). Metastasis formation was monitored every 3 - 4 days by IVIS spectrum. 
Day 0 represents 35 days post injection of PC-3M-luc2 dBP4 cells before treatment and 
treatment was initiated on day 1 (42 days post injection of PC-3M-luc2 dBP4 cells). Mice 
received an i.p. injection of luciferin (75 mg/kg) and were imaged 5 min later while kept 
under 2% (v/v) isoflurane. Mice were imaged for 1 s at f stop 1 from day 0 - day 8.
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Figure 5.22 shows the Kaplan Meier plot, no significant difference in survival was seen 
between controls and mice bearing dBP4-expressing liver metastases (19.7 + 6.1 days vs. 
12.5 + 1.5 days) even though mice bearing dBP4-expressing liver metastases died sooner, 
the n numbers may have been too small to see a significant difference. The dBP4 
expressing mice may have died sooner due to greater tumour burden at the beginning of the 
study.
Non-fasting glucose levels were measured using AlphaTRAK glucose meter before 
treatment initiation (pre-treatment) and before mice were sacrificed (post-treatment). A 
paired t-test was carried out to compare pre-treatment blood glucose to post-treatment 
levels in controls and mice bearing dBP4-expressing liver metastases (Figure 5.23). No 
significant change in glucose levels was seen upon sacrifice in controls (7.8 + 0.05 mmol/L 
vs. 5.5 + 0.6 mmol/L) or mice bearing dBP4-expressing liver metastases (7 + 0.9 mmol/L vs. 
6.6 + 0.2 mmol/L). Serum IGF I levels were measured in duplicate by ELISA. There was no 
significant difference in serum IGF I levels between controls or mice bearing dBP4- 
expressing liver metastases (1092.7 + 9.2 ng/ml vs. 941.3 + 169 ng/ml) (Figure 5.24).
5.3.4.2 Effect of inducible vector expressed dBP4 on metastases following IV injection
of PQ-3M-luc2 cells . ; .
The second method for development of metastases is IV injection. PC-3M-luc2 dBP4 (2 x 
106 cells/250 pl) cells were injected into the lateral tail vein of NSG mice (n=20). Metastasis 
formation was monitored by IVIS imaging. Once it was established that metastases were 
growing, mice with bioluminescent deposits (metastases) were randomised into 2 treatment 
groups. After 43 days, 10 out of 20 mice developed metastases. dBP4 expression was 
induced by feeding chow containing doxycycline (200 mg/kg) (n=5). Controls were given 
normal chow (n=5). Mice were sacrificed once any sign of illness was seen. Figure 5.25, 
shows BLI images for controls and mice bearing dBP4 expressing liver metastases. Mice 
were monitored for 14 days by BLI as mice were not metabolising the luciferin after day 14 
leading to abnormal bioluminescent readings, this may have been due to illness. One of the 
control mice showed a large increase in tumour burden by day 4, with the majority of the 
liver taken up with tumour cells at day 14 (Figure 5.25). Three of the 5 control mice and 2 of 
the 5 dBP4-expressing mice showed bone metastasis formation. However, BLI of the bone 
metastases fluctuated between each imaging session, therefore the effect of dBP4 on bone 
metastasis growth was not monitored. dBP4-expressing liver metastases remained localised 
within the liver (Figure 5.25). Bioluminescence was not seen in some of the mice on certain 
days of imaging, but upon sacrifice all mice showed tumours within the liver.
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Figure 5.22: dBP4 had no effect on survival in liver metastasis bearing mice following 
intracardiac injection of PC-3M-luc2 dBP4 cells. Kaplan-Meier plot showing percent 
survival (time to sacrifice) in mice with liver métastasés following intracardiac injection of 
PC-3M-luc2 dBP4 cells. Controls fed normal chow (n=3) and dBP4-expressing mice fed 
doxycycline chow (200 mg/kg, n=3). Time to sacrifice was based on signs of illness 
including depressed activity, unkept haircoat, hunched posture or decreased food/water 
intake (p = ns).
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Figure 5.23: Non-fasting blood glucose levels are unaffected post-induction of dBP4.
Blood glucose levels were measured in controls (normal chow, n=3) and dBP4 mice 
(doxycycline chow (200 mg/kg), n=3) using AlphaTRAK glucose meter. Pre-treatment and 
post-treatment blood glucose was measured from the lateral tail vein and upon sacrifice of 
mice by cardiac puncture, respectively. Data (n=3 mice/group) are expressed as mean + 
SEM. A paired t-test was carried out to test for differences between pre-treatment glucose 
and post-treatment glucose levels for each group (p = ns).
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Figure 5.24: Serum IGF I levels were unaffected following dBP4 expression compared 
with controls in liver metastases following intracardiac injection of PC-3M-luc2 dBP4 
cells. Serum was collected from NSG mice with. PC-3M-luc2 dBP4 liver metastases 
(intracardiac injection) treated with doxycycline chow (200 mg/kg, n=3) or controls fed 
normal chow (n=3). Serum IGF I levels were measured in duplicate by ELISA. Data (n=3 
mice/group) is expressed as mean + SEM. Data was analysed by student t-test (p = ns).
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One control mouse was sacrificed before day 11 of treatment, another control mice and one 
mouse bearing dBP4-expressing liver metastases were sacrificed before day 14 of 
treatment. Percent survival as length of time to sacrifice was calculated for both groups. In 
this experiment mice were sacrificed when a sign of illness including depressed activity, 
unkept haircoat, hunched posture or decreased food/water intake was noted. Figure 5.26, 
the Kaplan Meier plot showed that no significant difference in survival was seen between 
controls and mice bearing dBP4-expressing liver metastases even though mice bearing 
dBP4-expressing liver metastases survived longer than controls (11.7 + 5 days vs. 19.8 + 5 
days). The n numbers may have been too small (n=5/group) to see a significant difference.
Non-fasting glucose levels were measured using AlphaTRAK glucose meter before 
treatment initiation (pre-treatment) and before mice were sacrificed (post-treatment). A 
paired t-test was carried out to compare pre-treatment glucose levels to post-treatment 
levels in controls and mice bearing dBP4-expressing liver metastases. No significant change 
in glucose levels was seen post-treatment in controls (6.86 + 0.7 mmol/L vs. 9.36 + 0.3 
mmol/L) or mice bearing dBP4-expressing liver metastases (7.41 + 0.9 mmol/L vs. 9.5 + 0.7 
mmol/L) (Figure 5.27). Serum IGF I levels were measured in duplicate by ELISA. No 
significant difference in serum IGF I was seen between controls or mice bearing dBP4- 
expressing liver metastases (812.9 + 52.2 ng/ml vs. 695.5 + 52.8 ng/ml) (Figure 5.28).
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Figure 5.25: Bioluminescent imaging of PC-3M-luc2 dBP4 cells following IV injection 
and induction of dBP4. PC-3M-luc2 cells (2 x 106 cells) were injected via IV injection 
(lateral tail vein) in NSG mice (n=20). Mice were randomised into treatment groups based on 
the presence of metastases. Controls received normal chow and dBP4-expressing mice 
received doxycycline chow (200 mg/kg) (n=5 mice/group). Day 0 represents 42 days post 
injection of PC-3M-luc2 dBP4 cells before treatment and treatment was initiated on day 1 (47 
days post injection of PC-3M-luc2 dBP4 cells). Metastasis formation was monitored every 
3 - 4 days by IVIS spectrum. Mice received an i.p. injection of luciferin (75 mg/kg) and were 
imaged 5 min later while kept under 2% (v/v) isoflurane. Mice were imaged for 1 s at f-stop 1 
from day 0 - day 14. 174
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Figure 5.26: dBP4 expression had no effect on survival in liver metastasis 
bearing mice following IV injection of PC-3NMuc2 dBP4 cells. Kaplan-Meier plot 
showing percent survival (time to sacrifice) in mice with liver métastasés following IV 
injection of PC-3M-luc2 dBP4 cells. Controls fed normal chow (n=5) or dBP4- 
expressing mice fed doxycycline chow (200 mg/kg, n=5). Time to sacrifice was based 
on signs of illness including depressed activity, unkept haircoat, hunched, posture or 
decreased food/water intake (p = ns).
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Figure 5.27: Non-fasting blood glucose levels were unchanged post-induction of 
dBP4. Blood glucose levels were measured in controls fed normal chow (n=5) or 
dBP4-expressing mice fed doxycycline chow (200 mg/kg, n=5) using AlphaTRAK 
glucose meter. Pre-treatment and post-treatment blood glucose was measured from 
the lateral tail vein and upon sacrifice of mice by cardiac puncture, respectivèly. Data 
(n=5 mice/group) are expressed as mean + 3EM. A paired t-test was carried out to test 
for differences between pre-treatment glucose and post-treatment glucose levels for 
each group (p = ns).
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Figure 5.28: Serum IGF I levels were unaffected following dBP4 expression 
compared with controls in liver metastases formed after IV injection of PC- 
3M-luc2 dBP4 cells. Serum was collected from NSG mice with PC-3M-luc2 dBP4 
liver metastases (IV injection) treated with doxycycline chow (200 mg/kg, n=5) or 
controls received normal chow (n=5). IGF I levels were measured in duplicate by 
ELISA in serum Data (n=3 mice/group) are expressed as mean + SEM. No 
significance difference in serum IGF I was seen between controls or dBP4- 
expressing mice Data was analysed by student t-test (p = ns).
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5.4 Discussion
dBP4 may prove to be superior to other existing strategies to block IGF signalling in cancer 
as current therapies (mAbs and TKIs) lead to undesirable side effects such as 
hyperinsulinaemia and hyperglycaemia due to effects on the IR (Mulvihill et a/., 2009). 
Blocking the IGF I ligand with dBP4 instead of targeting the IGF IR may avoid these side 
effects.
A Tet inducible system was used to introduce a doxycyciine-inducible dBP4 
construct into PC-3M-luc2 in order to assess dBP4 in vivo. HEK 293 and PC-3M-luc2 cells 
were transduced with the pTet-On Advanced plasmid which produces the rtTA protein that 
switches on dBP4 expression in the presence of doxycycline. pTet-On HEK 293 cells were 
transfected with a luciferase reporter gene (pLVX Tight Puro-luc) and bioluminescence was 
only seen in HEK 293 cells upon addition of d-luciferin and doxycycline demonstrating 
doxycycline inducible expression of luciferase. Western blot analysis showed that the rtTA 
protein was expressed by PC-3M-luc2 cells transduced with the pTet-On Advanced vector. 
Following selection of stable clones expressing rtTA, pTet-On PC-3M-luc2 cells were 
transduced with the pLVX Tight Puro dBP4 response plasmid creating PC-3M-luc2 dBP4 
cells. Conditioned medium and cell lysates from doxycycline treated PC-3M-luc2 dBP4 cells 
showed expression of dBP4 detected using anti-His-tag antibody which differentiates 
between dBP4 and endogenous IGFBP 4. In PC-3M-luc2 dBP4 conditioned medium, dBP4 
was at a lower molecular weight than the cell lysates and this was attributed to cleavage of 
the signal peptide upon secretion of dBP4. dBP4 was not present in PC-3M-luc2 dBP4 cells 
without doxycycline; therefore dBP4 was under tight regulation and was not ‘leaky’ in the 
absence of doxycycline in vitro.
Once PC-3M-luc2 dBP4 cells were shown to express dBP4 following doxycycline 
induction, in vivo models of prostate cancer were set up to test the effect of vector- 
expressed dBP4 on tumour growth and metastasis. A preliminary study was carried out to 
assess doxycycline-induced dBP4 expression in PC-3M-luc2 dBP4 tumours growing 
subcutaneously in the right flank of NSG mice. The effects of dBP4 on tumour growth were 
compared with that of a known IGF IR TKI, NVP-AEW541 for 7 days. Both the 
subcutaneous and orthotopic models were carried out simultaneously. NVP-AEW541 at the 
dose used (50 mg/kg) did not inhibit tumour growth in the subcutaneous tumour model or 
activation of the IGF IR thus suggesting NVP-AEW541 was inactive. In vitro, NVP-AEW541 
inhibited IGF-induced proliferation of PC-3M-luc2 cells (Figure 4.10). However, NVP- 
AEW541 inhibited IGF IR activation in the orthotopic model, but did not inhibit prostate 
tumour growth. NVP-AEW541 has not been previously tested in prostate cancer models. 
Therefore, the 50 mg/kg dose used in this study was based on previous published data 
using different model systems. Numerous studies have shown that NVP-AEW541 inhibits
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tumour growth in vivo. Neuroblastoma cell lines (HTLA-230 or S-KN-BE2c cells) were 
implanted subcutaneously in nude mice and treated with NVP-AEW541 (50 mg/kg). NVP- 
AEW541 inhibited tumour growth, decreased VEGF mRNA and decreased metastasis 
formation (Tanno et al., 2006). NVP-AEW541 was also assessed in vitro in Ewing's sarcoma 
(10 cell lines), rhabdomyosarcoma (5 cell lines) and osteosarcoma (8 cell lines). Ewing’s 
sarcoma cells were more sensitive to the effects of NVP-AEW541 compared with 
rhabdomyosarcoma and osteosarcoma, which is in agreement with the high dependency of 
Ewing’s sarcoma on IGF IR signalling (Scotlandi et a/., 2005). In an in vivo Ewing’s sarcoma 
model, NVP-AEW541 at a dose of 50 mg/kg was only effective in combination with 
vincristine and a higher dose (100 mg/kg) was required to see a significant reduction in 
tumour volume (Manara et ai., 2007). Therefore, a higher dose of NVP-AEW541 may have 
been required in this study. From this, a comparison between dBP4 and NVP-AEW541 
could not be made.
IGF I levels were assessed in the serum and tumours of control, dBP4 subcutaneous 
tumours to determine if dBP4 would cause a compensatory production of IGF I due to 
blockade of the IGF IR and IGF I by dBP4. Two mice from each group were sacrificed 
(controls or doxycycline treated) at day 3 and day 7. As only 2 mice from each group were 
. assessed no statistics were performed. Tumours from controls (nr?) or dBP4-expressing 
mice (n=2) were assessed by Western blotting with anti-His-tag antibody to confirm 
induction of dBP4 in doxycycline treated mice. dBP4 expression was seen after day 3 and 
remained expressed at day 7 in the doxycycline treated group. A low level of dBP4 was 
seen in controls. However, dBP4 was strongly expressed in the doxycycline treated 
tumours. Serum IGF I did not change in controls or dBP4-expressing mice from day 3 to day 
7. Tumour IGF I levels increased in the control tumours from day 3 to day 7. No change in 
tumour IGF I was reported in dBP4-expressing tumours.
To test the effect of dBP4 on prostate tumour growth and metastasis NSG mice were 
chosen for implantation of PC-3M-luc2 dBP4 cells. Nude mice have been used for many 
years for xenograft models, since they lack T lymphocytes, but growth of cancer cells in 
these mice can be slow (Pretlow et ai., 1991) and they have shown a 38 % rate of 
xenotransplantation of prostate cancer cells (Van Weerden et al.t 1996). Many different 
models have been developed from athymic mice. SCID mice are unable to mount an 
immune response due to a genetic defect in Chromosome 16 responsible for deficient 
activity of an enzyme involved in DNA repair, which inhibits B and T lymphocyte 
differentiation, leading to loss of these cell types (Bosma et ai., 1983). In order to increase 
the immunodeficient properties of the SCID model, SCID mice were crossed with NOD mice, 
which are deficient in natural killer cells, complement and functional antigen presenting cells 
(Greiner et al., 1995). The resulting NOD-SCID mice were more immunodeficient than SCID
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mice and accepted foreign tissue with a higher success rate. Following injection of human 
CEM T-lymphoblastoid cells, splenic eogr.aftment of these cells was fourfold greater in NOD- 
SCID mice than in SCID mice (Shultz et a/., 1995). Finally, NSG mice were developed by 
crossing NOD-SCID mice with IL-2R y null mice and are the most severely immunodeficient 
mouse available (Ito et a/., 2002). NSG mice have a higher engraftment rate than NOD- 
SCID mice (13/13 compared with 8/13, when human haematopoietic stem cells were 
injected) (Shultz et al., 2005). When E0006A cells (prostate cancer cells) were implanted 
subcutaneously in NSG or nude mice, tumours stopped growing in the nude mice after 6 - 
16 weeks, whereas tumours in the NSG mice continued to grow and did not regress 
(D’antonio et a/., 2010). The NOD background should not effect non-fasting blood glucose 
readings as diabetes formation in these mice is due to an autoimmune response resulting in 
leukocyte infiltration of pancreatic islets (Tang et a/., 2008). Crossing of the NOD mice with 
SCID mice leads to a severely immunodeficient strain, which do not develop diabetes due to 
lack of an immune system.
Using a larger cohort of NSG mice the long-term effect of dBP4-expression on 
subcutaneous PC-3M-luc2 dBP4 tumours was completed. Tumour growth was monitored by 
caliper measurements and BLI. Tumours were monitored for 20 days after initiation of 
t^reatment using BLI, but tumours became visibly necrotic after day 20 and as luciferase is 
only expressed in viable cells BLI would therefore under estimate tumour burden. In 
addition, BLI was not used in large subcutaneous tumours because the location results in 
saturation of signal and non-linear correlation with tumour size. However, inhibition  ^of 
angiogenesis can also cause necrosis. Transfection of rat C6 glioma cells with anti-sense 
VEGF cDNA implanted subcutaneously in nude mice led to a decreased number of blood 
vessels and increased degree of necrosis within tumours relative to control cells (Saleh et 
al., 1996). Therefore, following day 20 of treatment inhibition of VEGF by dBP4 may have 
led to necrosis in dBP4-expressing tumours. Caliper measurements were more reliable than 
BLI after this point. BLI images from each treatment group showed that dBP4-expressing 
subcutaneous tumours were smaller than controls. This was seen for all mice within the 
dBP4-expressing cohort. This was also reflected in caliper MTD measurements of dBP4- 
expressing subcutaneous tumours growing significantly slower than controls. However, 
when the average bioluminescence was calculated for each group no significant difference 
in bioluminescence was seen. Even though an increase in bioluminescence was seen in all 
groups, BLI may not have efficiently measured tumour size as large tumours saturate the 
signal leading to non-linear correlation with tumour size.
Mice bearing dBP4-expressing tumours survived (37 + 2.4 days) significantly longer 
than controls (27.8 + 2.4 days) with an increase of 33 %. Survival was based on time to 
reach 20 mm MTD or when signs of impaired mobility were reported. In a previous study
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using the 4T1.2 breast cancer model where 4T1.2 cells were transiently transfected with 
dBP4 and injected into the mammary fat pad, tumours expressing dBP4 grew significantly 
slower than controls or cells expressing wildtype IGFBP 4 (Ryan et a/., 2009). Damon et aI 
(1998) implanted androgen receptor negative M12 prostate cancer cells transfected with 
wildtype IGFBP 4 subcutaneously In nude mice. A delay in tumour onset was seen initially 
relative to controls. However, by week 7 one of the IGFBP 4 expressing clones did not show 
a significant difference in tumour formation relative to controls. This suggests that IGFBP 4 
may be cleaved by proteases such as PAPP-A which is highly expressed in the skin (Chen 
et a/., 2003). Therefore, a protease resistant IGFBP 4 may have been more useful. Also the 
wildtype IGFBP 4 was expressed in the M12 cells from the beginning which does not reflect 
the clinical situation as individuals are not given treatment before a tumour is established. 
Therefore, our study better reflects the clinical situation where tumours have become 
established and treatment is initiated accordingly. In the subcutaneous prostate cancer 
model, survival was based on time to sacrifice as few tumours were allowed to reach 20 mm 
diameter due to discomfort and leg paralysis. A difference in tumour growth was seen from 
treatment day 14 - day 20.
Hyperglycaemia leads to excessive glucose circulating in the blood and is most 
commonly associated with diabetes (Rossetti et a ii ?1993). Low insulin or insujin resistance 
results in an inability to regulate and maintain blood glucose levels within normal range. 
Certain drugs such as anti-psychotics induce hyperglycaemia (Goldstein et al., 1999), in 
particular a number of mAbs and TKIs to the IGF IR induce mild-moderate hyperglycaemia 
(Higano et al., 2007, Smith et a l 2008) due to cross-reactivity with the IR as it shares 60 % 
homology with the IGF IR (Ullrich et al., 1986). PC-3M-luc2 cells formed heterodimers with 
the IR and upon stimulation with IGF (E3R) an increase in phosphorylated IR was seen 
(Figure 3.10). However, hybrid receptors containing IGF IR and IR are thought to act as an 
IGF IR (Johansson and Arnqvist, 2006) and have a higher affinity for IGF I than insulin, 
hybrid receptors bind 20 times more IGF I than insulin (Soos etal., 1993). This suggests that 
blocking the IGF I ligand binding to these hybrid receptors should not effect metabolic 
functions. In this study, as hyperglycaemia is a common side effect of IGF IR blockade the 
effect of dBP4 on non-fasting blood glucose was measured in all mice before initiation of 
treatment and before sacrifice. Blood glucose was measured from non-fasting mice as blood 
glucose >200 mg/dL (11 mmol/L) is indicative of hyperglycaemia in non-fasting mice. 
Measurement of non-fasting glucose was used previously to genetically dissect diabetes- 
related traits, hyperglycaemia was seen as a non-fasting glucose reading of >200 mg/dL (11 
mmol/L) (Kobayashi et a/., 2003). Non-fasting glucose levels in NSG mice bearing dBP4- 
expressing subcutaneous tumours were significantly increased post-induction of dBP4 
relative to pre-treatment glucose levels. Blood glucose of dBP4-expressing mice did not
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exceed. 11 mmol/L suggesting that mice were not hyperglycaemic. When serum IGF I levels 
were measured in the same mice, a significant increase in serum IGF I was seen in NSG 
mice bearing dBP4-expressing tumours. Along with insulin, IGF I is known to regulate 
glucose levels within the body. IGF I increases insulin sensitivity thus decreasing glucose 
levels (Zenobi et al., 1992). From this it would suggest that increased IGF I levels should 
decrease glucose levels. As mentioned, serum IGF I levels were increased in mice bearing 
dBP4-expressing tumours relative to controls. Contrary to this, IGF I levels in dBP4- 
expressing tumours were significantly reduced relative to control tumours. Therefore, tumour 
IGF I levels did not differ over time within groups as shown in the preliminary study but 
differences were seen between groups. As tumour IGF I levels were significantly decreased, 
it suggests that dBP4 may affect IGF I levels within the tumours. Also, it may be possible 
that IGF I bound to dBP4 was not detected in the ELISA assay. dBP4 may decrease tumour 
IGF I due to an increased reservoir of local IGF I; therefore tumours may reduce expression 
of IGF I. A decrease in tumour IGF I may lead to a compensatory mechanism to overcome 
reduced local IGF I levels. This mechanism may involve an increase in GH secretion, which 
raises IGF l-hepatic production leading to elevated serum IGF I. High levels of GH can lead 
to insulin resistance resulting in hyperglycemia (Takala et al., 1999). This may explain why 
an increase in serum- IGF I and blood glucose was seen in mice bearing dBP4-expressing 
subcutaneous tumours.
At the molecular level, IGF I signals via the IGF IR activating Akt and ERK. In the 
subcutaneous tumour mouse model, dBP4-expressing tumours showed a decrease in 
activated IGF IR relative to controls. Phospho Akt was decreased in the dBP4-expressing 
tumours relative to controls. Phospho ERK was not inhibited by dBP4.
Angiogenesis is important in tumour growth as blood vessels supply the tumour with 
oxygen and nutrients (Folkman et at., 1971). VEGF-A is the main factor involved in 
angiogenesis. There are several isoforms expressed within the body, VEGF12i, VEGF145, 
VEGF165, VEGFis9, VEGF2o6 and a splice variant of VEGF165 called VEGF165b which has 
anti-angiogenic properties (Woolard et a/., 2004) compared with the other isoforms. VEGF12i 
is acidic and does not bind heparin making it a diffusible protein (Houck et al., 1992). 
VEGF165 is the most abundant VEGF isoform and is the most potent in stimulating 
angiogenesis. It is a secreted protein, but can also bind the cell surface and extracellular 
matrix (Park et al., 1993). VEGF189and VEGF^are basic and bind heparin which results in 
these proteins becoming sequestered in the extracellular matrix (Houck et al., 1992). IGF I 
stimulates production of VEGF (Poulaki et al., 2003, Slomiany and Rosenzweig, 2004). 
Therefore, inhibition of IGF I by dBP4 may inhibit VEGF production. In the subcutaneous 
tumours, VEGF165 and VEGF18g were the main isoforms reported as the antibody only 
detects VEGF121, VEGF165 and VEGF189. The control tumours only expressed VEGF165.
182
i-1«:A
whereas VEGFies expression was abolished in dBP4-expressing tumours suggesting that 
dBP4 inhibited IGF I Induced production of VEGF. The VEGF produced by the tumours may 
have been predominantly produced by the PC-3M-luc2 dBP4 cells, but the murine host cells 
may have also contrjbuted to the VEGF production. The murine isoforms consist of VEGF12o 
(14 kDa), VEGF164 (23 kDa) and VEGF188(27 kDa)(Ng et a/., 2001). The difference in length 
also leads to a difference in size. However, it is difficult to distinguish between the human 
and murine isoforms as the murine isoforms are only one amino acid shorter. Previously 
saw that dBP4 decreased angiogenesis in vitro (Chapter 4) and in vivo (Ryan et a/., 2009).
Subcutaneous tumours were tested for expression of dBP4 following doxycycline 
treatment so as to determine if tumours maintained dBP4 expression at the end of the study. 
Three out of the 4 tumours tested showed dBP4 expression. The lack of inhibition seen in 
pERK by dBP4 was not due to loss of dBP4 expression. As previously mentioned inhibition 
of the IGF IR may lead to cross talk from alternative pathways. As discussed in section 3.3, 
the IGF IR forms heterodimers with the IR and EGFR. Activation of Akt and ERK may be 
facilitated by other growth factor signalling via other receptors (Nahta et ai., 2005, 
Riedemann et ai, 2007).
The second model to test dBP4 in vivo was an orthotopic model, implantation of PC- 
3M-luc2 dBP4 cells into the prostate. This mode! reflects human prostate cancer and reflects 
the behaviour of human prostate cancer. Similar to the subcutaneous model, BLI images 
showed that dBP4-expressing prostate tumours grew significantly slower than controls by 
day 19 of treatment. This was seen as a decrease in BLI, which is also indicative of a 
decrease in cell viability as viable cells will only bioluminescence (Rehemtulla et ai., 2000). 
Prostate tumours were smaller than subcutaneous tumours so necrosis was probably not a 
factor in the decreased BLI and in this model BLI probably reflects tumour size. dBP4 
expression in prostate tumours did not increase survival of mice relative to controls. Survival 
was based on the point where mice showed signs of depressed activity, unkept haircoat, 
hunched posture or decreased food/water intake. No difference in survival was seen as 
prostate tumours impinge on other organs in the abdomen such as the bladder and 
intestine, therefore mice became sick sooner compared with those implanted with 
subcutaneous PC-3M-luc2 dBP4 cells.
Non-fasting glucose levels were measured in prostate tumour bearing mice pre and 
post-treatment induction. Control mice showed a significant decrease in non-fasting glucose 
upon sacrifice whereas no change in glucose levels were seen in dBP4-expressing mice 
post-treatment relative to pre-treatment glucose levels. A decrease in blood glucose in 
controls from the orthotopic model may be attributed to control mice not eating as a result of 
illness, but hypoglycaemia is also associated with cancer as tumours utilise the majority of 
available glucose putting a strain on the host’s ability to maintain normal glucose levels
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(Takeda et a/., 1984). Hypoglycaemia may indicate large tumour burden in the control mice 
compared with dBP4-expressing mice, which was seen in patients with advanced 
gastrointestinal stromal tumours (Pink et a/., 2005). This is supported by the BLI where 
controls showed a significant increase in bioluminescence relative to dBP4-expressing 
tumours. When assessing IGF I levels, in contrast to that seen in the subcutaneous model, 
serum IGF I levels did not change in dBP4-expressing mice relative to controls, but a 
significant decrease in tumour IGF I was observed in dBP4-expressing tumours relative to 
controls which correlates with that seen in the subcutaneous model. Similar to the 
subcutaneous model the decrease in tumour IGF I may have been attributed to the IGF I 
ELISA not detecting IGF I bound to dBP4.
To determine the effect of dBP4 at a cellular level, activated IGF IR, Akt and ERK 
was assessed in prostate tumours. Activated IGF IR was decreased in dBP4-expressing 
tumours and NVP-AEW541-treated tumours. However, no inhibition of phospho Akt (pAkt) 
and ERK (pERK) was seen in dBP4-expressing tumours. A higher level of pAkt was noted in 
dBP4-expressing tumours. However, unequal loading (a-tubulin) shows higher protein levels 
in dBP4-expressing prostate tumours. dBP4 remained expressed at the end of the study; 
therefore lack of pAkt and pERK inhibition was not due to loss of dBP4 expression within 
•tumours; . . . .
To further examine the effect of dBP4 in vivo two models of experimental metastasis 
were used which give rise to bone, lung and liver metastases. Bone metastasis is most 
commonly associated with prostate cancer (Dai et a/., 2008). Each model was used to give 
a greater chance of metastases formation in mice. Unfortunately, few mice developed bone 
metastases with the majority of metastases formed in the liver. PC-3M cells were derived 
from a mouse liver metastasis following injection of parental PC-3 cells into mouse spleen 
(Kozlowski et a/., 1984). Therefore, PC-3M may have had a higher propensity to form 
metastasis in the liver. However, PC-3M cells were injected into nude mice via intracardiac 
injection in order to monitor tumour relapse and metastasis, bone metastasis formation was 
seen in these mice (Jenkins et a/., 2003).
Following intracardiac injection of PC-3M-luc2 dBP4, only 6 developed metastases, 3 
controls and 3 dBP4-expressing. Mice were monitored closely using BLI, dBP4-expressing 
liver metastases was localised to one area within in the liver 8 days post dBP4 induction 
whereas one of controls showed the liver metastases spread throughout the liver by day 8. 
Survival was based on the point where mice showed signs of depressed activity, unkept 
haircoat, hunched posture or decreased food/water intake. Mice with dBP4-expressing liver 
metastases were sacrificed sooner than control mice, this may be due to dBP4-expressing 
mice having higher BLI at day 0, but no significant difference in the Kaplan Meier curve was 
seen. This may have been due to small n numbers. Non-fasting glucose levels did not
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change in controls or dBP4-expressing liver metastases mice post dBP4 induction relative to 
pre-treatment glucose levels. There was no difference in serum IGF I levels in mice bearing 
dBP4-expressing liver metastases relative to control mice. Therefore dBP4 was not affecting 
systemic IGF L
Following IV injection of PC-3M-luc2 dBP4, 10 mice developed liver metastases with 
bone metastases present in some of the mice. However, the BLI for the bone metastases 
appeared to fluctuate between imaging days due to the position of the mice within the 
chamber, therefore they were not included in the study. Metastases formation and growth 
post dBP4 induction was monitored by BLI up to day 14. dBP4-expressing liver metastases 
appeared localised to one area within the liver post dBP4 induction whereas the controls 
showed an increase in metastatic burden. Survival was based on the point where mice 
showed signs of depressed activity, unkept haircoat, hunched posture or decreased 
food/water intake. dBP4 did not have a significant effect on survival. However, n numbers 
may have been too small to see an effect. Non-fasting glucose levels did not change in 
controls or dBP4-expressing liver metastases mice post dBP4 induction relative to pre­
treatment glucose levels. There was no difference in serum IGF I levels in mice bearing 
dBP4-expressing liver metastases relative to control mice. Therefore, dBP4 was not 
affecting: systemic IGF I. Both the intracardiac and-IV.-experimental metastasis models 
showed similar patterns of tumour growth. However, the effect of dBP4 on metastasis 
growth could not be deduced from either of these models as tumour burden was large 
before induction of dBP4, therefore long-term effect of dBP4 could not be fully completed as 
mice were sacrificed early in the study. Also, the liver is the main source of IGF I within the 
body (Sjogren et al., 1999), therefore the PC-3M-luc2 dBP4 cells may not have produced 
enough dBP4 to block IGF I effects. As the PC-3M cells were originally derived from a liver 
metastasis (Kozlowski et a/., 1984) this may also explain the high level of liver metastasis 
seen in the intracardiac and IV experimental metastasis models.
The key findings from this chapter were that dBP4 slowed tumour growth in the 
subcutaneous and prostate tumour models. dBP4 increased survival in the subcutaneous 
model. IGF I levels were decreased in tumours from both the subcutaneous and prostate 
tumour models. At the cellular level, dBP4 decreased activation of plGFR and phospho Akt 
in the subcutaneous model. dBP4 inhibited VEGF production in subcutaneous tumours. 
However, dBP4 only decreased plGFR in the orthotopic model. NVP-AEW541 inhibited IGF 
IR activation, but had no effect on prostate tumour growth. As IGF I is involved in 
angiogenesis and in Chapter 4 dBP4 inhibited endothelial cell tubule formation, it would be 
of benefit to assess dBP4 effects on tumour angiogenesis. dBP4 was shown to inhibit 4T1.2 
breast cancer cell growth in vivo, overexpression of dBP4 in mice showed a reduction in 
tumour growth and increased survival relative to controls as well as anti-angiogenic effects
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(Ryan et a/., 2009). A comparison between dBP4 and NVP-AEW541 could not be made as 
NVP-AEW541 was either inactive in the subcutaneous model or a higher dose was required 
in order to see an inhibition in tumour growth in both the subcutaneous and orthotopic 
models. However, this may suggest that blocking IGF I ligand is more effective than 
inhibition of the tyrosine kinase domain in PC-3M-luc2 cells. Unfortunately, the experimental 
metastasis models did not give insight into the effects of dBP4 in metastasis. Therefore, this 
study would need to be repeated and dBP4 induction carried out sooner to determine dBP4 
effect on inhibiting metastasis formation. The data presented shows that dBP4 inhibits IGF I, 
thus inhibiting tumour growth suggesting that dBP4 may have a therapeutic value in prostate 
cancer.
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C h a p t e r  6
C o n c l u d i n g  D i s c u s s i o n
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One of the major clinical challenges in treating prostate cancer is the development of 
androgen independent disease and metastasis. Therapies used against the primary tumour 
are often less effective against Al disease and metastasis due to changes in gene 
expression as tumours progress to an androgen independent state (Best et al., 2005). Ten 
androgen independent tumours and 10 androgen dependent tumours were assessed for 
differences in gene expression. Two main genes were found to be different between 
androgen independent and androgen dependent tumours: macromolecule biosynthesis was 
down-regulated and cell adhesion was up-regulated in androgen independent tumours 
relative to androgen dependent tumours. Other differentially expressed genes linked to 
angiogenesis, cell adhesion, apoptosis, oxidative stress and hormone response were 
identified along with 9 regions of potential chromosomal deletion in androgen independent 
tumours (Best et al., 2005). Androgen independent prostate cancer typically develops 18 - 
24 months after hormone ablation therapy (Rau et al., 2005). Once testosterone production 
is blocked tumours adapt by numerous pathways to overcome the growth inhibition 
(Me Donnell et al., 1992, Miyamoto et a/., 1998, Yeh et al., 1999). This leads to a more 
aggressive and invasive phenotype, ultimately leading to bone metastasis (Gingrich et al.,
1997). Interactions between the tumour cells and the host microenvironment are crucial in 
the establishment of tumours and metastases (Fidler et *1 2007). Therefore, targeting 
factors involved in this interaction may be key in inhibiting tumour growth and metastasis 
(Allavena et al., 2005, Bauerle et al., 2008, Espinoza et al., 2011).
One potential therapeutic target is the IGF signalling pathway, which is involved in 
differentiation, transformation, proliferation and angiogenesis (Kaleko et al., 1990, Moser et 
al., 2008, Stewart et al., 1990, Valentinis et al., 1999). The IGF pathway has been implicated 
in tumour growth and metastasis (Parker et al., 2002, Tang et al., 2003). In this study, 
plasma IGF I levels were assessed in BPH, Gleason score 5 and Gleason score 7 prostate 
cancer patients. Although no significant difference in plasma IGF I was identified between 
BPH and prostate cancer patients this may be due to small patient numbers used compared 
with other studies of IGF I in prostate cancer as this study had a total of 33 patient samples 
compared with patient numbers of n=520, n=447, n= 210, respectively (Chan et al., 1998, 
Stattin et al., 2000, Wolk et al., 1998). Those studies have shown a positive association 
between elevated IGF I levels and prostate cancer risk (Chan et al., 1998, Stattin et al.% 
2000, Wolk et al., 1998). In those studies healthy individuals were used as controls whereas 
in this study BPH patients were used. However, it has been reported that there is no 
association between IGF I levels and BPH suggesting that IGF I does not play a role in the 
development of BPH (Mantzoros et ai, 1997). As PAPP-A cleaves IGFBP 4 releasing IGF I 
(Lawrence et al., 1999), plasma PAPP-A was also measured in the same patient samples 
(n=33). PAPP-A proteolytic activity in vitro accelerated anchorage independent growth and
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increased invasion through Matrigel of PAPP-A overexpressing SKOV3 (ovarian cancer) 
cells relative to SKOV3 cells expressing a mutant PAPP-A with no proteolytic activity (Boldt 
and Conover, 2011). This suggests that PAPP-A may be important in tumour growth and 
invasion as a consequence of proteolysis of IGFBP 4 leading to increased IGF I activity. In 
this study, PAPP-A was significantly higher in Gleason score 5 patients relative to BPH 
patients. PAPP-A levels have not been previously assessed in prostate cancer patients. 
However, no association between IGF I levels and PAPP-A levels was seen. PAPP-A 
indirectly reflects IGF I released from IGFBP 4 whereas the ELISA used in this study 
measured total IGF I and over 70 % of circulating IGF I is bound to IGFBP 3 in a complex 
with ALS (Baxter et a/., 1989). PAPP-A is associated with acute coronary syndromes and 
although elevated PAPP-A was reported in patients with unstable angina and acute 
mycocardial infarction, no association was seen between PAPP-A and total IGF I levels, 
whereas a weak positive association was seen between free IGF I and PAPP-A (Bayes- 
Genis et al., 2001). Therefore, measurement of free IGF I in prostate cancer patients may 
also identify an association between plasma PAPP-A and plasma IGF I levels. PAPP-A was 
elevated in the serum of lung cancer patients (75 men and 8 women) and a significant 
increase was seen relative to healthy controls (30 men and 3 women). In the same study a 
positive association was reported between PAPP-A levels and age (Bulut et al., 2009) 
whereas in this study a negative association was seen between PAPP-A and age. 
Therefore, PAPP-A measurement may be a useful prognostic marker for younger men with 
early stage prostate cancer. However, a study using healthy controls and a higher patient 
number will be necessary to validate that PAPP-A levels are elevated in prostate cancer 
patients.
The IGF IR has also been implicated in prostate cancer. Increased IGF IR 
expression has been shown in prostate cancer tissue relative to benign prostatic epithelium 
and remains expressed in metastatic disease (Hellawell et al., 2002). An association 
between IGF IR expression and Gleason grade was identified in this study by staining TMAs 
of prostate cancer tissue (45 tumours) with anti-IGF IR antibody. A significant increase in 
IGF IR staining was seen in prostate cancer tissue compared with BPH/normal tissue. IGF 
IR staining was highest in Gleason grade 3, but decreased in Gleason grade 5 as previously 
reported by Liao et al (2005) (56 tumours). This further supports the involvement of the IGF 
pathway in prostate cancer. A decrease in IGF IR expression has been demonstrated in 
aggressive tumours, which is associated with impaired AR activity (Schayek et al., 2010a). 
Enhanced AR binding to the IGF IR promoter was reported in wildtype AR-overexpressing 
M12 prostate cancer cells relative to mutant AR-expressing M12 prostate cancer cells. In a 
xenograft model, total and phosphorylated IGF IR levels progressively decreased as 
prostate cancer cells became more tumourigenic and metastatic (Schayek et a/., 2010b).
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Therefore, immunohistochemicai analysis of the IGF IR may be of value in pre-therapeutic 
assessment of prostate cancer aggressiveness and could contribute to an improved initial 
patient management.
Due to accumulating evidence supporting a role for the IGF pathway in cancer 
initiation and progression (De Graff et a/., 2009, Kaleko et a/., 1990, Kanety et a/., 1993, Kim 
et a/., 2007, Parker et al., 2002, Peiro et a/., 2011, Rochester et a/., 2004) attention has 
turned towards developing strategies to inhibit the IGF pathway. The 2 main strategies that 
are furthest along in clinical development are mAbs and TKIs targeting the IGF IR (Higano 
et a/., 2007, Lacy et al., 2008, Lindsay et al., 2009, Smith et al., 2008). In clinical trials they 
have proven to be well tolerated. IGF antagonists such as anti-IGF IR mAbs, which act by 
blocking IGF binding to the IGF IR may also alter insulin action at the IR leading to 
development of hyperglycaemia (Haluska et al., 2007). Targeting the IGF I ligand should 
avoid cross reactivity with the IR. The IGFBPs are specific for the IGFs and should not affect 
insulin signalling. As the IGFBPs bind IGFs with higher affinity (kd=10"10 -10'11 M) than IGF IR 
(kd=1O"0-1O'9 M) (Kiefer et al., 1992, Oh et al., 1993b), they should effectively compete with 
the receptor for IGF ligand binding.
The strategy used in this study involved the use of a protease resistant form of 
IGFBP 4 (dBP4) to inhibit IGF I effects. IGFBP 4 is solely inhibitory to IGFs unlike other 
IGFBPs, which have IGF dependent and independent effects that can either inhibit or 
enhance IGF I function depending on the context. IGFBP 3 induced apoptosis via a 
caspase-mediated pathway independent of IGF I in MCF-7 cells transfected with a mutant 
IGFBP 3 that could not bind IGF I (Kim et al., 2004). Human ectocervical cells, immortalised 
by retroviral transduction with the human papillomavirus type 16 E6/E7 oncogenes 
expressed higher levels of IGFBP 3 mRNA relative to parental cells. Late-passage, 
immortalized E6/E7-transduced cells secreted high levels of IGFBP 3 and exhibited an 
increased sensitivity to IGF I, including increased phosphorylation of the IGF IR, increased 
DNA synthesis and cell proliferation (Baege et al., 2004). The majority of circulating IGF I is 
bound to IGFBP 3 in a complex with ALS which cannot cross endothelial barriers thus 
impairing delivery of recombinant IGFBP 3 to tumours (Payet et al., 2004). There are a 
number of reasons why a protease resistant IGFBP 4 may be a superior way of blocking IGF 
signalling than other recombinant IGFBPs or mAbs directed against the IGF IR. Firstly, 
IGFBP 4 is small enough (28 - 34 kDa) to cross endothelial barriers (Boes et al., 1992) 
unlike IGFBP 3 which is bound as a large complex with an acid labile subunit (Payet et al., 
2004) and should therefore penetrate tumour tissue more effectively. Secondly, mAbs 
directed against the IGF IR can interfere with insulin signalling due to binding to 
heterödimers of IGF IR and IR (Pandini et al., 2007, Treadway et al., 1991). Thirdly, as 
dBP4 is resistant to PAPP-A it may have a relatively long half-life in vivo (Eldridge et al.,
t *1
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2009). One of the first uses of a protease resistant IGFBP 4 was in smooth muscle cells of 
transgenic mice. Expression of protease resistant IGFBP 4 transgene under the control of 
the smooth muscle actin promoter led to muscle hypotrophy and decreased aortic, bladder 
and stomach weight relative to mice expressing the wild type IGFBP 4 transgene (Zhang et 
a/., 2002a). A protease resistant rat IGFBP 4 was previously assessed by the Harmey group 
in the mouse 4T1.2 breast cancer model. Mammary tumours expressing rat dBP4 grew 
significantly slower than controls or tumours expressing wildtype rat IGFBP 4 along with 
increased survival. Inhibition of tumour growth was accompanied by increased endothelial 
cell apoptosis in dBP4-expressing tumours (Ryan et a/., 2009). As IGF I is implicated in 
prostate cancer growth and metastasis we evaluated the effects of dBP4 expression in 
prostate cancer models.
PC-3M-luc2 cells were chosen for in vitro and in vivo work. These cells are androgen 
independent (Tilley etai., 1990) which reflects advanced stage prostate cancer. The PC-3M- 
Iuc2 cells expressed the IGF IR and IGF (E3R) increased their proliferation. Inhibition of the 
IGF IR in vitro with TKIs AG1024 and NVP-AEW541 led to a significant decrease in baseline 
proliferation and IGF-induced proliferation, which suggested that inhibition of IGF signalling 
with dBP4 may be effective in PC-3M-luc2 tumour models in vivo. IGF I was shown to 
increase metabolic activity in the MTS assay whereas no effect was seen in the Brdy 
proliferation assay. This difference in effect may be due to a difference in seeding density. 
Furthermore, MTS assay measures metabolic activity assuming a direct correlation with cell 
number and IGF I may increase metabolic activity as well as DNA synthesis which is 
measured by the BrdU assay.
In the Ryan et ai (2009) study, rat dBP4 was expressed from a plasmid vector under 
control of a constitutive promoter. To better reflect the clinical situation where treatment can 
only be initiated after detection of a tumour, in this study dBP4 expression was induced once 
PC-3M-luc2 dBP4 tumours were established. Furthermore, in this study dBP4 was 
introduced using a lentiviral vector to integrate dBP4 into the genome for sustained IGFBP 4 
expression. An inducible Tet-On system was used in the PC-3M-luc2 cells where dBP4 
expression was induced by doxycycline. The effectiveness of dBP4 in inhibiting tumour 
growth was compared with a well established TKI, NVP-AEW541. Tanno et ai (2006) 
showed that NVP-AEW541 inhibited neuroblastoma cell growth in nude mice and decreased 
tumour microvascularisation relative to controls. Quantitative real-time PCR detected a 
significant down-regulation of VEGF mRNA in response to NVP-AEW541 relative to controls 
(Tanno et a/., 2006). The effect of dBP4 on tumour growth was monitored in all models by 
IVIS bioluminescence imaging as well as caliper measurements in the subcutaneous model. 
A number of studies have used the IVIS system to assess drug effects in vivo (Zeng et ai.,
2010) and to monitor tumour relapse following drug withdrawal (Jenkins et a/., 2003).
This system allowed individual mice to be monitored and compared throughout the study. 
NSG mice were chosen for the in vivo studies as they are more immunodeficient than nude, 
NOD and SCID mice (Ito et a/., 2002) and have a high engraftment rate compared with other 
xenograft models (Shultz et al., 2005). The MTD of PC-3M-luc2 dBP4-expressing 
subcutaneous tumours was significantly smaller than controls. Therefore, dBP4-expressing 
tumours grew significantly more slowly than controls. A similar effect was seen when PC- 
3M-luc2 dBP4 cells were implanted into the prostate. A significant decrease in 
bioluminescence was observed in dBP4-expressing tumours relative to controls. Both of 
these results are consistent with the mouse 4T1.2 breast cancer model, which showed 
dBP4-expressing tumours were significantly smaller than controls or wildtype IGFBP 4- 
expressing tumours (Ryan et al., 2009). Contrary to this, treatment of PC-3M-!uc2 cells in 
vitro with dBP4 did not inhibit proliferation as IGF I did not stimulate proliferation of PC-3M- 
Iuc2 cells in this experiment such that it was technically impossible to show the effect of 
dBP4 on IGF-induced proliferation in vitro. However, dBP4 inhibited endothelial cell 
proliferation (Ryan et al., 2009) and inhibited IGF-induced tubule formation. dBP4 did not 
increase survival in the prostate tumour bearing mice whereas dBP4 enhanced survival by 
33 % in subcutaneous tumour bearing mice relative to controls. This suggests that the 
anatomical site of the tumour may have been important in determining survival as prostate 
tumours impinge on other organs within the abdominal cavity whereas subcutaneous 
tumours are located externally on the flank and do not interfere with other organs. dBP4- 
expressing subcutaneous and prostate tumours expressed 0.6 ng/mg and 0.5 ng/rhg total 
IGF I, respectively. In addition, serum IGF I in dBP4-expressing prostate tumour bearing 
mice was lower than dBP4-expressing subcutaneous tumour bearing mice (690 ng/ml vs. 
808 ng/ml, respectively). Therefore, the failure of dBP4 to increase survival within the 
prostate tumour group is not related to IGF I levels.
NVP-AEW541 did not inhibit tumour growth in either of the prostate cancer models 
but it did inhibit activation of the IGF IR in the orthotopic model. In vitro, NVP-AEW541 
inhibited IGF-induced proliferation of PC-3M-luc2 cells. Other studies have used the same 
dose of NVP-AEW541 used in this study. Tanno et al (2006) used a dose of 50 mg/kg NVP- 
AEW541 in a subcutaneous model of neuroblastoma (HTLA-230 or S-KN-BE2c cells). NVP- 
AEW541 inhibited tumour growth, decreased VEGF mRNA and decreased metastasis 
formation. Similarly, Moser et al (2008) showed that NVP-AEW541 (50 mg/kg) inhibited 
growth of BxPC-3 pancreatic cancer cells in a subcutaneous and orthotopic model of 
pancreatic cancer. Conversely, in an in vivo Ewing’s sarcoma model, NVP-AEW541 at a 
dose of 50 mg/kg was ineffective and a higher dose (100 mg/kg) was required to see a 
significant reduction in tumour volume (Manara et al., 2007). Therefore, a higher dose of
192
NVP-AEW541 may have been required to inhibit tumour growth in both prostate cancer 
models. Therefore, no conclusions could be drawn from the NVP-AEW541 groups.
As hyperglycaemia is a common side effect associated with therapies blocking the 
IGF IR (Haluska et a/., 2007) non-fasting blood glucose levels were measured. Non-fasting 
glucose levels >200 mg/dL (11 mmol/L) are indicative of hyperglycaemia in non-fasting mice 
and fasting causes a decrease in IGF I levels (Lee et al, 2010), which could have interfered 
with the study. The IGF IR formed hybrid receptors with the IR in the PC-3M-luc2 cells in 
vitro. Following stimulation with IGF (E3R), an increase in phosphorylated IR was observed 
in PC-3M-luc2 cells. Due to this interaction, it was important to measure blood glucose 
levels following dBP4 Induction. Interestingly, blood glucose levels were elevated post­
induction of dBP4 in mice bearing subcutaneous tumours relative to pre dBP4 induction. 
However, the increased glucose levels did not reach hyperglycaemic levels (>11 mmol/L) 
(Kobayashi et al., 2003). The involvement of IGFBP 4 in glucose homeostasis has not been 
established. IGFBP 1 is the main binding protein involved in glucose homeostasis. Impaired 
glucose homeostasis was reported in transgenic mice that overexpressed IGFBP 1. 
Overexpression of IGFBP 1 led to hyperglycaemia, which was attributed to inhibition of IGF I 
(Rajkumar et al., 1996). However, no change in pre or post-treatment non-fasting glucose 
was seen in mice bearing dBP4-expressing prostate tumours or in the experimental 
metastasis models. Moreover, control mice bearing prostate tumours showed a significant 
decrease in blood glucose relative to pre-treatment levels. The absence of hypoglycaemia in 
the mice bearing dBP4-expressing prostate tumours might indicate less tumour burden than 
controls. However, as dBP4 was expressed locally within the tumours and metastases it 
may not have reached systemic circulation. Systemic administration of dBP4 should give 
more insight into whether dBP4 effects blood glucose as other therapies (mAbs and TKIs) 
where hyperglycaemia has been reported are given systemically (Haluska et a/., 2007, 
Lindsay et al., 2009). Future studies should include assessing IR activation in the tumours. 
From this data, the control prostate tumour bearing mice were suffering from hypoglycaemia 
(<5 mmol/L) due to an increased tumour burden (Pink et al., 2005). In 142 consecutive 
patients with hepatocellular carcinomas, 38 were found to have hypoglycaemia. . In 124 of 
the 142 patients, the tumour was rapidly growing and poorly differentiated and there was 
rapid wasting and profound muscle weakness. Hypoglycaemia developed in 17 % within two 
weeks of death and was associated with a slow decrease in blood glucose on fasting. 
Hypoglycaemia was a consequence of a progressive increase in demand for glucose by the 
tumour (Mcfadzean and Yeung, 1969). Hypoglycaemia induced by non-pancreatic tumours 
is termed non-islet cell tumour hypoglycaemia, which prostate tumours have been 
categorised as (Marks and Teale, 1998). Therefore, the subcutaneous tumours may not 
have resulted in hypoglycaemia as tumour burden increased due to site of implantation.
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Serum IGF I levels and tumour IGF I levels were assessed to determine if dBP4 
affected IGF I systemically and locally. Tumour IGF I levels were significantly decreased in 
dBP4-expressing subcutaneous and prostate tumours. Serum IGF I levels were elevated ¡n 
mice bearing subcutaneous dBP4-expressing tumours relative to controls, whereas mice 
bearing prostate dBP4-expressing tumours or liver metastases showed no change in serum 
IGF I levels relative to controls. These data suggest that dBP4 reduced local, but not 
systemic IGF I levels, thus inhibiting tumour growth, which was reflected in the 
subcutaneous MTD and prostate tumour BLI.
At a cellular level, dBP4 decreased activated IGF IR and decreased phospho Akt in 
the subcutaneous and only decreased pIGFR in the orthotopic PC-3M-luc2 dBP4 tumours. 
In vitro, PC-3M-luc2 cells treated with IGF I or IGF (E3R) showed an increase in phospho 
Akt which was inhibited by wortmannin. Therefore, blockade of IGF I by dBP4 would be 
expected to inhibit Akt activation in PC-3M-luc2 cells. PC-3M-luc2 cells are PTEN negative 
(Vliestra et ai, 1998) therefore the Akt pathway may be predominant over the MAPK 
pathway in these cells. This was reflected in vitro where IGF I or IGF (E3R) did not increase 
activation of ERK in PC-3M-luc2 cells. Therefore, blockade of IGF I by dBP4 was not 
expected to inhibit ERK activation.
VEGF is a potent factor involved in angiogenesis. VEGF expression is induced by 
hypoxia via activation of HIF 1a (Forsythe et ai., 1996) or by growth factors such as IGF I 
(Warren et a/., 1996, Poulaki et a/., 2003). Due to its involvement in tumour growth and 
metastasis, therapies against VEGF have been developed. In prostate cancer, VEGF 
expression has been positively associated with Gleason score (Mazzucchelli et a/., 2000). 
Overexpression of VEGF in androgen independent PC-3 cells under hypoxic conditions 
showed increased invasion through Matrigel in the presence of HUVECs relative to wildtype 
PC-3 cells (Ackerstaff et a/., 2004). VEGF has also been shown to promote osteoblast 
activity. C4-2B prostate cancer cells which expressed VEGF165 and VEGF189 were injected 
into the tibia of mice and after the tumours grew for 6 weeks, mice were administered the 
VEGFR inhibitor, PTK787. PTK787 decreased intratibial tumour burden and C4-2B-induced 
osteoblastic activity (Kitagawa et a/., 2005). The androgen independent prostate cancer cell 
line DU 145 was implanted subcutaneously in SCID mice and following treatment with a 
monoclonal antibody to VEGF a significant decrease in tumour growth and metastasis was 
seen relative to controls (Melnyk et a/., 1999). In this study, it was shown in vitro that IGF 
(E3R) increased VEGF165 production by PC-3M-luc2 cells relative to untreated controls. In 
human endothelial cells, dBP4 significantly decreased IGF-induced tubule formation 
(angiogenesis) relative to untreated controls, or IGF I treated endothelial cells. This supports 
a role for dBP4 in the inhibition of angiogenesis. In the dBP4-expressing subcutaneous 
tumours, expression of VEGF165 was abolished relative to controls.
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Systemic administration of wildtype IGFBP 4 in female mice increased bone 
formation parameters such as serum osteocalcin and alkaline phosphatase as well as 
serum IGF I. This was not seen in mice administered a protease resistant IGFBP 4. The 
increase in IGF I bioavailability in mice administered wildtype IGFBP 4 was due to an IGFBP 
4 protease-dependent pathway (Miyakoshi ef a/., 2001). That study did not elucidate the 
protease involved in the degradation of IGFBP 4. However, PAPP-A is the main protease 
involved in IGFBP 4 proteolysis and is expressed by osteoblasts (Lawrence et a/., 1999) 
which could explain the increase in bone formation parameters in wildtype IGFBP 4 treated 
mice. Therefore, dBP4 should not increase bone formation as seen with the wildtype IGFBP
4 used by Miyakoshi et al (2001).
Bone metastasis is a common cause of morbidity in prostate cancer patients 
(Bubendorf et al., 2000) with limited therapies available. IGF I regulates tumour cell invasion 
via matrix metalloproteinases (MMPs) and uPA (Dunn et ai, 2000). Up-regulation of the IGF 
IR increased MMP-2 expression, invasion and metastasis in H-59 cells, a subline of Lewis 
lung carcinoma cells relative to controls (Long et a/., 1998). Therefore, blockade of IGF I 
and/or the IGF IR could reduce metastasis formation. Two models of metastasis were used 
in this study to generate bone and liver metastases. Intracardiac and IV injection of PC-3M- 
Iuc2 dBP4 cells did not give rise to a large number of,mice with bone metastases. The liver 
was the main site of metastasis formation, probably because PC-3M cells are derived from a 
PC-3 liver metastasis (Kozlowski et al., 1984). dBP4-expressing liver metastases appeared 
to remain localised within the liver relative to controls where bioluminescence appeared 
diffuse throughout the liver when monitored using the IVIS imaging system. Due to time 
constraints, further analysis of the liver metastases were not carried out. No definitive 
conclusion could be drawn from the metastasis models possibly due to relatively small 
numbers in the intracardiac (n=3/group) and IV experimental metastasis groups (n=5/group). 
However, Jenkins et al., (2003) previously utilised PC-3M cells in an intracardiac model of 
bone metastasis with 5 mice per treatment group the same as the IV experimental 
metastasis model. In the intracardiac experimental metastasis model, after day 8 of dBP4 
induction the BLI decreased in both the controls and dBP4-expressing mice. This suggests 
that the liver metastases became necrotic. Since the liver is the main source of serum IGF I 
within the body (Sjogren et al., 1999), dBP4 levels may not have been sufficient to inhibit 
IGF I leading to continued growth of PC-3M-luc2 dBP4-expressing liver metastases and no 
growth difference relative to controls. Colon adenocarcinoma tissue fragments were 
orthotopically transplanted to the surface of the caecum in control and liver-specific deficient 
(LID) mice in which serum IGF I levels are 25% of that in control mice (Wu et al., 2002). 
Mice were divided randomly into two groups; one group received recombinant human IGF I 
and the other group received saline. In the saline group, the incidence of hepatic metastasis
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was significantly higher in control mice relative to LID mice. Control or LID mice treated with 
recombinant human IGF I had significantly increased rates of liver metastases compared 
with saline-injected mice. The number of metastatic nodules in the liver was significantly 
higher in control mice relative to LID mice (Wu et a/., 2002). This further supports the role of 
IGF I in the development of liver metastases.
Overall, dBP4 expression inhibited primary tumour growth in subcutaneous and 
orthotopic prostate cancer models. However, PC-3M-luc2 cells are PSA negative 
(Stephenson et al., 1992). PSA cleavage of dBP4 led to an increased number of fragments 
relative to cleavage of recombinant IGFBP 4. Therefore, mutation of the PAPP-A sequence 
may have introduced more cleavage sites for PSA due to either the change in amino acid 
sequence or a change in conformation. The PSA cleavage site for IGFBP 4 has not yet 
been established. However, the substrate specificity of PSA has been investigated, with 
tyrosine being the preferred site of hydrolysis. The consensus sequence SS(Y/F)Y|SG was 
determined as the sequence for most efficient peptide hydrolysis by PSA (Coombs et al.,
1998). Within IGFBP 4, there are 2 tyrosine residues, but the consensus sequence is not 
found in this protein (Appendix 13). Clinically, elevated PSA is indicative of prostate cancer 
(Fall et a/., 2007). PSA is secreted by the luminal cells of the epithelium within the prostate 
(Peehl, 2006). Therefore, dBP4 may not be useful in prostate cancer patients with elevated 
PSA. However, < *1 % of men present with PSAmegative prostate carcinoma, which is 
defined as PSA <10 ng/ml (Lee and Oesterling, 1997). Patients presenting with treatment- 
naive PSA-negative metastatic prostate cancer showed similar characteristics to that of 
patients with high serum PSA levels, but their median survival and response to hormone 
therapy was much shorter than prostate cancer patients with high PSA levels (Birtle et a/., 
2003). Overall survival is poorer in patients with PSA-negative metastatic prostate cancer 
relative to patients with PSA-positive metastatic prostate cancer (Yamamoto et al., 2001). 
Even though a small percentage of patients present with PSA-negative prostate cancer, 
treatment of the disease has proved to be difficult. dBP4 may be useful in such cases where 
abnormally low PSA levels are seen.
Future studies should assess apoptosis and angiogenesis (CD31+ staining) in the 
subcutaneous and prostate tumours, since dBP4 inhibited IGF-induced microvascular 
endothelial cell proliferation in vitro (Ryan et a l 2009J, dBP4 decreased IGF-induced tubule 
formation and dBP4 induced endothelial cell apoptosis in 4T1.2 breast cancer tumours 
suggesting an anti-angiogenic mechanism of action (Ryan et al., 2009). As this study 
suggested that locally expressed dBP4 either did not reach the systemic circulation or was 
not expressed at high enough levels to effect circulating IGF I, future studies with systemic 
administration of dBP4 should yield insight into the side effects of dBP4. In vitro, the PC-3M- 
Iuc2 cells expressed IGFBP 3, IGFBP 4 and produced low levels of IGF I. Therefore, dBP4
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was probably blocking tumour and locally produced IGF I, but not circulating IGF I, most of 
which is produced by the liver. Kinome profiling of subcutaneous and prostate tumours may 
also give insight into alternative pathways that are inhibited or enhanced following dBP4 
expression. To test the effect of dBP4 on bone metastasis intratibial injection of PC-3M-luc2 
cells or use of orthotopic model with a different cell line may be a superior bone metastasis 
model. Systemic administration of dBP4 would reflect the clinical situation and would allow 
determination of the effect of dBP4 on tumour growth and side effects (hyperglycaemia) that 
may be associated with systemic administration of dBP4. Other future work may involve 
determining the PSA cleavage site in dBP4, to generate a PSA and PAPP-A protease 
resistant IGFBP 4. The effect of this protein could then be assessed using a PSA positive 
cell line such as LNCaP cells, which would reflect the majority of human prostate cancers.
dBP4 may prove useful as a neoadjuvant or adjuvant therapy to slow the growth of 
tumours, particularly tumours that are IGF I driven as dBP4 blocked IGF IR activation in 
vivo. Inhibition of the IGF pathway using dBP4 proved effective in inhibiting tumour growth in 
vivo in this study. However, resistance pathways can occur following long-term treatment 
with most cancer treatments (Chen et a/., 2004, Desbois-Mouthon et a/., 2009, Garofalo et 
a/., 2011, Kute et ai., 2004). In PC-3M-luc2 cells, the IGF IR was shown to form 
heterodimers with the EGFR; therefore, future studies may include using dBP4 in 
combination with an EGFR inhibitor such as Lapatinib (Glaxo Smith Kline).
Frequent re-evaluation of response and changing treatment when necessary 
analogous to HIV treatments where therapy is changed when CD4+ count increases may be 
beneficial in cancer treatment regimes. Therefore, reliable serum biomarkers to indicate 
tumour re-growth or progression are needed. Moreover, molecular profiling of tumours now 
gives information on tumour status and predicts response to therapy, thus allowing each 
individual patient to receive a specific drug regime based on tumour type and expression of 
genes or proteins (Diamandis et a i, 2010, Garman et a i, 2007, Malinowsky et a i 2011). 
There is now a general acceptance that eradicating all cancer cells is probably impossible 
with any therapy and achieving disease stabilisation is a more realistic goal (Kelly, 2003). 
Preventing cancer progression would increase patient survival and make cancer a 
manageable disease rather than a curable one.
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Append ix 6: M aterials and buffers fo r  W estern blot, FPLC and DNA e lectrophoresis
6 x Laemmli Buffer Electrode buffer 500 ml
To prepare 10 ml: Trisma Base 6.06 g
Trisma Base 6.06 g HEPES 11.9g
SDS 1-3 g SDS 8.64 g
Glycerol 4.7 ml dH20 up to 500 ml
Bromophenol blue 0.6 g
DTT 0.93 g
dH20 2.1 ml
10 x Transfer Buffer Workinq Transfer Buffer
Trisma Base 21.7g 10 x Transfer buffer 100 ml
Glycine 112.6 g 100 % Methanol 200 ml
SDS 1g dH20 700 ml
dH20 up to 1 L 
10 x TBS Wash Buffer 1 * TBST
Trisma Base 30.27 g 10 x TBS 100 ml
NaCI 87.66 g Tween 1 ml
dH20 900 ml dH20 899 ml
Adjust to pH 7.6 with HCI 
Adjust to 1 L with dH20
Blockina Buffer RIPA Buffer (100 mh
1 x t b s t 50 ml Tris HCI 0.39 g
Marvel fat free milk 2.5 g NaCI 0.12 g
Or NP-40 1 ml
BSA 2.5 g Sodium deoxycholate 1 g
SDS 0.1 g
dH20 upto 100 ml
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FPLC Running Buffer 6 x DNA loading buffer (10 mh
HEPES 
NaCI 
CaCI2 
pH 7.5
dH20 make up to 1L
1 x TAE Buffer 
Tris
Acetic Acid 
EDTA
dH20 make up to 1 L
2.38 g Bromophenol blue 0.025 g
12.3 g Xylene cyanol FF 0.025 g
0.01 g Glycerol 3.3 ml
dH20 make up to 10 ml
4.84 g
1.2g 
0.29 g
248
Append ix 7: Representative prote in  assay standard curve
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A ppend ix 8: A ntibod ies used fo r IHC, IP and W estern b lo tting
ANTIGEN
APPLICATION
WB/IP/IHC
BLOCK PRIMARY
SOURCE,DILUTION, 
BUFFER
SECONDARY I 
SOURCE,DILUTION, 
BUFFER
IGFBP 4 WB 5% 
Marvel 
in TBST 
(0.1 % 
Tween)
Millipore (MA, USA) 
rabbit anti-human/mouse 
IGFBP4 1:4000 in 5 % 
marvel in TBST (0.1 %),
) incubate overnight @ 
4°C
DAKO (Glostrup, 
Denmark) HRP goat 
anti-rabbit 1:2000 in 5 
% marvel TBST (0.1 
%),
Incubate @ room temp 
for 1 hr
IGF1R p WB 5 % 
Marvel 
in TBST 
(0.1 % 
Tween)
Cell Signalling 
Technology (MA, USA) 
rabbit anti­
human/mouse, 1:1000 in 
5 % BSA TBST (0.1 % 
tw een)) incubate 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) HRP anti­
rabbit 1:2000 in 5 % 
marvel TBST (0.1 %), 
Incubate @ room temp 
for 1 hr
pIGFIR
(Tyr
1131)
WB 5%  
Marvel 
in TBST 
(0.1 % 
Tween)
Invitrogen, rabbit anti­
human, 1:2000 in 5 % 
marvel TBST (0.1 % 
tween)) incubate 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) HRP anti­
rabbit 1:2000 in 5 % 
marvel TBST (0.1 %), 
Incubate @ room temp 
for 1 Hr
Akt H WB 5%  
Marvel 
in TBST 
(0.1 % 
Tween)
Cell Signalling 
Technology (MA, USA) 
rabbit anti­
human/mouse, 1:2000 in 
5%  BSA TBST (0.1 % 
tween) incubate 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) HRP anti­
rabbit 1:2000 in 5 % 
marvel TBST (0.1 %), 
Incubate @ room temp 
for 1 hr
pAkt
(Ser 473)
WB 5%  
Marvel 
in TBST 
(0.1 % 
Tween)
Cell Signalling 
Technology (MA, USA) 
monoclonal mouse anti­
human/mouse, 1:2000 in 
5%  Milk TBST (0.1 % 
tween)) incubate 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) HRP anti­
mouse 1:5000 in 5 % 
marvel TBST (0.1 %), 
Incubate @ room temp 
for 1 hr
IGFBP 3 WB 3%
Marvel 
in PBST 
(0.05 % 
tween)
Millipore (MA, USA), 
rabbit anti human/mouse 
1:1000 in 3% marvel 
PBST (0.05 % tween)) 
incubate overnight @ 
4°C
DAKO (Glostrup, 
Denmark) HRP anti­
rabbit 1:2000 in 3% 
marvel PBST (0.05%) 
Incubate @ room temp 
for 1 hr
EGFR WB 5%  
Marvel 
in TBST 
(0.1 % 
Tween)
Cell signalling 
Technology (MA, USA), 
rabbit anti-human/mouse 
1:2000 in 5 % BSA 
TBST (0.01% tween)) 
incubate overnight @ 
4°C
DAKO (Glostrup, 
Denmark) HRP anti­
rabbit 1:2000 in 5 % 
marvel TBST (0.1 %), 
Jncubate @ room temp 
for 1 hr
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EGFR IP Cell signalling 
Technology (MA, USA), 
rabbit anti-human 1:100
pEGFR
(Tyr
1173)
IP Cell signalling 
Technology (MA, USA) 
rabbit monoclonal anti­
human 1:100
pEGFR
(Tyr
1173)
WB 5%  
Marvel 
in TBST 
(0.1 % 
Tween)
Cell signalling 
Technology (MA, USA) 
rabbit monoclonal anti­
human/mouse, 1:2000 in 
5 % BSA in TBST (0.1 % 
tween)) incubate 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) HRP anti­
rabbit 1:2000 in 5 % 
marvel TBST (0.1 %, 
Incubate @ room temp 
for 1 hr)
Insulin R WB 5%  
Marvel 
in TBST 
(0.1 % 
Tween)
Cell Signalling 
technology (MA, USA) 
mouse monoclonal anti­
human/mouse, 1:1000 
in 5 % marvel in TBST 
(0.1 % tween)) incubate 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) HRP anti­
mouse 1:2000 in 5 % 
marvel TBST (0.1 %), 
Incubate @ room temp 
for 1 hr
plnsulin R 
(Tyr 1185)
WB 5%  
Marvel 
in TBST 
(0.1 % 
Tween)
Cell Signalling 
technology (MA, USA) 
mouse monoclonal anti­
human/mouse, 1:1000 
in 5 % marvel in TBST 
(0.1 % tween)) 
incubated overnight at 
4°C
DAKO (Glostrup, 
Denmark) HRP anti­
mouse 1:2000 in 5 % 
marvel TBST (0.1 %), 
Incubate @ room temp 
for 1 hr
Insulin R IP Cell Signalling 
technology (MA, USA) 
mouse monoclonal anti­
human, 1:50
plnsulin R 
(Tyr 1185)
IP Cell Signalling 
technology (MA, USA) 
mouse anti-human, 1:50
IGF1R P IP Cell Signalling 
technology (MA, USA), 
rabbit anti-human, 1:100
pIGFIR 
(Tyr 1131)
IP Invitrogen (CA, USA), 
rabbit anti-human, 1:100
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IGF1RJ3 IHC Cell Signalling 
technology (MA, USA), 
rabbit anti- 
human/mouse1:100
His-tag WB 5%  
marvel 
in TBST 
(0.1 % 
tween)
Genscript (NY, USA), 
1:10000 in 5 % marvel 
TBST (0.1 % tween), 
overnight @ 4°C
No secondary, as 
primary is HRP 
conjugated
p-actin WB 5%  
marvel 
in TBST 
(0.1 % 
tween)
Abeam (MA, USA), 
rabbit anti-human 
1:5000 in 5 % marvel in 
TBST (0.1 % tween), 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) anti-rabbit 
HRP 1:2000 in 5 % 
Marvel in TBST (0.1 % 
tween) Incubate @ room 
temp for 1 hr
ERK p44/42 WB 5%  
marvel 
in TBST 
(0.1 % 
tween)
Cell signalling 
Technology (MA, USA) 
rabbit anti­
human/mouse, rat 
1:1000 in 5 % BSA in 
TBST (0. i % tween)) 
incubate overnight @ 
4°C
DAKO (Glostrup, 
Denmark) HRP anti­
rabbit 1:5000 in 5 % 
marvel TBST (0.1 %), 
Incubate @ room temp 
for 1 hr
ERK p44/42 
thr202/tyr204
WB 5%  
marvel 
in TBST 
(0.1 % 
tween)
Cell signalling 
Technology (MA, USA) 
rabbit anti­
human/mouse, rat 
1:1000 in 5%  BSA in 
TBST (0.1 % tween)) 
incubate
DAKO (Glostrup, 
Denmark) HRP anti­
rabbit 1:5000 in 5 % 
marvel TBST (0.1 %), 
Incubate @ room temp 
for 1 hr
a-tubulin
(clone
DM1A)
WB 5 %  
Marvel 
in TBST 
(0.1 % 
tween)
Sigma Aldrich (MO, 
USA) mouse anti­
human, rat 1:5000 in 5 
% Marvel in TBST (0.1 
% tween). Incubate 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) HRP anti­
mouse 1:2000 in 5 %  
marvel TBST (0.1 %). 
Incubate @ room temp 
for 1 hr
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rtTA WB 5%  
Marvel 
in TBST 
(0.1 % 
tween)
Clontech (CA, USA) 
mouse anti-human 
1:500 in 5 % Marvel in 
TBST (0.1 % tween). 
Incubate overnight @ 
4°C
DAKO (Glostrup, 
Denmark) HRP anti­
mouse 1:2000 in 5 % 
marvel TBST (0.1 %). 
Incubate @ room temp 
for 1 hr
VEGF WB 5%  
Marvel 
in TBST 
(0.1 % 
tween)
Santa Cruz (MA, USA) 
rabbit anti-human 1:250 
in 5 % Marvel in TBST 
(0.1 % tween). Incubate 
overnight @ 4°C
DAKO (Glostrup, 
Denmark) HRP anti- 
rabbit 1:2000 in 5 % 
marvel TBST (0.1 %). 
Incubate @ room temp 
for 1 hr
WB= Western blotting 
IP= immunoprecipitation 
IHC= ¡mmunohistochemistry
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Append ix 9: Representative VEGFies standard curve
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Append ix 10: Representative human IGF I standard curve
Plasma IGF I Standard Curve
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Append ix 11 : Representative m ouse IGF standard curve
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Append ix 12: Representative human PAPP-A standard curve
PAPPrA Standard curve
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N P C S A H D H R C L Q A A M A A V A D A S A M A I V G T P R E E P R P V P Q G S C
Q S E L H R A L E R L A A S Q S R T H E D L F I I P I P N C D R N G N F H P K Q C H P A
L D G Q R G K C W C V D R K T G V K L P G G L E P K G E L D C H Q L A D S F Q E D D
P P K S I E H H H H H H H H
Append ix 13: Am ino acid sequence o f protease resistant IGFBP 4
M V P F G L V A A L L L A A G P R P S L G  = Signal peptide 
A A M A A V A D A S A M A  = mutated PAPP-A cleavage site 
D D D D K S L E  = enterokinase 
H H H H H H H H  = His-tag
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